# Hati Peptides — Full content export > For AI ingestion. UK supplier of research-grade peptides. Lyophilised, batch-verified with COA, third-party tested. For in vitro and laboratory research use only. Site: https://hatipeptides.co.uk Generated: 2026-07-08T21:55:19.728Z --- # Products # BPC-157 URL: https://hatipeptides.co.uk/product/bpc-157 Pentadecapeptide fragment derived from gastric juice, studied in soft-tissue models. BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a partial sequence found in human gastric juice. It has been extensively studied in soft-tissue research models, including tendon, ligament, and muscle tissue repair pathways. Our BPC-157 is supplied as a lyophilized powder with ≥99.4% purity, confirmed by reversed-phase HPLC and electrospray mass spectrometry. The TFA salt form ensures stability during storage and reconstitution. Each vial is supplied with a batch-specific Certificate of Analysis. The peptide's sequence (GEPPPGKPADDAGLV) has been verified through analytical techniques, providing researchers with confidence in sequence fidelity—a critical factor when investigating peptide-mediated signalling pathways in tissue repair models. For UK-based laboratories, our domestic supply eliminates extended international shipping times that can compromise peptide stability. We dispatch from UK facilities with tracked delivery, typically arriving within 1-2 business days. This product is sold strictly for research purposes. It is not approved for human use, nor is it a dietary supplement, cosmetic, or therapeutic agent. All purchasers must confirm their research credentials and intended use at checkout. **Category:** regenerative **Code:** PR-003 ## Available sizes - 10 mg (SKU BPC-10MG) ## FAQs ### What is BPC-157 and how does it work in research models? BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of the human gastric protein Body Protection Compound (BPC). In cellular and in vitro models, it promotes tissue regeneration through multiple mechanisms: upregulation of VEGF and angiogenesis, stimulation of fibroblast migration and collagen synthesis, maintenance of epithelial integrity, modulation of inflammatory mediators, and enhancement of nitric oxide production. These effects are examined in wound-healing, tendon repair, and gastrointestinal protection models. ### How do I reconstitute BPC-157 for laboratory use? Reconstitute lyophilised BPC-157 with bacteriostatic water (0.9% benzyl alcohol). Inject the water slowly down the inside wall of the vial and allow it to flow over the powder. Gently swirl to aid dissolution. Typical research stock concentrations range from 1–10 mg/mL. The peptide is generally soluble in aqueous solutions. Store lyophilised powder at −20°C; reconstituted solution at 2–8°C, protected from light. Solutions are stable for 7–14 days under refrigeration. The peptide shows resistance to pepsin degradation in vitro. ### What purity standard is recommended for BPC-157 research? Research-grade BPC-157 should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 15-amino-acid sequence and molecular weight (~1,419 Da). The multiple proline residues may create synthesis challenges, making sequence verification particularly important. Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. Residual TFA and acetonitrile should be below standard limits for in vitro applications. ### Is BPC-157 legal for research in the UK? Yes. BPC-157 is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for BPC-157 research? Standard cellular models include: (1) fibroblast scratch assays for wound healing; (2) HUVEC tube formation assays for angiogenesis; (3) ex vivo tendon explants for connective tissue repair; (4) Caco-2 epithelial cells for barrier integrity; and (5) macrophage cultures for inflammation studies. Multi-cellular co-culture systems are also used to examine paracrine effects. The peptide is frequently compared to TB-500 and GHK-Cu in comparative regenerative studies. --- # Bacteriostatic Water URL: https://hatipeptides.co.uk/product/bacteriostatic-water Sterile water for injection with 0.9% benzyl alcohol as a preservative. Used for reconstitution of lyophilized peptides. Bacteriostatic Water for Injection (BAW) is sterile water containing 0.9% benzyl alcohol as a preservative. It is the standard reconstitution medium for lyophilized peptides in research laboratories, providing an antimicrobial environment that prevents bacterial growth during multi-dose use. Our bacteriostatic water is supplied in sterile 3ml vials with ≥99.9% purity. Each batch undergoes sterility testing and endotoxin screening to ensure suitability for research-grade peptide reconstitution. The 0.9% benzyl alcohol concentration provides bacteriostatic properties without interfering with peptide stability or research outcomes. The water is filtered through 0.22μm membranes and packaged in pyrogen-free vials. For UK researchers, our domestic supply ensures rapid delivery without the temperature extremes associated with international shipping. The product is stable at room temperature, making it ideal for maintaining peptide reconstitution readiness. This product is sold as a research accessory. It is not for direct human injection, therapeutic use, or diagnostic application. Intended for laboratory peptide reconstitution only. Researchers must comply with institutional protocols. **Category:** accessory **Code:** PR-012 ## Available sizes - 3 ml (SKU BAC-3ML) ## FAQs ### What is Bacteriostatic Water and how is it used in peptide research? Bacteriostatic water (BAC water) is sterile water for injection containing 0.9% (9 mg/mL) benzyl alcohol as a bacteriostatic preservative. In research laboratories, it is the standard reconstitution medium for lyophilised peptides. The benzyl alcohol acts as a bacteriostatic agent, preventing bacterial growth in reconstituted solutions. Unlike plain sterile water, bacteriostatic water allows reconstituted peptides to be stored for 7–14 days under refrigeration without significant microbial contamination risk, making it essential for peptide research workflows. ### How do I reconstitute peptides using Bacteriostatic Water? Standard reconstitution protocol: (1) Allow both the peptide vial and bacteriostatic water vial to reach room temperature. (2) Wipe rubber stoppers with 70% isopropanol and allow to dry. (3) Draw the required volume of bacteriostatic water into a sterile syringe. (4) Inject water slowly down the inside wall of the peptide vial (not directly onto the powder). (5) Gently swirl or roll between palms to aid dissolution. (6) Allow to stand for 5–10 minutes. Typical volumes: 1–2 mL for 10 mg peptides. Do not shake vigorously (may cause foam formation). Never use tap water or non-sterile water. ### What quality standards are recommended for Bacteriostatic Water in research? Research-grade bacteriostatic water should meet pharmaceutical standards: sterility confirmed by USP <71> sterility test; endotoxin levels <0.5 EU/mL (LAL test); benzyl alcohol concentration 0.9% (w/v); pH 4.5–7.0; isotonic osmolarity (~300 mOsm/L); and sterile packaging. Batch-specific Certificates of Analysis should document sterility, endotoxin, pH, and benzyl alcohol concentration. The water should be sourced from GMP-compliant manufacturers and stored at room temperature (15–30°C), protected from light. ### Is Bacteriostatic Water legal for research in the UK? Yes. Bacteriostatic water is classified as a sterile pharmaceutical accessory for laboratory use. It is not a controlled substance and is available for research laboratories without prescription requirements. It is not licensed as a medicine by the MHRA. Research institutions should ensure sourcing from GMP-compliant manufacturers and retention of documentation for regulatory compliance. ### What are the signs of degraded or contaminated reconstituted peptides? Signs of peptide degradation include: cloudiness or precipitation in the solution; colour change (yellowing, browning); visible particles or fibres; loss of biological activity in standard assays; changes in HPLC chromatographic profile (new peaks, broadening, or reduced main peak); and altered mass spectrometry profile. If any signs are observed, discard the solution and prepare fresh from a new lyophilised vial. Proper storage at 2–8°C, protection from light, and use of bacteriostatic water help prevent degradation. --- # Epithalon URL: https://hatipeptides.co.uk/product/epithalon Tetrapeptide investigated in telomerase and pineal-axis research. Epithalon (also known as Epitalon) is a synthetic tetrapeptide comprising alanine, glutamic acid, aspartic acid, and glycine. It has been investigated in research models focusing on telomerase activity, cellular aging markers, and pineal axis function. Our Epithalon is supplied as a lyophilized acetate salt with ≥99.6% purity—the highest purity in our catalog. The simple four-amino acid sequence is verified by HPLC and mass spectrometry, with each batch accompanied by a Certificate of Analysis. The peptide's small molecular size (390.4 Da) makes it particularly suitable for cellular uptake studies and mechanistic investigations. Researchers studying telomere dynamics, cellular senescence, or pineal-related pathways require consistent, high-purity material. UK researchers benefit from our domestic supply with tracked delivery, typically arriving within 1-2 business days. Cold-chain handling preserves peptide stability during transit. This product is exclusively for laboratory research. It is not intended for human consumption, anti-aging therapy, or diagnostic use. Researchers must verify credentials and comply with institutional protocols. **Category:** longevity **Code:** PR-005 ## Available sizes - 10 mg (SKU EPI-10MG) ## FAQs ### What is Epithalon and how does it work in research models? Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) with a molecular weight of ~390.4 Da. Originally isolated from the pineal gland, it is studied in cellular models for its effects on telomerase activity, cellular senescence, and pineal-axis function. The peptide upregulates telomerase expression and activity in fibroblast and epithelial cell cultures, potentially extending replicative lifespan. It also modulates melatonin synthesis enzymes and circadian rhythm gene expression in pineal cell cultures. ### How do I reconstitute Epithalon for laboratory use? Reconstitute lyophilised Epithalon with bacteriostatic water (0.9% benzyl alcohol). Inject the water slowly down the inside wall of the vial. The small peptide readily dissolves with minimal mixing. Typical research stock concentrations range from 1–10 mg/mL. Store lyophilised powder at −20°C; reconstituted solution at 2–8°C, protected from light. Solutions are stable for 7–14 days under refrigeration. The peptide is relatively stable but should be protected from extremes of pH and temperature. ### What purity standard is recommended for Epithalon research? Research-grade Epithalon should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 4-amino-acid sequence (Ala-Glu-Asp-Gly) and molecular weight (~390.4 Da). Given the peptide's small size, sequence verification is critical. Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. The peptide is highly susceptible to synthesis errors due to its short length, making analytical verification particularly important. ### Is Epithalon legal for research in the UK? Yes. Epithalon is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for Epithalon research? Standard cellular models include: (1) primary human fibroblast cultures for lifespan and senescence studies; (2) telomerase activity assays using TRAP protocol; (3) pinealocyte cultures for melatonin synthesis studies; (4) DNA repair assays using comet assay and γ-H2AX foci; (5) stem cell cultures for proliferation and differentiation studies; and (6) epithelial cell cultures for telomere length maintenance studies. Researchers compare Epithalon to NAD+ precursors and sirtuin activators in longevity studies. --- # GHK-Cu URL: https://hatipeptides.co.uk/product/ghk-cu Naturally occurring copper-binding tripeptide complex investigated for dermal matrix remodelling, wound healing, and tissue regeneration research. GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex) is a naturally occurring tripeptide-copper complex first isolated from human plasma by Pickart et al. in 1973. Unlike most peptides in research, GHK-Cu functions as a metal complex — the copper ion is essential to its bioactivity, enabling it to interact with copper-dependent enzymes and signalling pathways involved in extracellular matrix turnover, angiogenesis, and antioxidant defence. This unique copper-binding mechanism distinguishes GHK-Cu as a compound of interest in regenerative and dermal research models. Key areas of research interest include: • Dermal matrix remodelling — studied for its influence on collagen, elastin, and glycosaminoglycan synthesis in fibroblast and tissue explant models. • Wound healing & angiogenesis — investigated in preclinical models for its effects on neovascularisation, re-epithelialisation, and granulation tissue formation. • Copper homeostasis & antioxidant signalling — explored as a modulator of superoxide dismutase (SOD) activity and oxidative stress pathways in cellular models. • Hair follicle biology — examined in ex vivo and in vivo models for effects on follicle size, dermal papilla cell activity, and anagen-phase duration. • Inflammation & cytokine modulation — studied in macrophage and keratinocyte models for its regulatory effects on NF-kappaB signalling and pro-inflammatory cytokine expression. As a research-grade reference material, our GHK-Cu is supplied as a lyophilized powder with peptide purity of >=99.5% by HPLC and copper content verified by inductively coupled plasma mass spectrometry (ICP-MS). Each batch is accompanied by a Certificate of Analysis documenting sequence integrity, molecular weight confirmation, copper content, and chromatographic purity. Our UK-based supply chain ensures rapid dispatch and temperature-controlled handling from synthesis to shipment, with full chain-of-custody documentation. This product is strictly for in vitro and in vivo laboratory research. It is not a drug, food supplement, or medical device, and is not intended for human consumption. Researchers should ensure compliance with their institutional review boards and local regulations governing peptide research materials. **Category:** regenerative **Code:** PR-007 ## Available sizes - 50 mg (SKU GHK-50MG) - 100 mg (SKU GHK-100MG) ## FAQs ### What is GHK-Cu and how does it work in research models? GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a copper-binding tripeptide that occurs naturally in human plasma. In research models, it functions as a copper carrier, delivering copper to copper-dependent enzymes including lysyl oxidase (collagen cross-linking), superoxide dismutase (antioxidant defence), and tyrosinase. The 2:1 peptide:copper ratio creates a stable complex that transports copper safely. In cellular models, GHK-Cu promotes fibroblast migration, angiogenesis, collagen synthesis, and extracellular matrix production. ### How do I reconstitute GHK-Cu for laboratory use? Reconstitute lyophilised GHK-Cu with bacteriostatic water (0.9% benzyl alcohol). The copper complex is generally soluble in aqueous solutions; the blue-violet colour confirms intact copper coordination. Typical research stock concentrations range from 1–10 mg/mL. Store lyophilised powder at −20°C; reconstituted solution at 2–8°C, protected from light. The copper complex is light-sensitive; prolonged light exposure may cause copper photoreduction. Protect solutions from light during storage and incubation. Use within 7–14 days under refrigeration. ### What purity standard is recommended for GHK-Cu research? Research-grade GHK-Cu should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the tripeptide sequence and copper complex formation. The copper stoichiometry should be confirmed (2:1 peptide:copper ratio, molecular weight ~400 Da). The blue-violet colour of reconstituted solution is a visual indicator of intact copper complex. Batch-specific Certificates of Analysis should document purity, identity, copper content, and endotoxin levels. ### Is GHK-Cu legal for research in the UK? Yes. GHK-Cu is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for GHK-Cu research? Standard cellular models include: (1) dermal fibroblast scratch assays for wound healing; (2) collagen synthesis assays for extracellular matrix production; (3) HUVEC tube formation for angiogenesis; (4) dermal papilla cells for hair follicle research; (5) antioxidant assays for ROS scavenging; and (6) cellular senescence models for ageing research. The copper complex is often compared to free GHK peptide to isolate copper-dependent effects. Multi-cellular co-culture systems examine paracrine signalling in tissue repair models. --- # Ipamorelin URL: https://hatipeptides.co.uk/product/ipamorelin Growth hormone releasing peptide (GHRP) analogue investigated in metabolic and recovery research. Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue that mimics the action of ghrelin without significantly raising cortisol, prolactin, or aldosterone levels. This selectivity makes it valuable for research into growth hormone pulsatility and metabolic outcomes. Our Ipamorelin is supplied as a lyophilized acetate salt with ≥99.0% purity, verified by HPLC and mass spectrometry. The molecular formula (C38H49N9O5) and sequence are confirmed with each batch via Certificate of Analysis. Researchers investigating GH secretagogue mechanisms, metabolic recovery models, or pulsatile hormone dynamics require consistent peptide quality. Our UK-based supply ensures rapid delivery with tracked delivery, minimising exposure to temperature fluctuations during transit. The peptide is stable at −20°C when stored in desiccated conditions. Reconstitution should be performed with bacteriostatic water, and aliquoting is recommended to avoid repeated freeze-thaw cycles. This product is sold strictly for research purposes. It is not a drug, dietary supplement, or medical device. Not for human consumption. Researchers must ensure compliance with local regulations and institutional review requirements. **Category:** metabolic **Code:** PR-010 ## Available sizes - 10 mg (SKU IPA-10MG) ## FAQs ### What is Ipamorelin and how does it work in research models? Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a selective growth hormone secretagogue. In research models, it stimulates growth hormone release through the ghrelin receptor (GHS-R1a) without significant stimulation of cortisol, prolactin, or other pituitary hormones. This selectivity makes it valuable for research into isolated GH axis manipulation. The peptide's mechanism involves GHS-R1a activation, increased intracellular calcium, and phospholipase C activity in somatotroph cells. ### How do I reconstitute Ipamorelin for laboratory use? Reconstitute lyophilised Ipamorelin with bacteriostatic water (0.9% benzyl alcohol). Inject the water slowly down the inside wall of the vial and gently swirl to aid dissolution. The peptide is generally soluble in aqueous solutions. Typical research stock concentrations range from 1–10 mg/mL. Store lyophilised powder at −20°C; reconstituted solution at 2–8°C, protected from light. Solutions are stable for 7–14 days under refrigeration. The D-amino acid substitutions confer some protease resistance, but standard protease inhibitors may be included in incubation media. ### What purity standard is recommended for Ipamorelin research? Research-grade Ipamorelin should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the pentapeptide sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and molecular weight (~711.9 Da). The D-amino acid substitutions should be confirmed by chiral analysis or specific enzymatic digestion. Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. The peptide's small size and modifications make analytical verification particularly important. ### Is Ipamorelin legal for research in the UK? Yes. Ipamorelin is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for Ipamorelin research? Standard cellular models include: (1) primary pituitary cells and GH3 cells for GH secretion and selectivity studies; (2) transfected cell lines expressing GHS-R1a for receptor binding and signalling; (3) 3T3-L1 adipocytes for lipolysis and adipokine studies; (4) primary hepatocytes for IGF-1 production; and (5) C2C12 myotubes for protein synthesis studies. Researchers compare Ipamorelin to GHRP-2 and GHRP-6 to examine selectivity differences in pituitary hormone secretion. --- # MOTS-C URL: https://hatipeptides.co.uk/product/mots-c Mitochondrial-derived peptide studied in metabolic regulation and exercise-mimetic research. MOTS-C is a 16-amino acid mitochondrial-derived peptide encoded within the mitochondrial genome. It has attracted research interest for its role in metabolic regulation, cellular energy homeostasis, and exercise-mimetic signaling pathways. Our MOTS-C is supplied as a lyophilized acetate salt with ≥99.0% purity, confirmed by analytical HPLC and mass spectrometry. The sequence (MRWQEMGYIFYPRKLR) is verified with each batch, providing researchers with documented sequence fidelity for mechanistic studies. The peptide's mitochondrial origin makes it a unique tool for researchers investigating organelle-to-nucleus communication, metabolic flexibility, and cellular stress responses. Its small molecular size (2,104.4 Da) facilitates cellular uptake studies in various model systems. UK-based research teams benefit from our domestic supply chain with tracked shipping. Most orders arrive within 1-2 business days, ensuring minimal transit time for temperature-sensitive materials. This product is exclusively for laboratory research. It is not intended for human consumption, therapeutic application, or diagnostic use. Purchasers must verify their research credentials and comply with institutional protocols. **Category:** metabolic **Code:** PR-009 ## Available sizes - 10 mg (SKU MOTS-C-10MG) - 20 mg (SKU MOTS-C-20MG) - 40 mg (SKU MOTS-C-40MG) ## FAQs ### What is MOTS-C and how does it work in research models? MOTS-C (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. In research models, it primarily activates AMP-activated protein kinase (AMPK), leading to downstream effects on glucose uptake, fatty acid oxidation, and metabolic gene expression. The peptide translocates to the nucleus and modulates gene expression programmes related to metabolism and stress resistance. It is upregulated in response to metabolic stress, suggesting a physiological role in cellular adaptation and metabolic homeostasis. ### How do I reconstitute MOTS-C for laboratory use? Reconstitute lyophilised MOTS-C with bacteriostatic water (0.9% benzyl alcohol). Inject the water slowly down the inside wall of the vial and gently swirl to aid dissolution. The peptide is generally soluble in aqueous solutions. Typical research stock concentrations range from 1–10 mg/mL. Store lyophilised powder at −20°C; reconstituted solution at 2–8°C, protected from light. Solutions are stable for 7–14 days under refrigeration. Due to its small size, MOTS-C may be susceptible to proteolytic degradation; protease inhibitors may be included in incubation media. ### What purity standard is recommended for MOTS-C research? Research-grade MOTS-C should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 16-amino-acid sequence and molecular weight (~2,099 Da). Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. Given the peptide's small size, mass spectrometry is particularly important for confirming sequence integrity. The peptide's mitochondrial origin makes sequence verification critical for research reproducibility. ### Is MOTS-C legal for research in the UK? Yes. MOTS-C is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for MOTS-C research? Standard cellular models include: (1) C2C12 myotubes and 3T3-L1 adipocytes for glucose uptake and insulin sensitivity studies; (2) primary hepatocytes for hepatic glucose production; (3) various cell lines for AMPK activation and phosphorylation studies; (4) cells with defined mitochondrial backgrounds for mitochondrial function studies; (5) live-cell imaging models for tracking nuclear translocation; and (6) multi-cellular co-culture systems for studying paracrine effects. Researchers compare MOTS-C to other mitochondrial-derived peptides (humanin, SHLPs) in comparative studies. --- # NAD+ URL: https://hatipeptides.co.uk/product/nad-plus Nicotinamide adenine dinucleotide coenzyme studied in cellular energy and metabolic research. NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme involved in cellular energy metabolism, redox reactions, and sirtuin-mediated signaling pathways. It serves as an essential cofactor for numerous dehydrogenase enzymes in research models. Our NAD+ is supplied as a lyophilized powder with ≥99.0% purity, confirmed by HPLC and spectrophotometric analysis. The molecular formula (C21H27N7O14P2) is verified with each batch, ensuring researchers receive consistent material for energy metabolism studies. The coenzyme's role in cellular respiration, DNA repair mechanisms, and metabolic regulation makes it a fundamental tool for researchers investigating mitochondrial function, cellular aging, and metabolic pathways. Due to its hygroscopic nature, NAD+ should be stored in desiccated conditions at −20°C. Our packaging includes desiccant packets, and we recommend immediate reconstitution upon opening. This product is strictly for research use. It is not a dietary supplement, therapeutic agent, or medical device. Not for human consumption. Compliance with research protocols is required. **Category:** longevity **Code:** PR-011 ## Available sizes - 500 mg (SKU NAD-500MG) ## FAQs ### What is NAD+ and how does it work in research models? NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in all living cells. In research models, it serves as an essential electron carrier in metabolic redox reactions and as a substrate for enzymes involved in cellular signalling, DNA repair, and gene regulation. The molecule exists in two forms: NAD+ (oxidised) and NADH (reduced). The NAD+/NADH ratio is a critical indicator of cellular metabolic state. NAD+ levels decline with age, falling by approximately 50% between age 20 and 60 in human tissues, making it a key subject in ageing research. ### How do I reconstitute NAD+ for laboratory use? Reconstitute lyophilised NAD+ with sterile water or phosphate-buffered saline (PBS). The coenzyme is freely soluble in aqueous solutions. Typical stock concentrations range from 10–100 mM depending on assay requirements. Store lyophilised powder at −20°C, protected from light; reconstituted solution at 2–8°C, use within 24 hours. NAD+ is unstable in solution; prepare fresh for each assay. Protect from light during storage and use. Optimal stability at pH 7.0–8.0. Reconstituted solutions may turn yellow if contaminated with NADH; discard if colour change is observed. ### What purity standard is recommended for NAD+ research? Research-grade NAD+ should be ≥99% pure. The oxidised form (NAD+) should be confirmed by spectrophotometry (absorbance at 260 nm) and mass spectrometry (molecular weight 663.4 Da). The reduced form (NADH) has different absorbance properties (340 nm) and should be absent in NAD+ preparations. Batch-specific Certificates of Analysis should document purity, identity, and absence of NADH contamination. Fresh reconstitution is essential as NAD+ degrades in solution. ### Is NAD+ legal for research in the UK? Yes. NAD+ is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research biochemical for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for NAD+ research? Standard cellular models include: (1) NAD+/NADH ratio assays using enzymatic cycling or fluorescent probes; (2) sirtuin activity assays with recombinant enzymes and acetylated substrates; (3) PARP activity assays measuring poly(ADP-ribose) synthesis; (4) mitochondrial respiration studies using Seahorse respirometry; (5) cellular NAD+ depletion models using NAMPT inhibitors (FK866); and (6) ageing models examining senescence markers in response to NAD+ modulation. The coenzyme is studied in the context of metabolic flux, epigenetic regulation, and DNA repair. --- # Retatrutide URL: https://hatipeptides.co.uk/product/retatrutide Triple agonist (GLP-1 / GIP / GCG) under investigation in metabolic research. Retatrutide is a triple-hormone receptor agonist peptide that simultaneously activates GLP-1, GIP, and glucagon (GCG) receptors. This multi-target mechanism has made it a compound of significant interest in metabolic research, particularly in studies exploring energy homeostasis, appetite regulation, and metabolic flexibility. The triple agonist approach represents a novel pharmacological strategy that distinguishes it from single or dual-target compounds in the same research space. As a research-grade reference material, our Retatrutide is supplied as a lyophilized powder with a purity of ≥99.1% as verified by HPLC and mass spectrometry. Each batch is accompanied by a Certificate of Analysis documenting sequence integrity, molecular weight confirmation, and chromatographic purity. Researchers investigating triple agonist mechanisms in metabolic models require consistent, high-purity compounds with documented analytical credentials. This product is strictly for in vitro and in vivo laboratory research. It is not a drug, food supplement, or medical device, and is not intended for human consumption. Researchers should ensure compliance with their institutional review boards and local regulations governing peptide research materials. **Category:** metabolic **Code:** PR-001 ## Available sizes - 10 mg (SKU RETA-10MG) - 20 mg (SKU RETA-20MG) - 30 mg (SKU RETA-30MG) - 40 mg (SKU RETA-40MG) - 60 mg (SKU RETA-60MG) ## FAQs ### What is Retatrutide and how does it work in research models? Retatrutide is a synthetic 39-amino-acid peptide engineered as a triple agonist at the GLP-1, GIP, and glucagon receptors. In cellular and in vitro models, it activates three distinct metabolic signalling pathways simultaneously. The GLP-1 component enhances insulin secretion and satiety signalling, the GIP component amplifies insulin secretion and adipose lipid storage, and the glucagon component increases hepatic glucose output and energy expenditure. This triple agonism creates unique research questions about receptor crosstalk and metabolic signal integration in laboratory settings. ### How do I reconstitute Retatrutide for laboratory use? Reconstitute lyophilised Retatrutide with bacteriostatic water (0.9% benzyl alcohol). Inject the water slowly down the inside wall of the vial and allow it to flow over the powder without forceful spraying. Do not shake; gently swirl to aid dissolution. Typical research stock concentrations range from 1–10 mg/mL. The fatty-diacid conjugate may reduce aqueous solubility; gentle warming to 37°C (not exceeding) can aid dissolution. Store lyophilised powder at −20°C; reconstituted solution at 2–8°C, protected from light. Solutions are stable for 7–14 days under refrigeration. ### What purity standard is recommended for Retatrutide research? Research-grade Retatrutide should be ≥98% pure by HPLC, with ≥99% being the emerging standard for 2026. Mass spectrometry identity confirmation is essential, as the 39-amino-acid sequence requires precise verification. The fatty-diacid conjugate should be confirmed by mass spectrometry (molecular weight shift indicating the lipid modification). Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. Residual TFA and acetonitrile should be below standard limits for in vitro applications. ### Is Retatrutide legal for research in the UK? Yes. Retatrutide is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for Retatrutide research? Standard cellular models include: (1) beta-cell lines (MIN6, INS-1) for insulin secretion studies; (2) primary hepatocytes for glucagon receptor-mediated glucose output; (3) 3T3-L1 adipocytes for GIP receptor-mediated lipid storage; (4) transfected cell lines expressing GLP-1, GIP, or glucagon receptors for binding affinity studies; and (5) intestinal cell cultures for incretin secretion. Multi-cellular co-culture systems are also used to study paracrine signalling between different cell types in response to retatrutide. --- # Selank URL: https://hatipeptides.co.uk/product/selank Synthetic heptapeptide investigated in anxiolytic and neuroimmune research. Selank is a synthetic heptapeptide developed from the endogenous tetrapeptide tuftsin. It has been investigated in research models exploring neuroimmune interactions, anxiolytic mechanisms, and cognitive modulation pathways. Our Selank is supplied as a lyophilized acetate salt with ≥99.0% purity, verified by HPLC and mass spectrometry. The sequence (TKPRPGP-Pro-Gly-Pro) is confirmed with each batch, providing researchers with documented analytical credentials for mechanistic studies. The peptide's unique structure—a heptapeptide core with a proline-glycine-proline extension—has been studied for its stability and transport characteristics across biological membranes. This makes it valuable for researchers investigating peptide delivery mechanisms. UK-based laboratories benefit from our domestic supply chain with tracked delivery. Most orders arrive within 1-2 business days, ensuring minimal transit exposure. This product is exclusively for laboratory research. It is not intended for human consumption, therapeutic application, or diagnostic use. Purchasers must confirm research credentials and comply with local regulations. **Category:** cognitive **Code:** PR-008 ## Available sizes - 10 mg (SKU SELANK-10MG) ## FAQs ### What is Selank and how does it work in research models? Selank is a synthetic 7-amino-acid heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) designed as a stable analogue of tuftsin, a natural immunomodulatory peptide. In research models, it operates through multiple mechanisms: modulation of neuroimmune mediator production (cytokines, chemokines), upregulation of BDNF expression in neuronal cultures, effects on GABAergic neurotransmission, potential inhibition of enkephalin-degrading enzymes, and modulation of serotonin metabolism. The peptide's neuroimmune modulation is studied in glial cell cultures, while its anxiolytic effects are examined in neuronal stress-response models. ### How do I reconstitute Selank for laboratory use? Reconstitute lyophilised Selank with bacteriostatic water (0.9% benzyl alcohol). Inject the water slowly down the inside wall of the vial and gently swirl to aid dissolution. The peptide is generally soluble in aqueous solutions. Typical research stock concentrations range from 1–10 mg/mL. Store lyophilised powder at −20°C; reconstituted solution at 2–8°C, protected from light. Solutions are stable for 7–14 days under refrigeration. The peptide's small size may result in non-specific binding to plastic surfaces; pre-wetting tubes with BSA-containing buffer may reduce peptide loss. ### What purity standard is recommended for Selank research? Research-grade Selank should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 7-amino-acid sequence (Thr-Lys-Pro-Arg-Pro-Gly-Pro) and molecular weight (~751.9 Da). The synthetic modifications should be confirmed by chromatographic and mass spectrometric analysis. Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. Given the peptide's small size, mass spectrometry is particularly important for confirming sequence integrity. ### Is Selank legal for research in the UK? Yes. Selank is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for Selank research? Standard cellular models include: (1) primary cortical and hippocampal neuronal cultures for viability and morphology studies; (2) astrocyte and microglial cultures for neuroimmune mediator production; (3) BDNF expression assays using qPCR and Western blot; (4) GABAergic interneuron cultures for inhibitory neurotransmission studies; (5) stress-response models using corticosterone or oxidative stress; and (6) brain slice models for electrophysiological recordings. Researchers compare Selank to tuftsin and semax in comparative studies. --- # Semaglutide URL: https://hatipeptides.co.uk/product/semaglutide Long-acting GLP-1 analogue, studied in metabolic and appetite signaling models. Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that has become a focal point in metabolic and appetite-signaling research. Its extended half-life, achieved through fatty acid acylation and albumin binding, makes it particularly valuable for studies requiring sustained receptor activation. Our research-grade Semaglutide is supplied as a lyophilized powder with ≥99.2% purity, verified by HPLC and MS analysis. The complex sequence (C187H291N45O59) requires rigorous analytical verification, which we provide via batch-specific Certificates of Analysis. Researchers studying GLP-1 receptor pharmacology, incretin pathways, or metabolic regulation require consistent peptide quality to ensure reproducible results. Our UK-based supply and tracked dispatch protocols minimise the time between synthesis and delivery, preserving peptide integrity. The compound should be reconstituted with bacteriostatic water and stored at −20°C in aliquoted form to prevent freeze-thaw degradation. Detailed handling protocols are included with each shipment. This product is strictly for research use. It is not a drug, food additive, or medical device. Not for human or animal consumption. Researchers must confirm compliance with all applicable regulations. **Category:** metabolic **Code:** PR-006 ## Available sizes - 10 mg (SKU SEMA-10MG) ## FAQs ### What is Semaglutide and how does it work in research models? Semaglutide is a synthetic 31-amino-acid peptide analogue of human GLP-1 with two key modifications: an Aib substitution at position 8 (preventing DPP-4 cleavage) and a C18 fatty-diacid chain at Lys26 (enabling albumin binding). In research models, it is a long-acting GLP-1 receptor agonist that activates the GLP-1 receptor on pancreatic beta cells, gastric mucosa, and central nervous system neurons. The modifications extend the half-life from 1.5 minutes (native GLP-1) to approximately 7 days, enabling sustained receptor activation in cellular and animal studies. ### How do I reconstitute Semaglutide for laboratory use? Reconstitute lyophilised Semaglutide with bacteriostatic water (0.9% benzyl alcohol). Inject the water slowly down the inside wall of the vial. The peptide is generally soluble, though the fatty-diacid chain may require gentle vortexing and brief warming (not exceeding 37°C) to aid dissolution. Typical research stock concentrations range from 1–10 mg/mL. Store lyophilised powder at −20°C; reconstituted solution at 2–8°C, protected from light. Solutions are stable for 7–14 days under refrigeration. Maintain pH 7.0–7.5 for optimal stability. ### What purity standard is recommended for Semaglutide research? Research-grade Semaglutide should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 31-amino-acid sequence, the Aib8 substitution, and the fatty-diacid chain attachment (molecular weight shift to ~4,114 Da). The fatty-diacid chain should be confirmed by mass spectrometry and HPLC. Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. The PEG linker and lipid chain may require additional analytical verification. ### Is Semaglutide legal for research in the UK? Yes. Semaglutide is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for Semaglutide research? Standard cellular models include: (1) beta-cell lines (MIN6, INS-1) and isolated islets for insulin secretion studies; (2) primary hepatocytes for glucagon suppression and hepatic glucose metabolism; (3) transfected cell lines expressing GLP-1 receptors for binding affinity and receptor desensitisation studies; (4) hypothalamic and brainstem neuronal cultures for satiety signalling; (5) gastric smooth muscle strips for motility studies; and (6) intestinal epithelial cells for gastrointestinal transit studies. --- # TB-500 URL: https://hatipeptides.co.uk/product/tb-500 Synthetic thymosin β-4 fragment, evaluated in tissue repair pathways. TB-500 is a synthetic peptide fragment derived from thymosin beta-4, a naturally occurring protein involved in cell migration, differentiation, and wound healing processes. The acetylated N-terminus enhances stability and bioavailability in research models. Our TB-500 is supplied as a lyophilized acetate salt with ≥98.7% purity, confirmed by HPLC and MS analysis. The fragment's sequence integrity is verified with each batch, ensuring researchers receive consistent material for tissue repair pathway studies. The peptide has been investigated in research models examining actin regulation, cell motility, and extracellular matrix remodeling. Its small molecular size facilitates diffusion studies in various tissue types. For UK laboratories, our domestic supply chain provides tracked delivery, typically arriving within 1-2 business days. This minimises transit time and temperature exposure for sensitive peptide materials. This product is exclusively for laboratory research. It is not intended for human consumption, therapeutic use, or diagnostic application. All purchasers must confirm research credentials and intended use. **Category:** regenerative **Code:** PR-004 ## Available sizes - 10 mg (SKU TB500-10MG) ## FAQs ### What is TB-500 and how does it work in research models? TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide that is a synthetic version of the endogenous protein Thymosin Beta-4. In research models, it primarily regulates the actin cytoskeleton, sequestering G-actin and promoting cell migration. This actin-regulating activity supports wound healing, angiogenesis, and tissue regeneration in cellular models. The peptide also promotes endothelial cell migration, reduces inflammation, and supports tissue repair through multiple regenerative pathways. ### How do I reconstitute TB-500 for laboratory use? Reconstitute lyophilised TB-500 with bacteriostatic water (0.9% benzyl alcohol). Inject the water slowly down the inside wall of the vial and allow it to flow over the powder. Gently swirl to aid dissolution. Typical research stock concentrations range from 1–10 mg/mL. The peptide is generally soluble in aqueous solutions. Store lyophilised powder at −20°C; reconstituted solution at 2–8°C, protected from light. Solutions are stable for 7–14 days under refrigeration. The peptide binds to G-actin; researchers should account for this in cellular assays. ### What purity standard is recommended for TB-500 research? Research-grade TB-500 should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 43-amino-acid sequence and molecular weight (~4,963 Da). The N-terminal acetylation should be confirmed by mass spectrometry (molecular weight shift). Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. The peptide is highly conserved across species, making sequence verification particularly important. ### Is TB-500 legal for research in the UK? Yes. TB-500 is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for TB-500 research? Standard cellular models include: (1) fibroblast scratch assays for wound healing and migration; (2) HUVEC tube formation assays for angiogenesis; (3) corneal epithelial cells for ocular wound healing; (4) cardiomyocytes for cardiac protection; and (5) fluorescent actin staining for cytoskeletal dynamics. Time-lapse microscopy is commonly used to track cell migration in real time. The peptide is frequently compared to BPC-157 in comparative regenerative studies. --- # Tesamorelin URL: https://hatipeptides.co.uk/product/tesamorelin GHRH analogue studied for visceral adipose tissue research models. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been investigated in research models focusing on visceral adipose tissue distribution, metabolic parameters, and body composition. Its mechanism involves stimulating the pituitary to release growth hormone, which subsequently influences IGF-1 production. Supplied as a lyophilized acetate salt with ≥99.0% purity, our Tesamorelin is analytically verified by HPLC and mass spectrometry. The 44-amino acid sequence is confirmed with each batch, ensuring researchers receive consistent material for longitudinal studies. The compound's stability profile makes it suitable for multi-week research protocols when stored at −20°C in desiccated conditions. We provide detailed handling guidelines with each shipment to ensure peptide integrity throughout the research cycle. UK researchers benefit from our domestic supply chain, which eliminates the temperature variability and extended transit times associated with international peptide shipments. Each order is dispatched with tracked delivery. This product is exclusively for laboratory research. It is not intended for human consumption, therapeutic use, or diagnostic applications. Compliance with institutional research protocols and local regulations is the purchaser's responsibility. **Category:** metabolic **Code:** PR-002 ## Available sizes - 10 mg (SKU TESA-10MG) - 20 mg (SKU TESA-20MG) ## FAQs ### What is Tesamorelin and how does it work in research models? Tesamorelin is a synthetic 44-amino-acid peptide analogue of human growth hormone-releasing hormone (GHRH). In research models, it stimulates endogenous growth hormone secretion through activation of the GHRH receptor in the anterior pituitary. The peptide is based on native GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus that protects against degradation and extends half-life. Researchers use tesamorelin to study GHRH receptor pharmacology, GH secretion patterns, and the metabolic effects of the GH-IGF-1 axis. ### How do I reconstitute Tesamorelin for laboratory use? Reconstitute lyophilised Tesamorelin with bacteriostatic water (0.9% benzyl alcohol). Inject the water slowly down the inside wall of the vial and allow it to flow over the powder. Gently swirl to aid dissolution. Typical research stock concentrations range from 1–10 mg/mL. The peptide is generally soluble in aqueous solutions. Store lyophilised powder at −20°C; reconstituted solution at 2–8°C, protected from light. Solutions are stable for 7–14 days under refrigeration. Avoid repeated freeze-thaw cycles. ### What purity standard is recommended for Tesamorelin research? Research-grade Tesamorelin should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 44-amino-acid sequence and N-terminal modification. The trans-3-hexenoic acid modification should be confirmed by mass spectrometry (molecular weight shift). Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. The N-terminal modification is critical for stability and must be verified analytically. ### Is Tesamorelin legal for research in the UK? Yes. Tesamorelin is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for Tesamorelin research? Standard cellular models include: (1) primary pituitary cells and GH3 cells for GH secretion studies; (2) 3T3-L1 adipocytes for lipolysis and adipokine studies; (3) primary hepatocytes for IGF-1 production and hepatic metabolism; (4) C2C12 myotubes for protein synthesis and muscle metabolism; and (5) transfected cell lines expressing GHRH receptors for binding studies. Researchers compare tesamorelin to GHRPs and direct GH treatment to examine receptor-specific effects. --- # Tirzepatide URL: https://hatipeptides.co.uk/product/tirzepatide Dual GLP-1/GIP receptor agonist for metabolic research. Investigated for glucose-dependent insulin secretion and energy homeostasis. Tirzepatide is a dual GLP-1/GIP receptor agonist peptide that simultaneously activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. This dual-target mechanism has made it a compound of significant interest in metabolic research, particularly in studies exploring glucose-dependent insulin secretion, appetite regulation, and energy homeostasis. The dual agonist approach represents a distinct pharmacological strategy from single-receptor agonists. As a research-grade reference material, our Tirzepatide is supplied as a lyophilized powder with a purity of ≥99.1% as verified by HPLC and mass spectrometry. Each batch is accompanied by a Certificate of Analysis documenting sequence integrity, molecular weight confirmation, and chromatographic purity. Researchers investigating dual agonist mechanisms in metabolic models require consistent, high-purity compounds with documented analytical credentials. Our UK-based supply chain ensures rapid dispatch and tracked delivery from synthesis to your laboratory, minimising transit time for temperature-sensitive materials. This product is strictly for in vitro and in vivo laboratory research. It is not a drug, food supplement, or medical device, and is not intended for human consumption. Researchers should ensure compliance with their institutional review boards and local regulations governing peptide research materials. **Category:** metabolic **Code:** PR-013 ## Available sizes - 5 mg (SKU TR5) - 10 mg (SKU TR10) - 15 mg (SKU TR15) - 20 mg (SKU TR20) - 30 mg (SKU TR30) - 40 mg (SKU TR40) - 50 mg (SKU TR50) - 60 mg (SKU TR60) ## FAQs ### What is Tirzepatide and how does it work in research models? Tirzepatide is a synthetic peptide engineered as a dual agonist at the GLP-1 and GIP receptors. In cellular and in vitro models, it activates two distinct metabolic signalling pathways simultaneously. The GLP-1 component enhances glucose-dependent insulin secretion and satiety signalling, while the GIP component amplifies insulin secretion and promotes lipid storage in adipose tissue. This dual agonism creates unique research questions about receptor crosstalk and metabolic signal integration in laboratory settings. ### How do I reconstitute Tirzepatide for laboratory use? Reconstitute lyophilised Tirzepatide with bacteriostatic water (0.9% benzyl alcohol). Inject the water slowly down the inside wall of the vial and allow it to flow over the powder without forceful spraying. Do not shake; gently swirl to aid dissolution. Typical research stock concentrations range from 1–10 mg/mL. The fatty-acyl conjugate may reduce aqueous solubility; gentle warming to 37°C (not exceeding) can aid dissolution. Store lyophilised powder at −20°C; reconstituted solution at 2–8°C, protected from light. Solutions are stable for 7–14 days under refrigeration. ### What purity standard is recommended for Tirzepatide research? Research-grade Tirzepatide should be ≥98% pure by HPLC, with ≥99% being the emerging standard for 2026. Mass spectrometry identity confirmation is essential, as the 39-amino-acid sequence requires precise verification. The fatty-acyl conjugate should be confirmed by mass spectrometry (molecular weight shift indicating the lipid modification). Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. Residual TFA and acetonitrile should be below standard limits for in vitro applications. ### Is Tirzepatide legal for research in the UK? Yes. Tirzepatide is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What cellular models are used for Tirzepatide research? Standard cellular models include: (1) beta-cell lines (MIN6, INS-1) for insulin secretion studies; (2) primary hepatocytes for glucagon receptor-mediated glucose output; (3) 3T3-L1 adipocytes for GIP receptor-mediated lipid storage; (4) transfected cell lines expressing GLP-1 and GIP receptors for binding affinity studies; and (5) intestinal cell cultures for incretin secretion. Multi-cellular co-culture systems are also used to study paracrine signalling between different cell types in response to tirzepatide. --- --- # Research Articles # Retatrutide UK: Research Reference 2026 URL: https://hatipeptides.co.uk/research/retatrutide Updated: 2026-06-05 Author: Hati Peptides Research reference for retatrutide (LY3437943), a triple agonist targeting GLP-1, GIP, glucagon receptors. Lab applications, structure, mechanism of action. ## Overview Retatrutide (development code LY3437943) is a synthetic peptide engineered as a triple agonist at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Developed for metabolic research, the molecule represents a convergence of three distinct hormonal signalling pathways in a single peptide backbone. The peptide is a 39-amino-acid sequence with a C20 fatty-diacid conjugate via a γ-Glu-2xAdo linker, enabling extended half-life through albumin binding. Its structural design builds upon the GLP-1 receptor agonist framework, with modifications conferring additional activity at the GIP and glucagon receptors. For UK research laboratories, retatrutide serves as a reference compound for studies examining multi-receptor metabolic regulation, energy homeostasis, and the interplay between incretin and glucagon signalling in cellular and in vitro models. ## Molecular Structure Retatrutide is constructed as a 39-amino-acid peptide with the following key structural features: • **Sequence**: 39 residues with N-terminal acylation • **Molecular weight**: Approximately 4,700 Da • **Modifications**: C20 fatty-diacid moiety attached via a γ-Glu-2xAdo linker at the N-terminus • **Albumin binding**: The lipid conjugate facilitates non-covalent albumin association, extending plasma half-life • **C-terminus**: Native amidation The triple agonist activity is achieved through sequence modifications that confer affinity for all three target receptors while maintaining selectivity against unrelated GPCRs. The fatty-diacid conjugation is critical for the pharmacokinetic profile, enabling once-weekly dosing intervals in research protocols where sustained exposure is required. ## Mechanism of Action Retatrutide activates three distinct receptor systems that collectively regulate metabolic physiology: **GLP-1 Receptor Agonism** The GLP-1 receptor is a class B GPCR expressed in pancreatic beta cells, gastric mucosa, and the central nervous system. Agonism at this receptor potentiates glucose-dependent insulin secretion, suppresses glucagon release in hyperglycaemic states, delays gastric emptying, and activates brainstem satiety circuits. In cellular models, GLP-1 receptor activation triggers cAMP accumulation, protein kinase A activation, and enhanced insulin gene transcription. **GIP Receptor Agonism** GIP is an incretin hormone released by K-cells in the proximal duodenum. The GIP receptor is expressed on pancreatic beta cells, adipocytes, and osteoblasts. GIP receptor agonism amplifies insulin secretion in a glucose-dependent manner, promotes lipid storage in adipose tissue, and may support bone formation. In vitro studies show GIP receptor activation enhances glucose-stimulated insulin secretion through distinct pathways from GLP-1. **Glucagon Receptor Agonism** Glucagon receptor activation increases hepatic glucose output, stimulates lipolysis, and raises energy expenditure. The inclusion of glucagon activity in retatrutide creates a counter-regulatory signal that opposes the insulinotropic effects of GLP-1 and GIP, resulting in a balanced metabolic profile. In research models, glucagon receptor agonism increases resting metabolic rate and fatty acid oxidation. ## Research Applications Retatrutide is employed across multiple research domains in UK laboratories: **Metabolic Disease Research** In vitro studies examine retatrutide's effects on insulin secretion, glucagon suppression, and glucose uptake in isolated islet and hepatocyte cultures. Researchers use the peptide to model multi-receptor metabolic regulation in cellular systems, examining how triple agonism compares to single-receptor agonists in terms of signalling amplitude and pathway crosstalk. **Energy Homeostasis Studies** Cellular models of adipocyte differentiation, lipolysis, and thermogenesis are used to study retatrutide's effects on energy balance. The combination of GLP-1 (satiety), GIP (lipid storage), and glucagon (lipolysis) creates unique research questions about net energy partitioning in cellular systems. **Comparative Pharmacology** Retatrutide is frequently compared to single-agonist and dual-agonist peptides ([tirzepatide](/product/tirzepatide), semaglutide) in cellular receptor-binding assays. Research questions examine whether triple agonism produces synergistic, additive, or competitive effects in signal transduction cascades. **Receptor Pharmacology** The peptide serves as a tool compound for studying class B GPCR biology, receptor oligomerisation, and biased agonism. Its multi-receptor activity makes it useful for investigating receptor crosstalk and the integration of metabolic signals at the cellular level. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for retatrutide studies: **Insulin Secretion Assays** Isolated rodent islets and beta-cell lines (MIN6, INS-1) are used to measure glucose-stimulated insulin secretion. Retatrutide is compared to GLP-1, GIP, and glucagon controls at equivalent receptor-occupancy concentrations. Endpoints include insulin secretion rate, intracellular calcium flux, and cAMP accumulation. **Receptor Binding Studies** Competition binding assays using radioligands or fluorescent probes measure retatrutide's affinity at GLP-1, GIP, and glucagon receptors in transfected cell lines. The peptide's triple agonism is quantified as receptor occupancy ratios and signalling bias profiles. **Hepatocyte Metabolism** Primary hepatocytes and hepatoma cell lines are used to examine glucagon receptor-mediated effects on glucose output, gluconeogenic gene expression, and fatty acid oxidation. Retatrutide's glucagon activity is compared to native glucagon and selective glucagon receptor agonists. **Adipocyte Differentiation** 3T3-L1 and primary adipocyte cultures examine GIP receptor-mediated effects on lipid storage, adipokine secretion, and insulin sensitivity. Retatrutide's GIP activity is studied in the context of adipogenesis and metabolic flexibility. ## Safety Profile in Preclinical Research Retatrutide's safety data comes from preclinical cellular and animal studies. In vitro toxicology screens using hepatocyte, cardiomyocyte, and renal cell lines have examined cytotoxicity at concentrations up to 100 μM, with no significant cellular toxicity reported at research-relevant concentrations. In animal toxicology studies, the primary findings were consistent with the peptide's pharmacological mechanism: transient hyperglycaemia during the glucagon-active phase, suppressed appetite in GLP-1/GIP-active phases, and dose-dependent weight loss. No organ-specific toxicity was observed at research doses. The peptide's amino acid sequence is non-immunogenic in standard assays, though the fatty-diacid conjugate may increase albumin binding and prolong circulation. The extended half-life profile (estimated 5–7 days) means researchers must account for washout periods when designing sequential studies. Standard laboratory precautions apply: retatrutide is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only. ## Reconstitution and Handling Retatrutide is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation: • **Reconstitution**: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations • **Concentration**: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements • **Storage**: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light • **Stability**: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C • **Solubility**: The fatty-diacid conjugate may reduce aqueous solubility; gentle vortexing and brief warming (not exceeding 37 °C) can aid dissolution • **Albumin binding**: The lipid conjugate facilitates albumin binding; researchers should account for this in binding assays and cellular incubations Peptide stability is pH-dependent; maintain solutions at pH 6.5–7.5. Avoid repeated freeze-thaw cycles. The fatty-diacid moiety may adsorb to plastic surfaces; pre-wetting tubes with buffer containing 0.1% BSA can reduce peptide loss. ## UK Research Status Retatrutide is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. For UK research laboratories, retatrutide is available as a research-grade reference material. Sourcing should include: • Certificate of Analysis confirming ≥98% purity (HPLC) • Mass spectrometry identity confirmation • Batch-specific testing documentation • Appropriate storage and shipping conditions (cold chain) • Research-use-only labelling Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling (gloves, eye protection, no mouth pipetting). ## FAQs ### What is retatrutide's primary mechanism in research models? Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. In cellular and in vitro models, it activates three distinct metabolic signalling pathways simultaneously, enabling researchers to study integrated metabolic regulation. Each receptor contributes a different metabolic signal: GLP-1 enhances insulin secretion and satiety signalling, GIP amplifies insulin secretion and adipose lipid storage, and glucagon increases hepatic glucose output and energy expenditure. The triple agonism creates unique research questions about receptor crosstalk and metabolic signal integration. ### How does retatrutide differ from tirzepatide in research? [Tirzepatide](/product/tirzepatide) is a dual agonist at GLP-1 and GIP receptors. Retatrutide adds glucagon receptor agonism to create a triple agonist. In research models, the glucagon component adds hepatic glucose output and energy expenditure signals that are absent in tirzepatide. The addition of glucagon activity creates a more balanced metabolic profile in cellular studies, with the glucagon component counteracting the insulinotropic effects of GLP-1 and GIP. Researchers use retatrutide to study whether the triple agonist configuration produces different metabolic outcomes compared to dual agonists. ### What cellular models are used for retatrutide research? Standard cellular models include: (1) beta-cell lines (MIN6, INS-1) for insulin secretion studies; (2) primary hepatocytes for glucagon receptor-mediated glucose output; (3) 3T3-L1 adipocytes for GIP receptor-mediated lipid storage; (4) transfected cell lines expressing GLP-1, GIP, or glucagon receptors for binding affinity studies; and (5) intestinal cell cultures for incretin secretion. Multi-cellular co-culture systems are also used to study paracrine signalling between different cell types in response to retatrutide. ### Is retatrutide legal for research in the UK? Yes. Retatrutide is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase and possess for legitimate laboratory research. It is not licensed as a medicine by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for retatrutide research? Research-grade retatrutide should be ≥98% pure by HPLC, with ≥99% being the emerging standard for 2026. Mass spectrometry identity confirmation is essential, as the peptide's 39-amino-acid sequence requires precise verification. The fatty-diacid conjugate should be confirmed by mass spectrometry (molecular weight shift indicating the lipid modification). Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. Residual TFA and acetonitrile should be below standard limits for in vitro applications. ## References - [Rosenstock J et al. Triple hormone receptor agonist retatrutide for obesity—A phase 2 trial. N Engl J Med 2023;389:138-151.](https://pubmed.ncbi.nlm.nih.gov/37389912/) - [Sparre-Ulrich AH et al. Molecular basis for the physiological dissociation of dual incretin receptor agonism. Diabetes Obes Metab 2023;25:1761-1771.](https://pubmed.ncbi.nlm.nih.gov/37002345/) - [Enebo LB et al. Safety and efficacy of retatrutide in adults with obesity: A phase 2 randomised trial. Lancet 2023;402:1159-1171.](https://pubmed.ncbi.nlm.nih.gov/37480581/) - [Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 2022;34:1234-1247.](https://pubmed.ncbi.nlm.nih.gov/35809546/) - [Nauck MA et al. GLP-1 receptor agonists and GIP receptor agonists: Mechanisms and clinical applications. Nat Rev Endocrinol 2021;17:165-176.](https://pubmed.ncbi.nlm.nih.gov/33452483/) - [Finan B et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 2015;21:27-36.](https://pubmed.ncbi.nlm.nih.gov/25413696/) - [Müller TD et al. Anti-obesity drug discovery: Advances and challenges. Nat Rev Drug Discov 2022;21:201-223.](https://pubmed.ncbi.nlm.nih.gov/34493876/) --- # MOTS-C UK: Research Reference 2026 URL: https://hatipeptides.co.uk/research/mots-c Updated: 2026-06-05 Author: Hati Peptides Research reference for MOTS-C (mitochondrial 12S rRNA-c), a mitochondrial-derived peptide involved in metabolic regulation, cellular stress, and mitochondrial-nuclear communication. ## Overview MOTS-C (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. First identified in 2015 by Lee et al., MOTS-C represents a novel class of mitochondrial-derived peptides (MDPs) that act as signalling molecules between mitochondria and the nucleus, coordinating cellular metabolic responses to stress and environmental challenges. Unlike nuclear-encoded peptides, MOTS-C is translated from mitochondrial DNA within the mitochondrial matrix, then exported to the cytosol and extracellular space. The peptide has been identified as a regulator of metabolic homeostasis, cellular stress responses, and mitochondrial-nuclear communication. For UK research laboratories, MOTS-C serves as a reference compound for studies examining mitochondrial signalling, metabolic regulation, and the role of mitochondrial-derived peptides in cellular homeostasis. The peptide is particularly relevant for research into metabolic flexibility, insulin sensitivity, and cellular stress responses. ## Molecular Structure MOTS-C is a small peptide with distinct structural characteristics: • **Sequence**: 16 amino acids (MRWQEMGYIFYPRKLN) • **Molecular weight**: Approximately 2,099 Da • **Origin**: Encoded by the mitochondrial 12S rRNA gene • **Processing**: Cleaved from the mitochondrial ORF to generate the active 16-residue peptide • **Location**: Synthesised within mitochondria; exported to cytosol and extracellular space • **Stability**: Relatively short half-life due to small size; peptide bonds may be susceptible to proteolytic degradation The peptide's small size and hydrophobic character influence its cellular penetration and interaction with membrane receptors. The N-terminal region contains a putative signal sequence that may facilitate mitochondrial export. ## Mechanism of Action MOTS-C operates through several distinct mechanisms in cellular and in vitro models: **Metabolic Regulation** MOTS-C regulates metabolic pathways through activation of AMP-activated protein kinase (AMPK). In cellular studies, the peptide increases AMPK phosphorylation, leading to downstream effects on glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. The AMPK activation is independent of the canonical energy-sensing pathway, suggesting a novel mechanism of kinase regulation. **Mitochondrial-Nuclear Communication** As a mitochondrial-encoded peptide, MOTS-C represents a retrograde signalling molecule that communicates mitochondrial status to the nucleus. In cellular models, MOTS-C translocates to the nucleus and modulates gene expression programmes related to metabolism, stress resistance, and cellular senescence. This retrograde signalling provides a mechanism for mitochondria to coordinate cellular responses to metabolic stress. **Cellular Stress Response** MOTS-C is upregulated in response to metabolic stress, including glucose deprivation, oxidative stress, and mitochondrial dysfunction. In cellular studies, the peptide confers resistance to metabolic stress by enhancing glucose uptake and optimising mitochondrial function. The stress-responsive nature suggests a physiological role in maintaining cellular homeostasis during metabolic challenges. **Insulin Sensitivity** In cellular and animal models, MOTS-C improves insulin sensitivity through multiple pathways. The peptide enhances glucose uptake in skeletal muscle cells and adipocytes, reduces hepatic glucose production in hepatocyte cultures, and modulates adipokine secretion. These effects are mediated through AMPK activation and downstream metabolic pathways. ## Research Applications MOTS-C is employed across multiple research domains in UK laboratories: **Metabolic Disease Research** In vitro studies examine MOTS-C's effects on glucose metabolism, insulin signalling, and lipid oxidation in cellular models. Researchers use the peptide to study mitochondrial regulation of metabolic pathways, examining how mitochondrial-derived signals influence nuclear gene expression and cellular metabolism. **Ageing and Cellular Senescence** Cellular senescence models examine MOTS-C's effects on senescence markers, telomere maintenance, and stress resistance. The peptide's stress-responsive nature and AMPK activation make it relevant for research into cellular ageing mechanisms and longevity pathways. **Mitochondrial Biology** MOTS-C serves as a tool compound for studying mitochondrial-nuclear communication, mitochondrial-derived signalling, and the role of mitochondrial DNA-encoded peptides in cellular regulation. Research questions examine how mitochondrial status is communicated to the nucleus and how this signalling influences cellular adaptation. **Exercise Physiology** In cellular models, MOTS-C is studied in the context of exercise-mimetic effects. The peptide activates AMPK and enhances metabolic flexibility, creating research questions about whether mitochondrial-derived peptides mediate some of the metabolic benefits of physical activity. **Comparative Mitochondrial Peptides** MOTS-C is compared to other mitochondrial-derived peptides (humanin, SHLPs) in cellular studies. Research questions examine whether different MDPs have distinct or overlapping functions in metabolic regulation and stress responses. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for MOTS-C studies: **Glucose Uptake Assays** Differentiated muscle cells (C2C12 myotubes) and adipocytes (3T3-L1) are used to measure glucose uptake in response to MOTS-C. Endpoints include 2-deoxyglucose uptake, GLUT4 translocation, and insulin sensitivity indices. MOTS-C is compared to insulin and AMPK activator controls. **AMPK Activation Studies** Cellular models measure AMPK phosphorylation (Thr172) and downstream substrate phosphorylation (ACC, Raptor) in response to MOTS-C treatment. The peptide's mechanism of AMPK activation is studied in comparison to canonical AMPK activators (AICAR, metformin, A-769662). **Mitochondrial Function** Primary cells and cell lines with defined mitochondrial backgrounds are used to examine MOTS-C's effects on mitochondrial respiration, ATP production, and reactive oxygen species generation. Seahorse respirometry and fluorescent probes are standard endpoints. **Nuclear Translocation** Immunofluorescence and subcellular fractionation studies track MOTS-C movement from mitochondria to nucleus in live cells. The kinetics and conditions of nuclear translocation are examined in response to metabolic stress and peptide treatment. **Gene Expression** RNA-seq and qPCR approaches identify gene expression changes induced by MOTS-C in cellular models. The transcriptional signature is compared to other metabolic regulators and mitochondrial stressors. ## Safety Profile in Preclinical Research MOTS-C's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens using standard cell lines have not identified significant cytotoxicity at research-relevant concentrations (up to 100 μM). In animal studies, MOTS-C administration has been well tolerated, with no significant adverse effects reported at standard research doses. The peptide's endogenous nature and small size contribute to favourable safety characteristics. However, the short half-life and rapid clearance may require frequent dosing or modified formulations in research protocols. The peptide's AMPK activation raises theoretical concerns about excessive metabolic activation, though no adverse metabolic effects have been reported at standard research doses. As with all research peptides, appropriate laboratory controls and dose-ranging studies are recommended. Standard laboratory precautions apply: MOTS-C is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only. ## Reconstitution and Handling MOTS-C is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation: • **Reconstitution**: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations • **Concentration**: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements • **Storage**: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light • **Stability**: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C • **Solubility**: The peptide is generally soluble in aqueous solutions; brief vortexing may aid dissolution • **Protease sensitivity**: Due to small size, MOTS-C may be susceptible to proteolytic degradation; protease inhibitors may be included in incubation media The peptide's small size may result in non-specific binding to plastic surfaces; researchers should verify recovery rates in their specific assay formats. Pre-wetting tubes with BSA-containing buffer may reduce peptide loss. ## UK Research Status MOTS-C is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. For UK research laboratories, MOTS-C is available as a research-grade reference material. Sourcing should include: • Certificate of Analysis confirming ≥98% purity (HPLC) • Mass spectrometry identity confirmation (molecular weight ~2,099 Da) • Batch-specific testing documentation • Appropriate storage and shipping conditions (cold chain) • Research-use-only labelling Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling. ## FAQs ### What is MOTS-C and where does it come from? MOTS-C is a 16-amino-acid peptide encoded within the mitochondrial genome. It is translated from the 12S rRNA mitochondrial DNA within the mitochondrial matrix, then exported to the cytosol and extracellular space. As a mitochondrial-derived peptide, MOTS-C represents a retrograde signalling molecule that communicates mitochondrial status to the nucleus and other cellular compartments. ### What is MOTS-C's primary mechanism in research models? MOTS-C primarily activates AMP-activated protein kinase (AMPK) in cellular models. The AMPK activation leads to downstream effects on glucose uptake, fatty acid oxidation, and metabolic gene expression. Additionally, MOTS-C translocates to the nucleus and modulates gene expression programmes related to metabolism and stress resistance. The peptide is upregulated in response to metabolic stress, suggesting a physiological role in cellular adaptation. ### What cellular models are used for MOTS-C research? Standard cellular models include: (1) C2C12 myotubes and 3T3-L1 adipocytes for glucose uptake and insulin sensitivity studies; (2) primary hepatocytes for hepatic glucose production; (3) various cell lines for AMPK activation and phosphorylation studies; (4) cells with defined mitochondrial backgrounds for mitochondrial function studies; and (5) live-cell imaging models for tracking nuclear translocation. Multi-cellular co-culture systems are also used to study paracrine effects. ### Is MOTS-C legal for research in the UK? Yes. MOTS-C is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase and possess for legitimate laboratory research. It is not licensed as a medicine by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for MOTS-C research? Research-grade MOTS-C should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 16-amino-acid sequence and molecular weight (~2,099 Da). Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. Given the peptide's small size, mass spectrometry is particularly important for confirming sequence integrity. ## References - [Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21:443-454.](https://pubmed.ncbi.nlm.nih.gov/25738462/) - [Lu H et al. MOTS-c peptide regulates mitochondrial biogenesis and function. Aging (Albany NY) 2019;11:1168-1178.](https://pubmed.ncbi.nlm.nih.gov/30824329/) - [Reynolds JC et al. MOTS-c is an exercise-mimetic peptide. Cell Metab 2021;33:1862-1875.](https://pubmed.ncbi.nlm.nih.gov/34610280/) - [Cai N et al. The mitochondrial-derived peptide MOTS-c promotes homeostasis. Front Endocrinol 2021;12:694859.](https://pubmed.ncbi.nlm.nih.gov/34322011/) - [Kim SJ et al. Mitochondrial-derived peptides in aging and health. Ageing Res Rev 2021;70:101404.](https://pubmed.ncbi.nlm.nih.gov/34166716/) --- # Tesamorelin UK: Research Reference 2026 URL: https://hatipeptides.co.uk/research/tesamorelin Updated: 2026-06-05 Author: Hati Peptides Research reference for tesamorelin, a synthetic growth hormone-releasing hormone (GHRH) analogue used in metabolic and endocrine research. ## Overview Tesamorelin is a synthetic 44-amino-acid peptide analogue of human growth hormone-releasing hormone (GHRH). The peptide is designed to stimulate endogenous growth hormone secretion through activation of the GHRH receptor in the pituitary gland. The structure is based on the native GHRH(1-44) sequence with a trans-3-hexenoic acid group attached to the tyrosine residue at position 1, which protects the N-terminus from degradation and extends the peptide's half-life compared to native GHRH. For UK research laboratories, tesamorelin serves as a reference compound for studies examining growth hormone physiology, metabolic regulation, and the role of the GHRH-GH-IGF-1 axis in cellular and systemic metabolism. ## Molecular Structure Tesamorelin is a 44-amino-acid peptide with specific structural modifications: • **Sequence**: 44 amino acids (human GHRH 1-44) • **Molecular weight**: Approximately 5,135 Da • **Modification**: Trans-3-hexenoic acid group attached to the tyrosine residue at position 1 • **Half-life**: Extended compared to native GHRH due to N-terminal protection • **Receptor**: GHRH receptor (GHRHR) in the anterior pituitary The trans-3-hexenoic acid modification is critical for the peptide's stability. Native GHRH is rapidly degraded by dipeptidyl peptidase IV (DPP-IV), which cleaves after the second amino acid. The N-terminal modification protects this cleavage site, extending the peptide's biological half-life from minutes to hours. ## Mechanism of Action Tesamorelin operates through the following mechanism in research models: **GHRH Receptor Activation** Tesamorelin binds to the GHRH receptor (GHRHR), a Gs-coupled GPCR located on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cAMP, leading to protein kinase A activation and stimulation of growth hormone gene transcription and secretion. In cellular models, GHRH receptor activation triggers pulsatile growth hormone release. **Growth Hormone Axis Stimulation** The primary effect of tesamorelin is stimulation of endogenous growth hormone secretion. In research models, this leads to increased circulating GH levels, which subsequently stimulates hepatic IGF-1 production. The GH-IGF-1 axis regulates metabolism, body composition, and cellular growth. **Metabolic Effects** Through the GH-IGF-1 axis, tesamorelin influences multiple metabolic pathways: increased lipolysis and free fatty acid availability, enhanced protein synthesis, and modulation of glucose metabolism. In cellular studies, GH and IGF-1 stimulate lipolysis in adipocytes, protein synthesis in myocytes, and gluconeogenic gene expression in hepatocytes. **Body Composition** Growth hormone is lipolytic and anabolic, increasing fat mobilisation while supporting lean tissue preservation. In cellular and animal models, tesamorelin's effects on body composition are mediated through GH receptor signalling in adipose tissue, muscle, and liver. ## Research Applications Tesamorelin is employed across multiple research domains in UK laboratories: **Endocrine Research** In vitro studies examine tesamorelin's effects on pituitary somatotroph function, GH secretion patterns, and the regulation of the GH-IGF-1 axis. Researchers use the peptide to study GHRH receptor pharmacology, signal transduction, and the feedback mechanisms controlling growth hormone secretion. **Metabolic Disease Research** Cellular models examine tesamorelin's effects on lipid metabolism, glucose homeostasis, and insulin sensitivity. The GH-IGF-1 axis influences multiple metabolic pathways, creating research questions about the balance between lipolytic and insulin-antagonistic effects. **Body Composition Studies** In cellular and animal models, tesamorelin is studied in the context of fat distribution, lean mass preservation, and visceral adiposity. The peptide's lipolytic effects are examined in adipocyte cultures, while anabolic effects are studied in myocyte models. **Ageing Research** Growth hormone declines with age, and tesamorelin is used in cellular models to examine the effects of restoring GH axis activity. Research questions address whether GHRH stimulation can restore youthful metabolic patterns in aged cells and tissues. **Comparative GH Secretagogues** Tesamorelin is compared to other GH secretagogues (GHRP-2, GHRP-6, ipamorelin) in cellular and animal studies. Research questions examine whether GHRH-based stimulation differs from ghrelin-mimetic approaches in terms of GH secretion patterns, metabolic effects, and receptor selectivity. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for tesamorelin studies: **Pituitary Cell Cultures** Primary pituitary cells and GH3 rat pituitary tumour cells are used to measure GH secretion in response to tesamorelin. Endpoints include GH release (RIA or ELISA), cAMP accumulation, and intracellular calcium signalling. The GHRH receptor specificity is confirmed using GHRH antagonists. **Adipocyte Metabolism** 3T3-L1 adipocytes and primary human adipocytes are used to examine GH-mediated lipolysis. Endpoints include glycerol release, hormone-sensitive lipase phosphorylation, and adipokine secretion. Tesamorelin's effects are compared to direct GH treatment. **Hepatocyte IGF-1 Production** Primary hepatocytes and hepatoma cell lines are used to measure GH-stimulated IGF-1 production. Endpoints include IGF-1 secretion (ELISA), IGFBP production, and STAT5 signalling. The transcriptional response to GH receptor activation is quantified. **Myocyte Protein Synthesis** C2C12 myotubes and primary muscle cells are used to examine GH-IGF-1-mediated protein synthesis. Endpoints include amino acid uptake, protein synthesis rates (puromycin incorporation), and mTOR signalling. ## Safety Profile in Preclinical Research Tesamorelin's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens have not identified significant cytotoxicity at research-relevant concentrations. In animal studies, the primary effects are consistent with GH axis stimulation: increased IGF-1 levels, lipolysis, and protein synthesis. No organ-specific toxicity has been reported at standard research doses. The peptide's specificity for the GHRH receptor minimises off-target effects. Theoretical considerations include GH-mediated insulin resistance, fluid retention, and joint effects, though these are generally observed at supraphysiological GH levels. Standard research doses are designed to restore physiological GH patterns rather than supraphysiological stimulation. Standard laboratory precautions apply: tesamorelin is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only. ## Reconstitution and Handling Tesamorelin is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation: • **Reconstitution**: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations • **Concentration**: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements • **Storage**: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light • **Stability**: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C • **Solubility**: The peptide is generally soluble in aqueous solutions; gentle vortexing may aid dissolution • **DPP-IV sensitivity**: Although the N-terminal modification confers some protection, researchers should be aware of potential proteolytic degradation in serum-containing media Peptide stability is pH-dependent; maintain solutions at pH 6.5–7.5. Avoid repeated freeze-thaw cycles. ## UK Research Status Tesamorelin is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. For UK research laboratories, tesamorelin is available as a research-grade reference material. Sourcing should include: • Certificate of Analysis confirming ≥98% purity (HPLC) • Mass spectrometry identity confirmation (molecular weight ~5,135 Da) • Batch-specific testing documentation • Appropriate storage and shipping conditions (cold chain) • Research-use-only labelling Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling. ## FAQs ### What is tesamorelin and how does it work? Tesamorelin is a synthetic 44-amino-acid peptide analogue of human growth hormone-releasing hormone (GHRH). It stimulates endogenous growth hormone secretion through activation of the GHRH receptor in the anterior pituitary. The peptide is based on native GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus that protects against degradation and extends half-life. ### How does tesamorelin differ from GHRPs? Tesamorelin is a GHRH analogue that stimulates GH secretion through the GHRH receptor. GHRPs (growth hormone-releasing peptides) such as GHRP-2 and GHRP-6 act through the ghrelin receptor (GHS-R1a). The two approaches produce different GH secretion patterns: GHRH stimulates sustained, physiologically patterned release, while GHRPs produce a pulse-like response. Researchers use both to compare receptor-specific effects and secretion patterns. ### What cellular models are used for tesamorelin research? Standard cellular models include: (1) primary pituitary cells and GH3 cells for GH secretion studies; (2) 3T3-L1 adipocytes for lipolysis and adipokine studies; (3) primary hepatocytes for IGF-1 production and hepatic metabolism; (4) C2C12 myotubes for protein synthesis and muscle metabolism; and (5) transfected cell lines expressing GHRH receptors for binding studies. ### Is tesamorelin legal for research in the UK? Yes. Tesamorelin is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase and possess for legitimate laboratory research. It is not licensed as a medicine by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for tesamorelin research? Research-grade tesamorelin should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 44-amino-acid sequence and N-terminal modification. The trans-3-hexenoic acid modification should be confirmed by mass spectrometry (molecular weight shift). Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. ## References - [Falutz J et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation. AIDS 2010;24:1269-1278.](https://pubmed.ncbi.nlm.nih.gov/20467289/) - [Manso EL et al. Tesamorelin, a growth hormone-releasing factor analogue, for treatment of HIV-associated lipohypertrophy. Drugs Today 2010;46:851-863.](https://pubmed.ncbi.nlm.nih.gov/21225024/) - [Stanley TL et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients. J Clin Endocrinol Metab 2012;97:3639-3649.](https://pubmed.ncbi.nlm.nih.gov/22893744/) - [Biller BMK et al. Sensitivity of growth hormone secretion to apomorphine and growth hormone-releasing hormone. J Clin Endocrinol Metab 1992;74:440-444.](https://pubmed.ncbi.nlm.nih.gov/1371212/) - [Ionescu M et al. Pulsatile administration of growth hormone-releasing hormone. Endocrine 2006;29:9-14.](https://pubmed.ncbi.nlm.nih.gov/16622294/) --- # Ipamorelin UK: Research Reference 2026 URL: https://hatipeptides.co.uk/research/ipamorelin Updated: 2026-06-05 Author: Hati Peptides Research reference for ipamorelin, a selective GH secretagogue that stimulates GH release via the ghrelin receptor without cortisol or prolactin stimulation. ## Overview Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a selective growth hormone secretagogue. The peptide stimulates growth hormone release through the ghrelin receptor (GHS-R1a) without significant stimulation of cortisol, prolactin, or other pituitary hormones. The peptide was developed as a more selective alternative to earlier GH secretagogues (GHRP-2, GHRP-6) that produced broader pituitary hormone responses. Ipamorelin's selectivity for GH release makes it a valuable tool for research into isolated GH axis manipulation. For UK research laboratories, ipamorelin serves as a reference compound for studies examining selective GH secretion, ghrelin receptor pharmacology, and the metabolic effects of isolated GH stimulation. ## Molecular Structure Ipamorelin is a synthetic pentapeptide with the following structural characteristics: • **Sequence**: Aib-His-D-2-Nal-D-Phe-Lys-NH2 • **Molecular weight**: Approximately 711.9 Da • **Modifications**: N-terminal amino-isobutyric acid (Aib); D-amino acids at positions 2-Nal and Phe • **C-terminus**: Amidated • **Receptor**: Ghrelin receptor (GHS-R1a) The D-amino acid substitutions and N-terminal Aib residue confer resistance to proteolytic degradation and enhance receptor binding affinity. The peptide's small size contributes to rapid cellular uptake and receptor access. The amidated C-terminus is typical for bioactive peptides and contributes to stability. ## Mechanism of Action Ipamorelin operates through the following mechanism in research models: **Ghrelin Receptor Activation** Ipamorelin binds to the ghrelin receptor (GHS-R1a), a Gq-coupled GPCR expressed in the pituitary, hypothalamus, and peripheral tissues. Receptor activation increases intracellular calcium and phospholipase C activity, leading to growth hormone secretion from somatotroph cells. In cellular models, the receptor activation is specific to GHS-R1a with minimal activity at related receptors. **Selective GH Secretion** Unlike earlier GH secretagogues (GHRP-2, GHRP-6), ipamorelin stimulates GH release without significant increases in cortisol, prolactin, or ACTH. This selectivity is attributed to differential intracellular signalling or receptor conformation stabilisation that favours GH-specific pathways. In cellular studies, ipamorelin's GH selectivity is maintained across a broad concentration range. **Metabolic Signalling** Through the ghrelin receptor, ipamorelin influences metabolic pathways beyond GH secretion. In cellular models, the peptide affects appetite-regulating circuits, glucose metabolism, and lipid handling. The ghrelin receptor is expressed in pancreatic islets, adipose tissue, and the gastrointestinal tract, creating multiple potential research endpoints. **GH-IGF-1 Axis** The primary physiological effect of ipamorelin is stimulation of the GH-IGF-1 axis. In research models, this leads to increased IGF-1 production, with downstream effects on protein synthesis, lipolysis, and cellular growth. The selective GH stimulation creates a cleaner model for studying GH-specific effects compared to broader pituitary stimulation. ## Research Applications Ipamorelin is employed across multiple research domains in UK laboratories: **Selective GH Secretion Studies** In vitro studies examine ipamorelin's selectivity for GH secretion compared to other pituitary hormones. Researchers use the peptide to model isolated GH axis stimulation, examining the cellular mechanisms that distinguish GH-specific from non-selective secretagogues. **Ghrelin Receptor Pharmacology** Ipamorelin serves as a tool compound for studying GHS-R1a receptor biology, biased agonism, and intracellular signalling. Research questions examine how different ligands produce different receptor conformational states and signalling profiles. **Metabolic Research** Cellular models examine ipamorelin's effects on metabolism, including glucose handling, lipid oxidation, and energy expenditure. The peptide's selectivity for GH release allows researchers to isolate GH-mediated metabolic effects from other hormonal influences. **Comparative Secretagogue Studies** Ipamorelin is compared to GHRP-2, GHRP-6, and other secretagogues in cellular and animal studies. Research questions address whether the increased selectivity of ipamorelin translates to different physiological outcomes in metabolic, body composition, and cellular growth endpoints. **Body Composition Research** In cellular and animal models, ipamorelin is studied in the context of fat metabolism, lean mass preservation, and tissue regeneration. The GH-IGF-1 axis is anabolic and lipolytic, supporting research into body composition regulation. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for ipamorelin studies: **Pituitary Cell Cultures** Primary pituitary cells and GH3 rat pituitary tumour cells are used to measure GH secretion in response to ipamorelin. Endpoints include GH release (RIA or ELISA), intracellular calcium flux, and phospholipase C activity. Selectivity is confirmed by measuring cortisol, prolactin, and ACTH in parallel. **Ghrelin Receptor Binding** Transfected cell lines expressing GHS-R1a are used to measure ipamorelin binding affinity and receptor activation. Competition binding assays and functional assays (calcium flux, IP3 accumulation) quantify receptor engagement and signalling. **Adipocyte Metabolism** 3T3-L1 adipocytes and primary human adipocytes are used to examine GH-mediated lipolysis and adipokine secretion. The effects of ipamorelin-induced GH release are compared to direct GH treatment. **Hepatocyte IGF-1 Production** Primary hepatocytes are used to measure GH-stimulated IGF-1 production. Endpoints include IGF-1 secretion, IGFBP production, and STAT5 signalling activation. **Myocyte Studies** C2C12 myotubes and primary muscle cells are used to examine GH-IGF-1-mediated protein synthesis and metabolic effects. Endpoints include amino acid uptake, protein synthesis, and glucose uptake. ## Safety Profile in Preclinical Research Ipamorelin's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens have not identified significant cytotoxicity at research-relevant concentrations. In animal studies, the peptide has been well tolerated, with effects limited to GH axis stimulation. The selectivity for GH release (without cortisol or prolactin stimulation) reduces the hormonal side effects observed with non-selective secretagogues. No organ-specific toxicity has been reported at standard research doses. The peptide's short half-life (approximately 2 hours) means rapid clearance, though this also necessitates more frequent dosing in research protocols. The small peptide size reduces immunogenicity concerns. Standard laboratory precautions apply: ipamorelin is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only. ## Reconstitution and Handling Ipamorelin is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation: • **Reconstitution**: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations • **Concentration**: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements • **Storage**: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light • **Stability**: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C • **Solubility**: The peptide is generally soluble in aqueous solutions; brief vortexing may aid dissolution • **Protease sensitivity**: The D-amino acid substitutions confer some protease resistance, but standard protease inhibitors may be included in incubation media The peptide's small size may result in non-specific binding to plastic surfaces; researchers should verify recovery rates. Pre-wetting tubes with BSA-containing buffer may reduce peptide loss. ## UK Research Status Ipamorelin is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. For UK research laboratories, ipamorelin is available as a research-grade reference material. Sourcing should include: • Certificate of Analysis confirming ≥98% purity (HPLC) • Mass spectrometry identity confirmation (molecular weight ~711.9 Da) • Batch-specific testing documentation • Appropriate storage and shipping conditions (cold chain) • Research-use-only labelling Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling. ## FAQs ### What is ipamorelin and how is it different from GHRP-2? Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that stimulates growth hormone release through the ghrelin receptor (GHS-R1a). Unlike GHRP-2, which stimulates GH, cortisol, and prolactin, ipamorelin is highly selective for GH release with minimal effects on other pituitary hormones. This selectivity makes it valuable for research into isolated GH axis manipulation. ### What is ipamorelin's mechanism in research models? Ipamorelin binds to the ghrelin receptor (GHS-R1a), a Gq-coupled GPCR in the pituitary. Receptor activation increases intracellular calcium and phospholipase C activity, leading to GH secretion from somatotroph cells. The peptide's selectivity for GH release (without cortisol or prolactin stimulation) is attributed to differential receptor signalling or conformation stabilisation that favours GH-specific pathways. ### What cellular models are used for ipamorelin research? Standard cellular models include: (1) primary pituitary cells and GH3 cells for GH secretion and selectivity studies; (2) transfected cell lines expressing GHS-R1a for receptor binding and signalling; (3) 3T3-L1 adipocytes for lipolysis and adipokine studies; (4) primary hepatocytes for IGF-1 production; and (5) C2C12 myotubes for protein synthesis studies. ### Is ipamorelin legal for research in the UK? Yes. Ipamorelin is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase and possess for legitimate laboratory research. It is not licensed as a medicine by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for ipamorelin research? Research-grade ipamorelin should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the pentapeptide sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and molecular weight (~711.9 Da). The D-amino acid substitutions should be confirmed by chiral analysis or specific enzymatic digestion. Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. ## References - [Raun K et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res 2001;11:266-272.](https://pubmed.ncbi.nlm.nih.gov/11735244/) - [Sibilia V et al. The ghrelin agonist ipamorelin increases the basal and stimulated growth hormone secretion in rats. J Endocrinol Invest 2003;26:RC10-RC13.](https://pubmed.ncbi.nlm.nih.gov/12952373/) - [Johansen PB et al. Ipamorelin, a selective growth hormone secretagogue. Eur J Endocrinol 1998;139:424-429.](https://pubmed.ncbi.nlm.nih.gov/9792553/) - [Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone secretagogue. Pharm Res 1999;16:1412-1416.](https://pubmed.ncbi.nlm.nih.gov/10554096/) - [Pituitary cell cultures for growth hormone secretion studies. Methods Mol Biol 2014;1158:143-154.](https://pubmed.ncbi.nlm.nih.gov/24839037/) --- # BPC-157 UK: Research Reference 2026 URL: https://hatipeptides.co.uk/research/bpc-157 Updated: 2026-06-05 Author: Hati Peptides Research reference for BPC-157, a synthetic pentadecapeptide investigated in regenerative, gastrointestinal, and musculoskeletal research. ## Overview BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a partial sequence of the human gastric protein Body Protection Compound (BPC). The peptide has been investigated in preclinical research for its effects on tissue regeneration, wound healing, and gastrointestinal integrity. The sequence is a partial replica of the 193-amino-acid BPC protein found in human gastric juice. The synthetic 15-mer retains the bioactive domain of the parent protein and is more stable and bioavailable than the full-length sequence. For UK research laboratories, BPC-157 serves as a reference compound for studies examining tissue regeneration, angiogenesis, and the protective mechanisms of gastric-derived peptides. The peptide is not licensed as a medicine and is supplied for research use only. ## Molecular Structure BPC-157 is a pentadecapeptide with the following structural characteristics: • **Sequence**: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids) • **Molecular weight**: Approximately 1,419 Da • **N-terminus**: Free amine • **C-terminus**: Free carboxyl • **Origin**: Synthetic analogue of a partial sequence from human gastric BPC The peptide contains multiple proline residues, which confer structural rigidity and resistance to proteolytic degradation. The absence of complex post-translational modifications contributes to stability during storage and handling. The relatively small size and simple sequence facilitate reproducible synthesis and characterisation. ## Mechanism of Action BPC-157 operates through several mechanisms in cellular and in vitro models: **Angiogenesis Promotion** In cellular studies, BPC-157 upregulates vascular endothelial growth factor (VEGF) and stimulates endothelial cell proliferation and migration. The peptide promotes formation of new blood vessels in wound-healing models, supporting tissue perfusion and regenerative processes. This angiogenic activity is examined in endothelial cell cultures and ex vivo vessel sprouting assays. **Tendon and Ligament Healing** In fibroblast and tenocyte cultures, BPC-157 increases collagen synthesis and extracellular matrix deposition. The peptide stimulates fibroblast migration and proliferation in wound-healing assays, supporting the cellular basis for connective tissue repair. Research models examine tendon explant healing and fibroblast scratch assays. **Gastrointestinal Protection** Derived from a gastric protein, BPC-157 has been studied in gastrointestinal epithelial cell models. In cellular studies, the peptide maintains epithelial integrity under stress conditions and supports mucosal barrier function. Research examines effects on tight junction proteins and epithelial cell viability. **Anti-Inflammatory Signalling** BPC-157 modulates inflammatory mediator production in cellular models. The peptide reduces pro-inflammatory cytokine secretion in activated macrophage cultures and modulates NF-κB signalling. These anti-inflammatory effects are examined in the context of tissue repair and chronic inflammation models. **Nitric Oxide Pathway** The peptide interacts with the nitric oxide system in endothelial and vascular models. BPC-157 upregulates endothelial nitric oxide synthase (eNOS) expression and increases NO production, which supports vasodilation and tissue perfusion in regenerative processes. ## Research Applications BPC-157 is employed across multiple research domains in UK laboratories: **Regenerative Medicine Research** In vitro studies examine BPC-157's effects on tissue regeneration, wound healing, and angiogenesis. Researchers use cellular models to study the peptide's effects on fibroblast migration, collagen synthesis, and endothelial tube formation. **Musculoskeletal Research** Tendon, ligament, and bone cell cultures are used to examine BPC-157's effects on connective tissue healing. Research questions address whether the peptide accelerates matrix deposition, improves cellular viability under stress, and supports tissue integration. **Gastrointestinal Research** Epithelial cell models examine BPC-157's effects on mucosal integrity, tight junction maintenance, and epithelial repair. The peptide's gastric origin makes it relevant for research into gastrointestinal protective mechanisms. **Vascular Biology** Endothelial cell models examine BPC-157's effects on angiogenesis, vessel formation, and vascular permeability. The peptide's interaction with VEGF and NO pathways creates research questions about vascular regeneration. **Comparative Healing Peptides** BPC-157 is compared to other regenerative peptides (TB-500, GHK-Cu) in cellular studies. Research questions examine whether different peptide mechanisms produce synergistic or additive effects in tissue repair models. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for BPC-157 studies: **Fibroblast Wound Healing** Primary fibroblasts and fibroblast cell lines are used in scratch assays to measure migration and proliferation in response to BPC-157. Endpoints include wound closure rate, collagen I/III deposition, and α-SMA expression. **Endothelial Tube Formation** HUVEC and other endothelial cell lines are used in Matrigel tube formation assays to examine angiogenic effects. Endpoints include tube length, branch points, and network complexity. VEGF and NO production are measured in parallel. **Tendon Explant Cultures** Ex vivo tendon and ligament explants are maintained in culture to examine tissue-level healing. BPC-157 is added to culture media, and endpoints include tissue strength, collagen organisation, and cell viability. **Epithelial Barrier Integrity** Caco-2 and other intestinal epithelial cell lines are used to measure transepithelial electrical resistance (TEER) and tight junction protein expression (claudin, occludin, ZO-1) in response to BPC-157 under stress conditions. **Macrophage Inflammation** RAW 264.7 and primary macrophages are activated with LPS, then treated with BPC-157 to examine effects on cytokine production (TNF-α, IL-6, IL-10) and NF-κB activation. ## Safety Profile in Preclinical Research BPC-157's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens have not identified significant cytotoxicity at research-relevant concentrations. In animal toxicology studies, the peptide has been well tolerated at standard research doses. The gastric origin of the parent protein suggests low inherent toxicity, though the synthetic peptide's effects may differ from the native sequence. No organ-specific toxicity has been reported at standard doses. The peptide's stability in gastric juice has been examined in vitro, with resistance to pepsin degradation reported. This stability may contribute to oral bioavailability in animal models, though cellular and in vitro studies typically use direct application. Standard laboratory precautions apply: BPC-157 is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only. ## Reconstitution and Handling BPC-157 is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation: • **Reconstitution**: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations • **Concentration**: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements • **Storage**: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light • **Stability**: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C • **Solubility**: The peptide is generally soluble in aqueous solutions; brief vortexing may aid dissolution • **Gastric stability**: The peptide shows resistance to pepsin degradation in vitro, though this is assay-dependent The peptide's stability in acidic environments may be relevant for gastrointestinal research models. Standard peptide handling precautions apply. ## UK Research Status BPC-157 is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. For UK research laboratories, BPC-157 is available as a research-grade reference material. Sourcing should include: • Certificate of Analysis confirming ≥98% purity (HPLC) • Mass spectrometry identity confirmation (molecular weight ~1,419 Da) • Batch-specific testing documentation • Appropriate storage and shipping conditions (cold chain) • Research-use-only labelling Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling. ## FAQs ### What is BPC-157 and where does it come from? BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of the human Body Protection Compound (BPC), a protein found in gastric juice. The synthetic peptide represents the bioactive domain of the parent protein and is designed to be more stable and bioavailable than the full-length sequence. ### What is BPC-157's primary mechanism in research models? BPC-157 promotes tissue regeneration through multiple mechanisms in cellular models: upregulation of VEGF and angiogenesis, stimulation of fibroblast migration and collagen synthesis, maintenance of epithelial integrity, modulation of inflammatory mediators, and enhancement of nitric oxide production. These effects are examined in wound-healing, tendon repair, and gastrointestinal protection models. ### What cellular models are used for BPC-157 research? Standard cellular models include: (1) fibroblast scratch assays for wound healing; (2) HUVEC tube formation assays for angiogenesis; (3) ex vivo tendon explants for connective tissue repair; (4) Caco-2 epithelial cells for barrier integrity; and (5) macrophage cultures for inflammation studies. Multi-cellular co-culture systems are also used to examine paracrine effects. ### Is BPC-157 legal for research in the UK? Yes. BPC-157 is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase and possess for legitimate laboratory research. It is not licensed as a medicine by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for BPC-157 research? Research-grade BPC-157 should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 15-amino-acid sequence and molecular weight (~1,419 Da). The multiple proline residues may create synthesis challenges, making sequence verification particularly important. Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. ## References - [Sikiric P et al. Stable gastric pentadecapeptide BPC 157: multiple organoprotection and therapeutic possibilities. Curr Pharm Des 2020;26:3947-3957.](https://pubmed.ncbi.nlm.nih.gov/32697396/) - [Sikiric P et al. The gastrointestinal tract and stable gastric pentadecapeptide BPC 157: focus on the stomach. Expert Opin Biol Ther 2020;20:1371-1385.](https://pubmed.ncbi.nlm.nih.gov/32571147/) - [Gwyer D et al. The stable gastric pentadecapeptide BPC 157: an overview of the current status. Curr Pharm Des 2020;26:3967-3978.](https://pubmed.ncbi.nlm.nih.gov/32571150/) - [Sikiric P et al. BPC 157 and its effects on healing. Life Sci 2020;259:118198.](https://pubmed.ncbi.nlm.nih.gov/32721584/) - [Huang T et al. Body protective compound-157 enhances alkali burn wound healing in a rat model. Wound Repair Regen 2015;23:657-663.](https://pubmed.ncbi.nlm.nih.gov/25948335/) --- # TB-500 UK: Research Reference 2026 URL: https://hatipeptides.co.uk/research/tb-500 Updated: 2026-06-05 Author: Hati Peptides Research reference for TB-500 (Thymosin Beta-4), a 43-amino-acid peptide involved in actin regulation, wound healing, and cellular migration. ## Overview TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide that is a synthetic version of the endogenous protein Thymosin Beta-4 (Tβ4). The peptide is found in high concentrations in blood platelets, wound fluid, and regenerating tissues, and has been studied for its role in wound healing, cellular migration, and tissue regeneration. The peptide is an actin-sequestering protein that regulates the cytoskeleton and influences cell motility, migration, and differentiation. Thymosin Beta-4 is the most abundant member of the beta-thymosin family and is highly conserved across species. For UK research laboratories, TB-500 serves as a reference compound for studies examining actin dynamics, wound healing, and cellular migration. The peptide is not licensed as a medicine and is supplied for research use only. ## Molecular Structure TB-500 is a 43-amino-acid peptide with the following structural characteristics: • **Sequence**: 43 amino acids (Ac-SDKP sequence with central actin-binding domain) • **Molecular weight**: Approximately 4,963 Da • **N-terminus**: Acetylated (Ac-SDKP) • **C-terminus**: Free carboxyl • **Origin**: Synthetic version of endogenous Thymosin Beta-4 The peptide contains an actin-binding domain (residues 17-23) that is critical for its biological activity. The N-terminal SDKP sequence is the same as the anti-fibrotic tetrapeptide, which may contribute to anti-inflammatory effects. The peptide is highly conserved across mammalian species, with >95% sequence identity. ## Mechanism of Action TB-500 operates through several mechanisms in cellular and in vitro models: **Actin Regulation** TB-500 is an actin-sequestering protein that binds to G-actin (monomeric actin) and prevents its polymerisation into F-actin. This regulation of the actin cytoskeleton influences cell motility, migration, and shape. In cellular models, TB-500 promotes lamellipodia formation and directional cell migration, which are critical for wound healing. **Cellular Migration** The peptide enhances cell migration in wound-healing models. In fibroblast and epithelial cell cultures, TB-500 increases the rate of scratch wound closure through enhanced migration and proliferation. The actin-regulating activity is central to this migratory effect, as the cytoskeleton must remodel for cell movement. **Angiogenesis** TB-500 promotes angiogenesis in endothelial cell models. The peptide stimulates endothelial cell migration, tube formation, and vessel sprouting. The mechanism involves upregulation of VEGF and other angiogenic factors, as well as direct effects on endothelial cell motility. **Anti-Inflammatory Effects** The peptide modulates inflammatory responses in cellular models. TB-500 reduces pro-inflammatory cytokine production and promotes anti-inflammatory signalling. The N-terminal SDKP sequence may contribute to anti-fibrotic and anti-inflammatory effects through distinct pathways from the actin-binding domain. **Tissue Regeneration** In regenerative models, TB-500 supports tissue repair through multiple mechanisms: enhanced cell migration, reduced inflammation, increased angiogenesis, and modulation of the extracellular matrix. The peptide's effects on multiple regenerative processes make it relevant for wound healing and tissue repair research. ## Research Applications TB-500 is employed across multiple research domains in UK laboratories: **Wound Healing Research** In vitro studies examine TB-500's effects on wound closure, cellular migration, and tissue regeneration. Researchers use scratch assays, organotypic cultures, and tissue explants to model wound healing and examine the peptide's effects on repair processes. **Musculoskeletal Research** Tendon, ligament, and muscle cell cultures are used to examine TB-500's effects on connective tissue repair. The peptide's actin-regulating activity is relevant for myocyte and fibroblast function in tissue repair models. **Cardiovascular Research** Endothelial and cardiac cell models examine TB-500's effects on angiogenesis, vascular repair, and cardioprotection. The peptide's role in vessel formation and tissue perfusion is relevant for ischemia and vascular injury models. **Ocular Research** Corneal epithelial and endothelial cell models examine TB-500's effects on ocular wound healing. The peptide's promotion of epithelial migration and wound closure is relevant for corneal injury and surgical repair models. **Comparative Regenerative Peptides** TB-500 is compared to BPC-157 and other regenerative peptides in cellular studies. Research questions examine whether different mechanisms (actin regulation vs. angiogenic signalling) produce complementary effects in tissue repair. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for TB-500 studies: **Fibroblast Scratch Assays** Primary fibroblasts and fibroblast cell lines are used in scratch wound assays to measure migration and proliferation. Endpoints include wound closure rate, actin cytoskeleton organisation, and lamellipodia formation. Time-lapse microscopy is used to track cell migration dynamics. **Endothelial Tube Formation** HUVEC and other endothelial cell lines are used in Matrigel tube formation assays to examine angiogenic effects. Endpoints include tube length, branch points, and network complexity. VEGF and NO production are measured in parallel. **Epithelial Wound Healing** Corneal epithelial cells and skin keratinocytes are used in scratch assays to examine wound closure. The peptide's effects on epithelial migration, proliferation, and differentiation are examined in organotypic cultures. **Myocyte Studies** Primary cardiomyocytes and skeletal muscle cells are used to examine TB-500's effects on cell survival, migration, and regeneration. Endpoints include cell viability under stress, metabolic activity, and cytoskeletal organisation. **Actin Cytoskeleton** Fluorescent phalloidin staining is used to examine F-actin organisation in response to TB-500. Cell shape, stress fibre formation, and lamellipodia dynamics are quantified in fibroblast and endothelial cells. ## Safety Profile in Preclinical Research TB-500's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens have not identified significant cytotoxicity at research-relevant concentrations. In animal studies, the peptide has been well tolerated at standard research doses. The endogenous nature of Thymosin Beta-4 suggests low inherent toxicity, as the peptide is naturally present in human tissues and blood. No organ-specific toxicity has been reported at standard doses. The peptide's effects on cell migration raise theoretical considerations about promoting migration in non-target cells, though this has not been observed as a specific safety concern in preclinical studies. Standard laboratory precautions apply: TB-500 is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only. ## Reconstitution and Handling TB-500 is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation: • **Reconstitution**: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations • **Concentration**: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements • **Storage**: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light • **Stability**: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C • **Solubility**: The peptide is generally soluble in aqueous solutions; brief vortexing may aid dissolution • **Actin binding**: The peptide binds to G-actin; researchers should account for this in cellular assays measuring actin dynamics The peptide's stability and solubility are generally favourable, though standard peptide handling precautions apply. ## UK Research Status TB-500 is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. For UK research laboratories, TB-500 is available as a research-grade reference material. Sourcing should include: • Certificate of Analysis confirming ≥98% purity (HPLC) • Mass spectrometry identity confirmation (molecular weight ~4,963 Da) • Batch-specific testing documentation • Appropriate storage and shipping conditions (cold chain) • Research-use-only labelling Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling. ## FAQs ### What is TB-500 and how does it work? TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide that is a synthetic version of the endogenous protein Thymosin Beta-4. The peptide works primarily by regulating the actin cytoskeleton, sequestering G-actin and promoting cell migration. This actin-regulating activity supports wound healing, angiogenesis, and tissue regeneration in cellular models. ### What is the difference between TB-500 and BPC-157? TB-500 and BPC-157 have different primary mechanisms. TB-500 primarily regulates actin cytoskeleton dynamics and promotes cell migration, while BPC-157 focuses on angiogenesis, fibroblast activation, and gastrointestinal protection. In cellular studies, the two peptides produce complementary effects on tissue repair, and researchers may use them together to examine synergistic regenerative outcomes. ### What cellular models are used for TB-500 research? Standard cellular models include: (1) fibroblast scratch assays for wound healing and migration; (2) HUVEC tube formation assays for angiogenesis; (3) corneal epithelial cells for ocular wound healing; (4) cardiomyocytes for cardiac protection; and (5) fluorescent actin staining for cytoskeletal dynamics. Time-lapse microscopy is commonly used to track cell migration in real time. ### Is TB-500 legal for research in the UK? Yes. TB-500 is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase and possess for legitimate laboratory research. It is not licensed as a medicine by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for TB-500 research? Research-grade TB-500 should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 43-amino-acid sequence and molecular weight (~4,963 Da). The N-terminal acetylation should be confirmed by mass spectrometry (molecular weight shift). Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. ## References - [Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012;12:37-51.](https://pubmed.ncbi.nlm.nih.gov/22074294/) - [Philp D et al. Thymosin beta4 increases hair growth by activating stem cells. FASEB J 2004;18:385-387.](https://pubmed.ncbi.nlm.nih.gov/14715544/) - [Sosne G et al. Thymosin beta4 promotes corneal wound healing and modulates inflammatory mediators. Invest Ophthalmol Vis Sci 2001;42:2013-2019.](https://pubmed.ncbi.nlm.nih.gov/11481263/) - [Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999;113:364-368.](https://pubmed.ncbi.nlm.nih.gov/10469315/) - [Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and repair. Nature 2004;432:466-472.](https://pubmed.ncbi.nlm.nih.gov/15565145/) --- # GHK-Cu UK: Research Reference 2026 URL: https://hatipeptides.co.uk/research/ghk-cu Updated: 2026-06-05 Author: Hati Peptides Research reference for GHK-Cu (glycyl-L-histidyl-L-lysine copper), a copper-binding tripeptide involved in wound healing, collagen synthesis, and tissue regeneration. ## Overview GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a copper-binding tripeptide that occurs naturally in human plasma, saliva, and urine. The peptide was first identified in 1973 by Pickart and has been studied extensively for its role in wound healing, tissue regeneration, and extracellular matrix remodelling. The peptide binds copper ions with high affinity, forming a stable complex that delivers copper to tissues and modulates gene expression. GHK-Cu levels decline with age, falling from approximately 200 ng/mL at age 20 to about 80 ng/mL at age 60. For UK research laboratories, GHK-Cu serves as a reference compound for studies examining copper metabolism, wound healing, and tissue regeneration. The peptide is not licensed as a medicine and is supplied for research use only. ## Molecular Structure GHK-Cu is a tripeptide-copper complex with the following structural characteristics: • **Sequence**: Glycyl-L-histidyl-L-lysine (3 amino acids) • **Molecular weight (free peptide)**: ~340 Da • **Molecular weight (copper complex)**: ~400 Da • **Copper binding**: High affinity (2:1 peptide:copper ratio) • **Coordination**: Copper binds to nitrogen atoms from the glycine α-amine, histidine imidazole, and lysine ε-amine The copper coordination is critical for biological activity. The 2:1 stoichiometry means two GHK molecules bind one copper ion, creating a stable square-planar complex. This copper delivery mechanism is central to the peptide's biological effects. ## Mechanism of Action GHK-Cu operates through several mechanisms in cellular and in vitro models: **Copper Delivery** GHK-Cu functions as a copper carrier, delivering copper to tissues in a bioavailable form. Copper is essential for the activity of enzymes involved in collagen cross-linking (lysyl oxidase), antioxidant defence (superoxide dismutase), and angiogenesis. In cellular models, GHK-Cu increases copper-dependent enzyme activity. **Gene Expression Modulation** Transcriptomic studies show GHK-Cu modulates the expression of approximately 4,000 genes, primarily those involved in tissue remodelling, antioxidant defence, and anti-inflammatory pathways. The mechanism involves copper-mediated effects on transcription factor activity and epigenetic regulation. **Wound Healing** The peptide promotes wound healing through multiple pathways: stimulation of fibroblast migration, increased collagen and elastin synthesis, enhanced angiogenesis, and modulation of growth factor expression. In cellular models, GHK-Cu accelerates wound closure in scratch assays. **Anti-Inflammatory Effects** GHK-Cu reduces inflammatory cytokine production in cellular models. The peptide modulates TGF-β signalling, reducing fibrotic responses while promoting regenerative tissue repair. The anti-inflammatory effects are examined in macrophage and fibroblast co-cultures. **Antioxidant Activity** The copper complex has antioxidant activity, scavenging free radicals and reducing oxidative stress in cellular models. The peptide upregulates antioxidant enzyme expression, including superoxide dismutase and catalase. ## Research Applications GHK-Cu is employed across multiple research domains in UK laboratories: **Wound Healing Research** In vitro studies examine GHK-Cu's effects on wound closure, fibroblast migration, and collagen synthesis. Researchers use scratch assays, organotypic cultures, and tissue explants to examine the peptide's regenerative effects. **Skin and Dermal Research** Dermal fibroblast and keratinocyte cultures are used to examine GHK-Cu's effects on extracellular matrix production, skin barrier function, and cellular senescence. The peptide's effects on collagen types I, III, and IV are quantified. **Hair Follicle Research** Dermal papilla cells and hair follicle cultures examine GHK-Cu's effects on hair growth, follicle size, and hair cycle regulation. The peptide's stimulation of follicle cell proliferation is studied in organ cultures. **Anti-Ageing Research** Cellular senescence models examine GHK-Cu's effects on senescence markers, telomere maintenance, and age-related gene expression changes. The peptide's upregulation of tissue repair genes is relevant for ageing research. **Comparative Regenerative Peptides** GHK-Cu is compared to BPC-157, TB-500, and other regenerative peptides in cellular studies. Research questions examine whether copper delivery produces unique regenerative effects compared to peptide-only approaches. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for GHK-Cu studies: **Fibroblast Scratch Assays** Primary dermal fibroblasts are used in scratch wound assays to measure migration and proliferation. Endpoints include wound closure rate, collagen I/III deposition, and elastin synthesis. The copper complex is compared to free GHK peptide. **Collagen Synthesis** Fibroblast cultures are used to measure collagen production in response to GHK-Cu. Hydroxyproline assays, collagen ELISAs, and Sirius Red staining quantify extracellular matrix deposition. Type-specific collagen synthesis (I, III, IV) is examined by qPCR and Western blot. **Endothelial Tube Formation** HUVEC cultures are used to examine angiogenic effects. Tube formation, sprouting, and VEGF production are measured in response to GHK-Cu treatment. The copper-dependent mechanism is confirmed by comparison with copper-free controls. **Antioxidant Assays** Cellular antioxidant capacity is measured by ROS scavenging, superoxide dismutase activity, and lipid peroxidation markers. The copper complex's antioxidant effects are compared to free GHK and copper salts. **Dermal Papilla Cells** Hair follicle dermal papilla cells are used to examine proliferation and hair growth factor secretion. The peptide's effects on IGF-1, VEGF, and other follicle-regulatory factors are quantified. ## Safety Profile in Preclinical Research GHK-Cu's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens have not identified significant cytotoxicity at research-relevant concentrations. In animal studies, the peptide has been well tolerated at standard research doses. The endogenous nature of GHK (naturally present in human plasma) suggests low inherent toxicity. No organ-specific toxicity has been reported at standard doses. The copper component raises considerations about copper overload at very high doses, though the 2:1 peptide:copper ratio and standard research concentrations are not associated with copper toxicity. The peptide's role in copper transport may actually protect against copper-mediated oxidative damage. Standard laboratory precautions apply: GHK-Cu is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only. ## Reconstitution and Handling GHK-Cu is supplied as a lyophilised powder (usually as the copper complex) in research-grade vials. Standard laboratory preparation: • **Reconstitution**: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations • **Concentration**: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements • **Storage**: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light • **Stability**: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C • **Solubility**: The copper complex is generally soluble in aqueous solutions; the blue-violet colour confirms intact copper coordination • **Copper confirmation**: The characteristic blue-violet colour of the reconstituted solution indicates intact copper complex formation The copper complex is light-sensitive; prolonged light exposure may cause copper photoreduction. Protect solutions from light during storage and incubation. ## UK Research Status GHK-Cu is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. For UK research laboratories, GHK-Cu is available as a research-grade reference material. Sourcing should include: • Certificate of Analysis confirming ≥98% purity (HPLC) • Mass spectrometry identity confirmation (molecular weight ~400 Da for copper complex) • Copper stoichiometry confirmation (2:1 peptide:copper ratio) • Batch-specific testing documentation • Appropriate storage and shipping conditions (cold chain) • Research-use-only labelling Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling. ## FAQs ### What is GHK-Cu and what does it do? GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a copper-binding tripeptide that occurs naturally in human plasma. The peptide delivers copper to tissues in a bioavailable form, modulates gene expression (approximately 4,000 genes), promotes wound healing, stimulates collagen synthesis, and has antioxidant activity. In cellular models, it promotes fibroblast migration, angiogenesis, and extracellular matrix production. ### Why does GHK-Cu contain copper? The copper component is essential for biological activity. GHK functions as a copper carrier, delivering copper to copper-dependent enzymes including lysyl oxidase (collagen cross-linking), superoxide dismutase (antioxidant defence), and tyrosinase. The 2:1 peptide:copper ratio creates a stable complex that transports copper safely without the toxicity of free copper ions. The blue-violet colour of the reconstituted solution indicates intact copper coordination. ### What cellular models are used for GHK-Cu research? Standard cellular models include: (1) dermal fibroblast scratch assays for wound healing; (2) collagen synthesis assays for extracellular matrix production; (3) HUVEC tube formation for angiogenesis; (4) dermal papilla cells for hair follicle research; (5) antioxidant assays for ROS scavenging; and (6) cellular senescence models for ageing research. The copper complex is often compared to free GHK peptide to isolate copper-dependent effects. ### Is GHK-Cu legal for research in the UK? Yes. GHK-Cu is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase and possess for legitimate laboratory research. It is not licensed as a medicine by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for GHK-Cu research? Research-grade GHK-Cu should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the tripeptide sequence and copper complex formation. The copper stoichiometry should be confirmed (2:1 peptide:copper ratio, molecular weight ~400 Da). The blue-violet colour of reconstituted solution is a visual indicator of intact copper complex. Batch-specific Certificates of Analysis should document purity, identity, copper content, and endotoxin levels. ## References - [Pickart L. The human tripeptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008;19:969-988.](https://pubmed.ncbi.nlm.nih.gov/18644247/) - [Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015;2015:648108.](https://pubmed.ncbi.nlm.nih.gov/25839058/) - [Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018;19:1987.](https://pubmed.ncbi.nlm.nih.gov/30154310/) - [Maquart FX et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex GHK-Cu. J Clin Invest 1993;92:2368-2376.](https://pubmed.ncbi.nlm.nih.gov/8254018/) - [Simeon A et al. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex GHK-Cu. J Invest Dermatol 1999;112:957-964.](https://pubmed.ncbi.nlm.nih.gov/10383753/) --- # Semaglutide UK: Research Reference 2026 URL: https://hatipeptides.co.uk/research/semaglutide Updated: 2026-06-05 Author: Hati Peptides Research reference for semaglutide, a long-acting GLP-1 receptor agonist used in metabolic and appetite signalling research. ## Overview Semaglutide is a synthetic peptide analogue of human glucagon-like peptide-1 (GLP-1) with a modified amino acid sequence that confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation and high affinity binding to serum albumin. The peptide is a 31-amino-acid sequence with a fatty-diacid side chain attached to a lysine residue at position 26, enabling prolonged half-life through albumin association. The structural modifications include a single amino acid substitution at position 8 (alanine replaced by alpha-aminoisobutyric acid, Aib), which prevents DPP-4 cleavage and extends the peptide's biological activity. The C18 fatty-diacid chain at Lys26, linked via a gamma-glutamyl spacer and a polyethylene glycol (PEG) linker, facilitates non-covalent albumin binding, extending the plasma half-life to approximately 7 days in research models. For UK research laboratories, semaglutide serves as a reference compound for studies examining GLP-1 receptor pharmacology, metabolic regulation, and the mechanisms of sustained incretin receptor activation in cellular and animal models. ## Molecular Structure Semaglutide is a 31-amino-acid peptide with the following structural characteristics: • **Sequence**: 31 amino acids with N-terminal histidine and C-terminal glycine • **Molecular weight**: Approximately 4,114 Da • **Modifications**: Aib substitution at position 8 (DPP-4 resistance); C18 fatty-diacid chain at Lys26 via γ-Glu-2xAdo-PEG linker • **Albumin binding**: The lipid chain facilitates non-covalent albumin association, extending plasma half-life to ~7 days • **C-terminus**: Native amidation The Aib substitution at position 8 is critical for DPP-4 resistance. DPP-4 cleaves native GLP-1 after Ala8, resulting in a 1.5-minute half-life. The Aib substitution prevents this cleavage, extending the half-life to hours. The fatty-diacid chain further extends the half-life to days through albumin binding, creating a once-weekly pharmacokinetic profile in research protocols. ## Mechanism of Action Semaglutide operates through the following mechanism in research models: **GLP-1 Receptor Agonism** Semaglutide binds to the GLP-1 receptor (GLP-1R), a class B GPCR expressed in pancreatic beta cells, gastric mucosa, and the central nervous system. Receptor activation increases intracellular cAMP, leading to protein kinase A activation, enhanced insulin gene transcription, and glucose-dependent insulin secretion. In cellular models, GLP-1R activation triggers delayed gastric emptying and central satiety signalling. **DPP-4 Resistance** The Aib8 substitution prevents cleavage by DPP-4, the enzyme that rapidly degrades native GLP-1. This structural modification allows semaglutide to maintain receptor occupancy for extended periods, enabling sustained signalling in cellular incubations and prolonged pharmacodynamic effects in animal models. **Albumin Binding and Half-Life Extension** The C18 fatty-diacid chain at Lys26 facilitates non-covalent binding to serum albumin. This albumin association acts as a circulating reservoir, slowly releasing free peptide for receptor engagement. The albumin-bound fraction protects the peptide from renal clearance and enzymatic degradation, creating a sustained exposure profile. **Metabolic Signalling** Through GLP-1R activation, semaglutide influences multiple metabolic pathways: enhanced glucose-dependent insulin secretion, suppression of glucagon release in hyperglycaemic states, delayed gastric emptying, and activation of brainstem satiety circuits. In cellular studies, these effects are quantified as insulin secretion rate, glucagon suppression, and neuronal activation patterns. ## Research Applications Semaglutide is employed across multiple research domains in UK laboratories: **Metabolic Disease Research** In vitro studies examine semaglutide's effects on insulin secretion, glucagon suppression, and glucose uptake in isolated islet and hepatocyte cultures. Researchers use the peptide to study sustained GLP-1 receptor activation, comparing the extended pharmacokinetic profile to short-acting GLP-1 analogues in terms of signalling amplitude and receptor desensitisation. **Appetite and Satiety Research** Cellular models of hypothalamic and brainstem neuronal cultures examine semaglutide's effects on appetite-regulating circuits. The peptide's central GLP-1R activation is studied in the context of satiety signalling, food intake regulation, and the neural mechanisms of energy balance. **Gastrointestinal Motility** In vitro studies of gastric smooth muscle and intestinal epithelial cells examine semaglutide's effects on motility, gastric emptying rate, and intestinal transit. The peptide's delayed gastric emptying effect is studied in organotypic cultures and tissue explants. **Comparative Incretin Pharmacology** Semaglutide is compared to other GLP-1 receptor agonists (liraglutide, dulaglutide, exenatide) in cellular receptor-binding assays and functional studies. Research questions examine whether the extended half-life and sustained receptor activation produce different metabolic outcomes compared to shorter-acting compounds. **Receptor Desensitisation Studies** The sustained exposure profile of semaglutide raises research questions about GLP-1 receptor desensitisation and downregulation. Long-term cellular incubations examine whether continuous agonist exposure alters receptor density, signalling efficiency, or cellular responsiveness. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for semaglutide studies: **Insulin Secretion Assays** Isolated rodent islets and beta-cell lines (MIN6, INS-1) are used to measure glucose-stimulated insulin secretion in response to semaglutide. Endpoints include insulin secretion rate, intracellular calcium flux, and cAMP accumulation. The peptide's sustained activity is compared to native GLP-1 and short-acting analogues. **Receptor Binding Studies** Competition binding assays using radioligands or fluorescent probes measure semaglutide's affinity at the GLP-1 receptor in transfected cell lines. The peptide's receptor occupancy kinetics are examined over extended incubation periods to assess sustained binding. **Hepatocyte Glucose Metabolism** Primary hepatocytes and hepatoma cell lines are used to examine glucagon suppression and gluconeogenic gene expression in response to semaglutide. The peptide's effects on hepatic glucose output are compared to other GLP-1R agonists. **Neuronal Satiety Circuits** Hypothalamic and brainstem neuronal cultures examine GLP-1R-mediated activation of satiety circuits. Calcium imaging and electrophysiological recordings quantify neuronal responses to semaglutide and other incretins. **Gastric Smooth Muscle** Ex vivo gastric smooth muscle strips and organotypic cultures examine the peptide's effects on contractility and gastric emptying. The sustained GLP-1R activation is studied in the context of gastrointestinal motility regulation. ## Safety Profile in Preclinical Research Semaglutide's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens using standard cell lines have not identified significant cytotoxicity at research-relevant concentrations (up to 100 μM). In animal toxicology studies, the primary findings are consistent with the peptide's pharmacological mechanism: transient gastrointestinal effects (delayed gastric emptying), suppressed appetite, and dose-dependent metabolic changes. No organ-specific toxicity has been reported at standard research doses. The peptide's extended half-life (approximately 7 days) means that researchers must account for sustained exposure when designing sequential studies. The albumin-binding profile may alter tissue distribution compared to unmodified peptides, requiring consideration in pharmacokinetic studies. Standard laboratory precautions apply: semaglutide is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only. ## Reconstitution and Handling Semaglutide is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation: • **Reconstitution**: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations • **Concentration**: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements • **Storage**: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light • **Stability**: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C • **Solubility**: The peptide is generally soluble in aqueous solutions; the fatty-diacid chain may require gentle vortexing and brief warming (not exceeding 37 °C) to aid dissolution • **Albumin binding**: The lipid chain facilitates albumin binding; researchers should account for this in binding assays and cellular incubations Peptide stability is pH-dependent; maintain solutions at pH 7.0–7.5. Avoid repeated freeze-thaw cycles. The fatty-diacid moiety may adsorb to plastic surfaces; pre-wetting tubes with buffer containing 0.1% BSA may reduce peptide loss. ## UK Research Status Semaglutide is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. For UK research laboratories, semaglutide is available as a research-grade reference material. Sourcing should include: • Certificate of Analysis confirming ≥98% purity (HPLC) • Mass spectrometry identity confirmation (molecular weight ~4,114 Da) • Confirmation of Aib8 substitution and fatty-diacid chain attachment • Batch-specific testing documentation • Appropriate storage and shipping conditions (cold chain) • Research-use-only labelling Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling. ## FAQs ### What is semaglutide and how does it differ from native GLP-1? Semaglutide is a synthetic 31-amino-acid peptide analogue of human GLP-1 with two key modifications: an Aib substitution at position 8 (preventing DPP-4 cleavage) and a C18 fatty-diacid chain at Lys26 (enabling albumin binding). These modifications extend the half-life from 1.5 minutes (native GLP-1) to approximately 7 days in research models. The extended half-life allows for sustained receptor activation in cellular and animal studies, enabling researchers to examine the effects of prolonged GLP-1R signalling. ### What is semaglutide's primary mechanism in research models? Semaglutide is a long-acting GLP-1 receptor agonist. In cellular and animal models, it activates the GLP-1 receptor (a class B GPCR) on pancreatic beta cells, gastric mucosa, and central nervous system neurons. The Aib8 modification prevents DPP-4 degradation, maintaining sustained receptor occupancy. The fatty-diacid chain facilitates albumin binding, creating a circulating reservoir that slowly releases free peptide. Together, these modifications enable once-weekly dosing intervals in research protocols while maintaining continuous receptor activation. ### What cellular models are used for semaglutide research? Standard cellular models include: (1) beta-cell lines (MIN6, INS-1) and isolated islets for insulin secretion studies; (2) primary hepatocytes for glucagon suppression and hepatic glucose metabolism; (3) transfected cell lines expressing GLP-1 receptors for binding affinity and receptor desensitisation studies; (4) hypothalamic and brainstem neuronal cultures for satiety signalling; (5) gastric smooth muscle strips for motility studies; and (6) intestinal epithelial cells for gastrointestinal transit studies. ### Is semaglutide legal for research in the UK? Yes. Semaglutide is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase and possess for legitimate laboratory research. It is not licensed as a medicine by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for semaglutide research? Research-grade semaglutide should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 31-amino-acid sequence, the Aib8 substitution, and the fatty-diacid chain attachment (molecular weight shift to ~4,114 Da). The fatty-diacid chain should be confirmed by mass spectrometry and HPLC. Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. The PEG linker and lipid chain may require additional analytical verification. ## References - [Knudsen LB et al. The discovery and development of liraglutide and semaglutide. Front Endocrinol 2019;10:155.](https://pubmed.ncbi.nlm.nih.gov/30971904/) - [Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 2015;58:7370-7380.](https://pubmed.ncbi.nlm.nih.gov/26308095/) - [Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018;27:740-756.](https://pubmed.ncbi.nlm.nih.gov/29617640/) - [Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Obes Metab 2021;23:39-63.](https://pubmed.ncbi.nlm.nih.gov/33145985/) - [Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the tested drugs. Clin Pharmacol Ther 2015;97:495-501.](https://pubmed.ncbi.nlm.nih.gov/25670519/) --- # NAD+ UK: Research Reference 2026 URL: https://hatipeptides.co.uk/research/nad-plus Updated: 2026-06-05 Author: Hati Peptides Research reference for NAD+ (nicotinamide adenine dinucleotide), a coenzyme central to cellular metabolism, redox reactions, and energy production. ## Overview NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in all living cells. It is a dinucleotide composed of two nucleotides joined by their phosphate groups: one nucleotide contains an adenine base, and the other contains nicotinamide. NAD+ is central to metabolism, serving as an essential electron carrier in redox reactions and as a substrate for several classes of enzymes involved in cellular signalling and DNA repair. The molecule exists in two forms: NAD+ (oxidised) and NADH (reduced). The NAD+/NADH ratio is a critical indicator of cellular metabolic state, with high NAD+ levels associated with active metabolism and high NADH levels associated with reduced metabolic activity. NAD+ levels decline with age, falling by approximately 50% between age 20 and age 60 in human tissues. For UK research laboratories, NAD+ serves as a reference compound for studies examining cellular metabolism, redox biology, and the role of NAD+-dependent enzymes in ageing and metabolic regulation. The coenzyme is supplied in lyophilised form for maximum stability and is reconstituted immediately before use in assays. ## Molecular Structure NAD+ is a dinucleotide with the following structural characteristics: • **Formula**: C21H27N7O14P2 • **Molecular weight**: 663.4 Da (oxidised form) • **Structure**: Adenine + ribose + pyrophosphate + nicotinamide + ribose • **Redox centre**: Nicotinamide ring (accepts/donates hydride ion, H−) • **Charge**: Net negative charge at physiological pH due to phosphate groups The molecule consists of two nucleotides—adenosine monophosphate (AMP) and nicotinamide monophosphate (NMN)—joined by a pyrophosphate linkage. The nicotinamide moiety contains a positively charged pyridinium ring that is the site of redox chemistry. Upon reduction, NAD+ accepts a hydride ion (two electrons and one proton) at the C4 position of the nicotinamide ring, forming NADH. ## Mechanism of Action NAD+ operates through several distinct mechanisms in cellular and in vitro models: **Redox Metabolism** NAD+ serves as an electron carrier in metabolic reactions. In glycolysis, the citric acid cycle, and fatty acid oxidation, NAD+ accepts electrons from substrates, becoming NADH. The NADH then donates electrons to the electron transport chain, driving ATP synthesis. The NAD+/NADH ratio regulates metabolic flux and cellular energy status. **Sirtuin Activation** NAD+ is the essential substrate for sirtuins (SIRT1–SIRT7), a family of NAD+-dependent deacetylases. Sirtuins regulate gene expression, metabolic pathways, and cellular stress responses by removing acetyl groups from histones and other proteins. In cellular models, NAD+ availability directly determines sirtuin activity, linking metabolic state to epigenetic regulation. **PARP Activity** NAD+ is consumed by poly(ADP-ribose) polymerases (PARPs), enzymes that detect DNA damage and initiate repair. PARP1, the most abundant PARP, consumes NAD+ to synthesise poly(ADP-ribose) chains on target proteins, recruiting DNA repair machinery. In cellular studies, excessive DNA damage can deplete NAD+ through PARP overactivation. **CD38 and NAD+ Degradation** CD38 is a membrane-bound NADase that degrades NAD+ to cyclic ADP-ribose (cADPR) and nicotinamide. CD38 expression increases with age, contributing to NAD+ decline. In cellular models, CD38 inhibition preserves NAD+ levels and maintains sirtuin activity. **NAD+ Salvage Pathway** Cells regenerate NAD+ through the salvage pathway, converting nicotinamide to NMN via nicotinamide phosphoribosyltransferase (NAMPT), then to NAD+ via NMN adenylyltransferase (NMNAT). In cellular studies, NAMPT expression and activity determine the rate of NAD+ resynthesis. ## Research Applications NAD+ is employed across multiple research domains in UK laboratories: **Metabolic Research** In vitro studies examine NAD+ as a cofactor in glycolytic, citric acid cycle, and oxidative phosphorylation assays. Researchers use NAD+ to study metabolic flux, electron transport chain activity, and ATP production in cellular models. The NAD+/NADH ratio is measured as an indicator of metabolic state. **Ageing and Cellular Senescence** Cellular senescence models examine NAD+ decline as a marker of ageing. Researchers study the effects of NAD+ depletion on sirtuin activity, mitochondrial function, and DNA repair capacity. The relationship between NAD+ levels and cellular senescence markers (p16, p21, SA-β-gal) is quantified in ageing models. **DNA Repair and Genotoxic Stress** Cellular models of genotoxic stress examine NAD+ consumption by PARPs during DNA damage response. Researchers study whether NAD+ supplementation supports DNA repair capacity, reduces chromosomal aberrations, and maintains genomic stability in stressed cells. **Mitochondrial Function** NAD+ is essential for mitochondrial bioenergetics. In cellular models, NAD+ levels are correlated with mitochondrial membrane potential, ATP synthesis rate, and reactive oxygen species production. Researchers examine whether NAD+ availability supports mitochondrial biogenesis and function. **Sirtuin Pharmacology** NAD+ is used as a cofactor in sirtuin activity assays. Researchers compare NAD+ concentrations, sirtuin substrate specificity, and the effects of NAD+ modulators on deacetylase activity in cellular extracts. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for NAD+ studies: **NAD+/NADH Ratio Assays** Cellular lysates are assayed for NAD+ and NADH content using enzymatic cycling assays or fluorescent probes. The NAD+/NADH ratio is calculated as a metabolic indicator. NAD+ is added to cell culture media or directly to lysates depending on the assay format. **Sirtuin Activity Assays** Cellular extracts or recombinant sirtuins are incubated with NAD+ and acetylated substrate peptides. Deacetylation is measured by fluorescence or luminescence. NAD+ concentration is varied to determine Km and Vmax parameters for different sirtuin isoforms. **PARP Activity Assays** Cellular extracts or recombinant PARP1 are incubated with NAD+ and DNA substrates. Poly(ADP-ribose) synthesis is measured by antibody detection or radioactive labelling. NAD+ consumption is quantified as a function of DNA damage signal. **Mitochondrial Respiration** Seahorse respirometry and isolated mitochondria assays measure oxygen consumption rate in response to NAD+ availability. NAD+ is added to media or mitochondrial suspensions to examine effects on Complex I activity and electron transport chain function. **Cellular NAD+ Depletion Models** Cells are treated with NAD+ depleting agents (FK866, a NAMPT inhibitor) to model age-related NAD+ decline. The effects of NAD+ supplementation on cellular function, gene expression, and stress resistance are examined. ## Safety Profile in Preclinical Research NAD+ safety profile is based on cellular and biochemical studies. As a natural coenzyme present in all cells, NAD+ has low inherent toxicity. In vitro studies have not identified cytotoxicity at physiological and supraphysiological concentrations. In cellular models, excessive NAD+ supplementation may alter the NAD+/NADH ratio and metabolic flux, though cells regulate NAD+ uptake and utilisation through feedback mechanisms. The primary consideration is maintaining the oxidised/reduced ratio appropriate for the specific assay. NAD+ is light-sensitive and degrades in solution over time. Freshly prepared solutions are recommended for cellular assays. The coenzyme is generally stable as a lyophilised powder under proper storage conditions. Standard laboratory precautions apply: NAD+ is a research biochemical, not a medicine or dietary supplement. It is supplied for in vitro and laboratory research only. ## Reconstitution and Handling NAD+ is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation: • **Reconstitution**: Sterile water or phosphate-buffered saline (PBS) is recommended for laboratory preparations • **Concentration**: Typical stock concentrations range from 10–100 mM depending on assay requirements • **Storage**: Lyophilised powder at −20 °C, protected from light; reconstituted solution at 2–8 °C, use within 24 hours • **Stability**: NAD+ is unstable in solution; prepare fresh for each assay and avoid storage of reconstituted solutions • **Solubility**: Freely soluble in aqueous solutions; gentle vortexing may aid dissolution • **Light sensitivity**: Protect from light during storage and use; degradation products include NADH and nicotinamide • **pH**: Optimal stability at pH 7.0–8.0; avoid acidic or strongly alkaline conditions The lyophilised powder is hygroscopic; store in a desiccated environment. Reconstituted solutions may turn yellow if contaminated with NADH; discard if colour change is observed. Use glass or high-quality polypropylene containers to minimise adsorption. ## UK Research Status NAD+ is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research biochemical for laboratory use and is not licensed as a medicine by the MHRA. For UK research laboratories, NAD+ is available as a research-grade reference material. Sourcing should include: • Certificate of Analysis confirming ≥99% purity (HPLC) • Mass spectrometry or NMR identity confirmation (molecular weight 663.4 Da) • Confirmation of oxidised form (NAD+), not reduced form (NADH) • Batch-specific testing documentation • Appropriate storage and shipping conditions (cold chain, protected from light) • Research-use-only labelling Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for biochemical handling. ## FAQs ### What is NAD+ and why is it important in research? NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in all living cells. It serves as an essential electron carrier in metabolic redox reactions and as a substrate for enzymes involved in cellular signalling, DNA repair, and gene regulation. In research, NAD+ is studied as a central metabolic regulator, with its cellular levels declining with age and influencing sirtuin activity, mitochondrial function, and DNA repair capacity. ### How does NAD+ decline with age in cellular models? NAD+ levels decline by approximately 50% between age 20 and 60 in human tissues. In cellular models, this decline is attributed to increased CD38 expression (a NAD+ degrading enzyme), reduced NAMPT activity (the rate-limiting enzyme in NAD+ synthesis), and increased PARP activation due to accumulated DNA damage. Researchers model this decline using NAMPT inhibitors (FK866) to study the effects of NAD+ depletion on cellular function. ### What cellular models are used for NAD+ research? Standard cellular models include: (1) NAD+/NADH ratio assays using enzymatic cycling or fluorescent probes; (2) sirtuin activity assays with recombinant enzymes and acetylated substrates; (3) PARP activity assays measuring poly(ADP-ribose) synthesis; (4) mitochondrial respiration studies using Seahorse respirometry; (5) cellular NAD+ depletion models using NAMPT inhibitors; and (6) ageing models examining senescence markers in response to NAD+ modulation. ### Is NAD+ legal for research in the UK? Yes. NAD+ is not a controlled substance under UK law. It is classified as a research biochemical and is legal to purchase and possess for legitimate laboratory research. It is not licensed as a medicine by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for NAD+ research? Research-grade NAD+ should be ≥99% pure. The oxidised form (NAD+) should be confirmed by spectrophotometry (absorbance at 260 nm) and mass spectrometry (molecular weight 663.4 Da). The reduced form (NADH) has different absorbance properties (340 nm) and should be absent in NAD+ preparations. Batch-specific Certificates of Analysis should document purity, identity, and absence of NADH contamination. Fresh reconstitution is essential as NAD+ degrades in solution. ## References - [Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol 2014;24:464-471.](https://pubmed.ncbi.nlm.nih.gov/24786309/) - [Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr 2008;28:115-130.](https://pubmed.ncbi.nlm.nih.gov/18429699/) - [Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab 2018;27:513-528.](https://pubmed.ncbi.nlm.nih.gov/29719225/) - [Camacho-Pereira J et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab 2016;23:1127-1139.](https://pubmed.ncbi.nlm.nih.gov/27304511/) - [Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012;13:225-238.](https://pubmed.ncbi.nlm.nih.gov/22395762/) --- # Selank UK: Research Reference 2026 URL: https://hatipeptides.co.uk/research/selank Updated: 2026-06-05 Author: Hati Peptides Research reference for Selank, a synthetic heptapeptide investigated in anxiolytic, neuroimmune, and cognitive research. ## Overview Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed as a stable analogue of tuftsin, a natural immunomodulatory peptide. The peptide was designed to combine the immunomodulatory properties of tuftsin with anxiolytic effects, creating a compound with dual activity in neuroimmune research. The peptide is a 7-amino-acid sequence with a molecular weight of approximately 751.9 Da. Selank was developed to be resistant to proteolytic degradation while maintaining affinity for the same cellular targets as tuftsin. The C-terminal proline residue contributes to stability and receptor interactions. For UK research laboratories, Selank serves as a reference compound for studies examining neuroimmune interactions, anxiolytic mechanisms, and the relationship between immune modulation and central nervous system function. The peptide is not licensed as a medicine and is supplied for research use only. ## Molecular Structure Selank is a synthetic heptapeptide with the following structural characteristics: • **Sequence**: Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 amino acids) • **Molecular weight**: Approximately 751.9 Da • **Origin**: Synthetic analogue of tuftsin, a natural immunomodulatory peptide • **Stability**: Resistant to proteolytic degradation due to sequence modifications • **C-terminus**: Proline (contributes to stability and receptor binding) The peptide is a partial sequence of tuftsin with modifications conferring enhanced stability and anxiolytic activity. The proline-rich sequence creates a rigid secondary structure that may facilitate receptor interactions. The positively charged arginine and lysine residues contribute to cellular uptake and membrane interactions. ## Mechanism of Action Selank operates through several mechanisms in cellular and in vitro models: **Neuroimmune Modulation** Selank modulates the expression of neuroimmune mediators in cellular models. The peptide affects the production of cytokines (IL-1β, IL-6, TNF-α) and neurotrophic factors (BDNF, NGF) in glial cells and neuronal cultures. The immunomodulatory effects are examined in the context of neuroinflammation and stress response models. **Anxiolytic Signalling** In cellular and animal models, Selank influences anxiolytic pathways through modulation of GABAergic neurotransmission. The peptide affects GABA receptor expression and function in neuronal cultures, though the exact receptor mechanism is still under investigation. The anxiolytic effects are studied in stress-response and anxiety-related cellular models. **Neurotrophic Factor Modulation** Selank upregulates brain-derived neurotrophic factor (BDNF) expression in neuronal cultures. BDNF is a key regulator of synaptic plasticity, neuronal survival, and cognitive function. The peptide's effects on BDNF are examined in the context of neuroplasticity and cognitive enhancement research. **Enkephalinase Inhibition** Selank may inhibit enkephalin-degrading enzymes (enkephalinases), prolonging the activity of endogenous opioid peptides. This mechanism is studied in cellular models examining pain modulation, stress response, and emotional regulation pathways. **Serotonin System Interactions** In cellular studies, Selank affects serotonin (5-HT) metabolism and receptor expression. The peptide modulates tryptophan hydroxylase activity and serotonin transporter function in neuronal cultures, though the exact mechanism remains under investigation. ## Research Applications Selank is employed across multiple research domains in UK laboratories: **Neuroimmune Research** In vitro studies examine Selank's effects on neuroimmune mediator production in glial cells (astrocytes, microglia) and neuronal cultures. Researchers study the peptide's modulation of cytokine networks, chemokine expression, and the cross-talk between immune and nervous systems in cellular models. **Anxiety and Stress Research** Cellular models of stress response examine Selank's effects on corticotropin-releasing factor (CRF) signalling, glucocorticoid receptor expression, and stress-induced neuronal changes. The peptide's anxiolytic mechanism is studied in hypothalamic and amygdalar cell cultures. **Cognitive Enhancement Research** Neuronal cultures and brain slice models examine Selank's effects on synaptic plasticity, long-term potentiation (LTP), and neurotrophic factor expression. The BDNF-modulating activity is studied in the context of memory formation, learning, and cognitive resilience. **Neuroprotection Research** Cellular models of oxidative stress and excitotoxicity examine Selank's neuroprotective effects. The peptide is studied in the context of neuronal survival, antioxidant enzyme expression, and resistance to glutamate-induced toxicity in cortical and hippocampal cultures. **Comparative Neuroactive Peptides** Selank is compared to tuftsin, semax, and other neuroactive peptides in cellular studies. Research questions examine whether the synthetic modifications produce distinct neuroimmune or anxiolytic profiles compared to the parent peptide. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for Selank studies: **Neuronal Cultures** Primary cortical, hippocampal, and hypothalamic neuronal cultures are used to examine Selank's effects on neuronal viability, morphology, and receptor expression. Endpoints include cell survival, neurite outgrowth, and electrophysiological properties. **Glial Cell Cultures** Astrocyte and microglial cultures are used to examine Selank's effects on neuroimmune mediator production. Endpoints include cytokine release (IL-1β, IL-6, TNF-α), chemokine expression, and glial activation markers. **BDNF Expression Assays** Neuronal cultures are used to measure BDNF mRNA and protein expression in response to Selank treatment. qPCR, Western blot, and ELISA approaches quantify neurotrophic factor upregulation. The peptide is compared to known BDNF inducers. **GABAergic Signalling** Cultures of GABAergic interneurons or transfected cell lines expressing GABA receptors are used to examine Selank's effects on inhibitory neurotransmission. Electrophysiological recordings and receptor binding assays quantify changes in GABAergic function. **Stress Response Models** Neuronal cultures are subjected to corticosterone, oxidative stress, or glutamate excitotoxicity, then treated with Selank to examine neuroprotective effects. Endpoints include cell viability, oxidative stress markers, and apoptosis assays. ## Safety Profile in Preclinical Research Selank's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens using standard cell lines have not identified significant cytotoxicity at research-relevant concentrations (up to 100 μM). In animal studies, the peptide has been well tolerated at standard research doses. The synthetic design and small size contribute to favourable safety characteristics. The peptide does not appear to produce sedation, motor impairment, or cognitive disruption in preclinical models. The peptide's neuroimmune modulation raises theoretical considerations about immune system effects, though no significant immunosuppressive or immunostimulatory adverse effects have been reported at standard research doses. As with all research peptides, appropriate laboratory controls and dose-ranging studies are recommended. Standard laboratory precautions apply: Selank is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only. ## Reconstitution and Handling Selank is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation: • **Reconstitution**: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations • **Concentration**: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements • **Storage**: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light • **Stability**: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C • **Solubility**: The peptide is generally soluble in aqueous solutions; brief vortexing may aid dissolution • **Protease sensitivity**: The synthetic design confers some protease resistance, but standard protease inhibitors may be included in incubation media The peptide's small size may result in non-specific binding to plastic surfaces; researchers should verify recovery rates. Pre-wetting tubes with BSA-containing buffer may reduce peptide loss. The peptide is light-sensitive; protect from prolonged light exposure. ## UK Research Status Selank is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. For UK research laboratories, Selank is available as a research-grade reference material. Sourcing should include: • Certificate of Analysis confirming ≥98% purity (HPLC) • Mass spectrometry identity confirmation (molecular weight ~751.9 Da) • Batch-specific testing documentation • Appropriate storage and shipping conditions (cold chain) • Research-use-only labelling Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling. ## FAQs ### What is Selank and how does it differ from tuftsin? Selank is a synthetic 7-amino-acid heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) designed as a stable analogue of tuftsin, a natural immunomodulatory peptide. While tuftsin is a tetrapeptide (Thr-Lys-Pro-Arg) with primary immunomodulatory activity, Selank incorporates additional proline and glycine residues that confer enhanced stability and anxiolytic properties. The modifications allow Selank to resist proteolytic degradation while maintaining immunomodulatory activity and adding neuroactive effects. ### What is Selank's primary mechanism in research models? Selank operates through multiple mechanisms in cellular and animal models: modulation of neuroimmune mediator production (cytokines, chemokines), upregulation of BDNF expression in neuronal cultures, effects on GABAergic neurotransmission, potential inhibition of enkephalin-degrading enzymes, and modulation of serotonin metabolism. The peptide's neuroimmune modulation is studied in glial cell cultures, while its anxiolytic effects are examined in neuronal stress-response models. ### What cellular models are used for Selank research? Standard cellular models include: (1) primary cortical and hippocampal neuronal cultures for viability and morphology studies; (2) astrocyte and microglial cultures for neuroimmune mediator production; (3) BDNF expression assays using qPCR and Western blot; (4) GABAergic interneuron cultures for inhibitory neurotransmission studies; (5) stress-response models using corticosterone or oxidative stress; and (6) brain slice models for electrophysiological recordings. ### Is Selank legal for research in the UK? Yes. Selank is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase and possess for legitimate laboratory research. It is not licensed as a medicine by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for Selank research? Research-grade Selank should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 7-amino-acid sequence (Thr-Lys-Pro-Arg-Pro-Gly-Pro) and molecular weight (~751.9 Da). The synthetic modifications should be confirmed by chromatographic and mass spectrometric analysis. Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. Given the peptide's small size, mass spectrometry is particularly important for confirming sequence integrity. ## References - [Uchakina ON et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Bull Exp Biol Med 2001;131:563-565.](https://pubmed.ncbi.nlm.nih.gov/11517707/) - [Kozlovskaya MM et al. Metabolism of selank and its stability in biological media. Bull Exp Biol Med 2002;134:233-235.](https://pubmed.ncbi.nlm.nih.gov/12574475/) - [Kozlovskii II, Danchev ND. Inhibitory effect of selank on enkephalin-degrading enzymes. Bull Exp Biol Med 2001;132:926-928.](https://pubmed.ncbi.nlm.nih.gov/11785296/) - [Kolomin T et al. A new generation of drugs: nootropic dipeptide GVS-111 and neuroprotective peptide Selank. Neuroprotective and nootropic peptides. 2015.](https://pubmed.ncbi.nlm.nih.gov/25894474/) - [Medvedeva EV et al. The effects of heptapeptide Selank on the expression of BDNF and TrkB in the hippocampus of rats. Dokl Biol Sci 2014;456:134-137.](https://pubmed.ncbi.nlm.nih.gov/24985527/) --- # Epithalon UK: Research Reference 2026 URL: https://hatipeptides.co.uk/research/epithalon Updated: 2026-06-05 Author: Hati Peptides Research reference for Epithalon (epithalamin), a synthetic tetrapeptide investigated in telomerase activation, pineal gland, and longevity research. ## Overview Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) with a molecular weight of approximately 390.4 Da. The peptide was originally isolated from the pineal gland and was subsequently synthesised to study its effects on cellular ageing, telomerase activity, and the regulation of biological rhythms. The peptide is the shortest of the research peptides with only four amino acids. Its small size contributes to rapid cellular uptake and direct interaction with nuclear targets. The sequence is conserved across species and represents a biologically active fragment of the larger pineal peptide complex. For UK research laboratories, Epithalon serves as a reference compound for studies examining telomerase regulation, cellular senescence, and the pineal-axis contribution to ageing mechanisms. The peptide is not licensed as a medicine and is supplied for research use only. ## Molecular Structure Epithalon is a synthetic tetrapeptide with the following structural characteristics: • **Sequence**: Ala-Glu-Asp-Gly (4 amino acids) • **Molecular weight**: Approximately 390.4 Da • **Origin**: Synthetic version of a pineal gland peptide • **Size**: One of the smallest bioactive peptides in research use • **C-terminus**: Free carboxyl group The peptide's small size allows rapid diffusion across cellular membranes and direct nuclear localisation. The negatively charged glutamate and aspartate residues contribute to interactions with DNA and nuclear proteins. The N-terminal alanine provides stability, while the glycine C-terminus contributes to conformational flexibility. ## Mechanism of Action Epithalon operates through several mechanisms in cellular and in vitro models: **Telomerase Activation** The primary mechanism of Epithalon in research models is the upregulation of telomerase activity. Telomerase is a reverse transcriptase that adds telomeric repeats to chromosome ends, compensating for the end-replication problem in dividing cells. In cellular models, Epithalon increases telomerase expression and activity, particularly in fibroblast and epithelial cell cultures. **Pineal Axis Regulation** Epithalon is studied in the context of pineal gland function and melatonin secretion. The peptide modulates the expression of enzymes involved in melatonin synthesis (N-acetyltransferase, hydroxyindole-O-methyltransferase) in pineal cell cultures. The pineal axis is central to circadian rhythm regulation and its disruption is associated with ageing. **Cellular Senescence** In cellular senescence models, Epithalon is examined for its effects on senescence markers (p16, p21, SA-β-galactosidase) and replicative lifespan. The peptide is studied in the context of extending cellular replicative capacity through telomerase-mediated telomere maintenance. **DNA Repair and Genomic Stability** Epithalon is studied for its effects on DNA repair capacity and chromosomal stability. The peptide may influence the expression of DNA repair enzymes and reduce chromosomal aberrations in cellular models of genotoxic stress. **Gene Expression Modulation** Microarray and transcriptomic studies show Epithalon modulates the expression of genes involved in cell cycle regulation, apoptosis, and stress resistance. The peptide's effects on gene expression are examined in the context of cellular ageing and longevity pathways. ## Research Applications Epithalon is employed across multiple research domains in UK laboratories: **Telomerase Research** In vitro studies examine Epithalon's effects on telomerase activity in fibroblast, epithelial, and stem cell cultures. Researchers use the peptide to study telomerase regulation, telomere length maintenance, and the relationship between telomerase and cellular replicative lifespan. **Cellular Ageing Studies** Cellular senescence models examine Epithalon's effects on senescence markers, telomere attrition, and replicative capacity. The peptide is studied in the context of extending cellular lifespan through telomerase-mediated mechanisms and anti-senescence pathways. **Pineal Gland Research** Pineal cell cultures examine Epithalon's effects on melatonin synthesis, circadian rhythm gene expression, and pineal hormone secretion. The peptide's modulation of the pineal axis is studied in the context of biological rhythm regulation and age-related pineal decline. **Genomic Stability** Cellular models of genotoxic stress examine Epithalon's effects on DNA repair capacity, chromosomal aberrations, and genomic integrity. The peptide is studied for potential protective effects against oxidative DNA damage and radiation-induced cellular stress. **Comparative Longevity Peptides** Epithalon is compared to other longevity-related compounds (resveratrol, NAD+ precursors, sirtuin activators) in cellular studies. Research questions examine whether the telomerase-mediated mechanism produces distinct outcomes compared to metabolic or antioxidant approaches. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for Epithalon studies: **Telomerase Activity Assays** Cellular extracts or recombinant telomerase are incubated with Epithalon, and telomerase activity is measured by TRAP assay (Telomeric Repeat Amplification Protocol). Endpoints include telomerase expression (qPCR, Western blot) and telomere length (Southern blot, qPCR). **Fibroblast Lifespan Studies** Primary human fibroblast cultures are serially passaged with Epithalon treatment, and population doublings are counted. Senescence markers (SA-β-gal, p16, p21) are measured at each passage. Telomere length is monitored throughout the replicative lifespan. **Pineal Cell Cultures** Pinealocyte cultures are used to examine Epithalon's effects on melatonin synthesis, N-acetyltransferase activity, and circadian rhythm gene expression (CLOCK, BMAL1, PER). The peptide is compared to melatonin and other pineal compounds. **DNA Repair Assays** Cells are exposed to UV radiation, hydrogen peroxide, or ionising radiation, then treated with Epithalon to examine DNA repair capacity. Endpoints include comet assay, γ-H2AX foci, and chromosomal aberration frequency. **Stem Cell Cultures** Mesenchymal stem cells and embryonic stem cells are used to examine Epithalon's effects on stem cell proliferation, differentiation, and telomere maintenance. The peptide's effects on stem cell replicative capacity are of particular interest in regenerative medicine research. ## Safety Profile in Preclinical Research Epithalon's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens using standard cell lines have not identified significant cytotoxicity at research-relevant concentrations (up to 100 μM). In animal studies, the peptide has been well tolerated at standard research doses. The small size and natural amino acid composition contribute to favourable safety characteristics. The peptide does not appear to produce acute toxicity or organ-specific adverse effects in preclinical models. The theoretical consideration of telomerase activation raises questions about cellular immortalisation, though the peptide's effects on telomerase are modest and context-dependent. Standard research doses are designed to study physiological regulation rather than supraphysiological stimulation. Standard laboratory precautions apply: Epithalon is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only. ## Reconstitution and Handling Epithalon is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation: • **Reconstitution**: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations • **Concentration**: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements • **Storage**: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light • **Stability**: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C • **Solubility**: The small peptide is readily soluble in aqueous solutions; minimal mixing required • **Light sensitivity**: Protect from light during storage and use The peptide's small size may result in non-specific binding to plastic surfaces; researchers should verify recovery rates. Pre-wetting tubes with BSA-containing buffer may reduce peptide loss. The peptide is relatively stable but should be protected from extremes of pH and temperature. ## UK Research Status Epithalon is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA. For UK research laboratories, Epithalon is available as a research-grade reference material. Sourcing should include: • Certificate of Analysis confirming ≥98% purity (HPLC) • Mass spectrometry identity confirmation (molecular weight ~390.4 Da) • Batch-specific testing documentation • Appropriate storage and shipping conditions (cold chain) • Research-use-only labelling Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling. ## FAQs ### What is Epithalon and where does it come from? Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) with a molecular weight of ~390.4 Da. It was originally isolated from the pineal gland and subsequently synthesised for research purposes. The peptide is a short, stable sequence derived from a larger pineal peptide complex, designed to study telomerase regulation and pineal axis function in cellular ageing models. ### What is Epithalon's primary mechanism in research models? Epithalon's primary mechanism in cellular models is the upregulation of telomerase activity. Telomerase is a reverse transcriptase that maintains telomere length at chromosome ends. In fibroblast and epithelial cell cultures, Epithalon increases telomerase expression and activity, potentially extending replicative lifespan. The peptide also modulates pineal gland function, affecting melatonin synthesis and circadian rhythm gene expression. ### What cellular models are used for Epithalon research? Standard cellular models include: (1) primary human fibroblast cultures for lifespan and senescence studies; (2) telomerase activity assays using TRAP protocol; (3) pinealocyte cultures for melatonin synthesis studies; (4) DNA repair assays using comet assay and γ-H2AX foci; (5) stem cell cultures for proliferation and differentiation studies; and (6) epithelial cell cultures for telomere length maintenance studies. ### Is Epithalon legal for research in the UK? Yes. Epithalon is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase and possess for legitimate laboratory research. It is not licensed as a medicine by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for Epithalon research? Research-grade Epithalon should be ≥98% pure by HPLC, with ≥99% being the preferred standard. Mass spectrometry identity confirmation is essential to verify the 4-amino-acid sequence (Ala-Glu-Asp-Gly) and molecular weight (~390.4 Da). Given the peptide's small size, sequence verification is critical. Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels. The peptide is highly susceptible to synthesis errors due to its short length, making analytical verification particularly important. ## References - [Khavinson VKh et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003;135:590-592.](https://pubmed.ncbi.nlm.nih.gov/14565059/) - [Khavinson VKh et al. The effects of short peptides on gene expression. Bull Exp Biol Med 2009;147:248-251.](https://pubmed.ncbi.nlm.nih.gov/19513388/) - [Anisimov VN et al. Effects of epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003;4:193-202.](https://pubmed.ncbi.nlm.nih.gov/12954052/) - [Khavinson VKh, Anisimov VN. Peptide regulation of ageing. J Anti Aging Med 2000;3:131-135.](https://pubmed.ncbi.nlm.nih.gov/12954052/) - [Khavinson VKh et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Bull Exp Biol Med 2002;133:329-332.](https://pubmed.ncbi.nlm.nih.gov/12199088/) --- # Bacteriostatic Water: Research Reconstitution Guide 2026 URL: https://hatipeptides.co.uk/research/bacteriostatic-water Updated: 2026-06-05 Author: Hati Peptides Laboratory guide for bacteriostatic water use in peptide reconstitution. Sterile handling, storage protocols, and best practices for UK research laboratories. ## Overview Bacteriostatic water (BAC water) is sterile water for injection containing 0.9% (9 mg/mL) benzyl alcohol as a bacteriostatic preservative. It is the standard reconstitution medium for lyophilised peptides in research laboratories, providing a sterile, slightly preserved environment that inhibits bacterial growth while maintaining peptide stability. The benzyl alcohol content acts as a bacteriostatic agent, preventing the growth of bacteria and fungi in the reconstituted solution. Unlike sterile water for injection (which contains no preservative), bacteriostatic water allows reconstituted peptides to be stored for 7–14 days under refrigeration without significant microbial contamination risk. For UK research laboratories, bacteriostatic water is an essential accessory for peptide reconstitution, enabling the preparation of stable, research-ready solutions from lyophilised peptide powders. Proper handling, storage, and use of bacteriostatic water are critical for maintaining peptide integrity and experimental reproducibility. ## Composition and Properties Bacteriostatic water has the following composition and properties: • **Composition**: Sterile water (H2O) + 0.9% benzyl alcohol (C6H5CH2OH) • **Benzyl alcohol concentration**: 9 mg/mL (0.9% w/v) • **pH**: 4.5–7.0 (slightly acidic, optimal for peptide stability) • **Osmolarity**: Approximately 300 mOsm/L (isotonic) • **Packaging**: 3 mL or 10 mL sterile vials, multi-dose • **Storage**: Room temperature (15–30 °C), protected from light • **Shelf life**: 2–3 years from manufacture date when unopened The benzyl alcohol acts as a bacteriostatic preservative by disrupting bacterial cell membrane integrity. It is effective against Gram-positive and Gram-negative bacteria, as well as fungi. The concentration of 0.9% is sufficient for antimicrobial activity while minimising potential effects on peptide stability and cellular assays. ## Peptide Reconstitution Protocol Standard laboratory reconstitution protocol for lyophilised peptides using bacteriostatic water: **Preparation** 1. Allow the peptide vial and bacteriostatic water vial to reach room temperature (reduces condensation) 2. Wipe the rubber stoppers of both vials with an alcohol swab (70% isopropanol) 3. Allow the alcohol to evaporate completely before piercing the stopper **Reconstitution Steps** 1. Draw the required volume of bacteriostatic water into a sterile syringe (typically 1–2 mL for 10 mg peptides) 2. Inject the water slowly down the inside wall of the peptide vial (not directly onto the powder) 3. Allow the water to gently flow over the lyophilised powder without forceful spraying 4. Do not shake the vial; gently swirl or roll between palms to aid dissolution 5. Allow the vial to stand for 5–10 minutes at room temperature to ensure complete dissolution 6. Inspect the solution for clarity, particulates, or colour changes **Concentration Calculation** - 10 mg peptide in 1 mL = 10 mg/mL - 10 mg peptide in 2 mL = 5 mg/mL - Choose concentration based on assay requirements and dosing calculations **Important Notes** - Never use tap water, distilled water, or non-sterile water for reconstitution - Do not shake vigorously (may cause foam formation and peptide denaturation) - If the peptide does not dissolve completely, gentle warming to 37 °C (not exceeding) may aid dissolution - Do not freeze-thaw reconstituted solutions repeatedly; aliquot for long-term storage ## Storage and Handling Proper storage and handling of bacteriostatic water and reconstituted peptides: **Bacteriostatic Water (Unopened)** • Store at room temperature (15–30 °C) • Protect from direct light (store in original box or dark cabinet) • Do not freeze (may compromise benzyl alcohol efficacy and vial integrity) • Check expiry date before use; do not use expired vials • Inspect for clarity, particles, or discolouration before opening **Reconstituted Peptide Solutions** • Store at 2–8 °C (refrigerator) in the original vial or aliquoted into sterile microcentrifuge tubes • Use within 7–14 days for standard assays; aliquot and freeze at −20 °C for extended storage • Protect from light (wrap vial in aluminium foil or store in amber container) • Label with peptide name, concentration, reconstitution date, and expiry • Do not store at room temperature for extended periods (increases degradation risk) **Aliquoting for Long-Term Storage** • Divide reconstituted solution into single-use aliquots (e.g., 100 μL per tube) • Freeze immediately at −20 °C or −80 °C • Avoid repeated freeze-thaw cycles (causes peptide degradation and aggregation) • Thaw each aliquot once and use immediately; do not refreeze **Multi-Dose Vial Use** • Bacteriostatic water vials are multi-dose when properly handled • Wipe the rubber stopper with alcohol before each needle entry • Use a new sterile needle/syringe for each access • Do not store the vial with a needle permanently inserted (compromises sterility) • Discard the vial if the solution becomes cloudy, discoloured, or contains particles ## Safety and Precautions Safety considerations for handling bacteriostatic water and reconstituted peptides: **Sterility Maintenance** • Always work in a clean environment (laminar flow hood preferred for critical applications) • Use sterile needles, syringes, and containers • Minimise the time the vial is open to air • Do not touch the needle tip, rubber stopper, or inside of the vial cap • If sterility is compromised, discard the solution and prepare fresh **Benzyl Alcohol Considerations** • Benzyl alcohol is toxic to neonates and infants (not relevant for standard research, but important for comparative safety data) • Some cellular assays may be sensitive to benzyl alcohol at high concentrations • For benzyl alcohol-sensitive assays, consider using sterile water for injection (single-use, no preservative) and preparing fresh solutions for each assay • The 0.9% concentration is generally well tolerated in standard cell culture and biochemical assays **Peptide Stability** • Reconstituted peptides are more susceptible to degradation than lyophilised powders • Maintain pH 6.5–7.5 for optimal peptide stability • Avoid exposure to extreme temperatures, light, and oxidising agents • Monitor for signs of degradation: precipitation, colour change, loss of activity in bioassays **Disposal** • Dispose of expired or contaminated solutions according to institutional hazardous waste protocols • Do not pour peptide solutions down the drain • Needles and syringes must be disposed of in designated sharps containers ## Quality Control and Verification Quality control measures for bacteriostatic water and reconstituted peptides: **Visual Inspection** • Bacteriostatic water should be clear, colourless, and free of particles • Reconstituted peptides should be clear or slightly opalescent (some peptides may have a faint colour) • Cloudiness, precipitates, or colour changes indicate contamination or degradation • Discard any solution that fails visual inspection **Sterility Testing** • For critical applications, test reconstituted solutions for sterility using standard microbiological methods • Incubate samples on bacterial and fungal growth media for 48–72 hours • A negative result (no growth) confirms sterility; positive results require solution discard **Peptide Integrity Verification** • Verify peptide integrity after reconstitution using HPLC or mass spectrometry • Compare chromatographic profile to the Certificate of Analysis • Test biological activity in a standard assay (e.g., receptor binding, cell response) • Document all QC data for experimental reproducibility **pH Measurement** • Measure pH of reconstituted solution using a calibrated pH meter • Optimal pH range: 6.5–7.5 • Adjust pH if necessary using minimal volumes of dilute HCl or NaOH • Avoid extreme pH adjustments (may cause peptide degradation) ## Troubleshooting Common Issues Common issues and solutions for peptide reconstitution with bacteriostatic water: **Peptide Does Not Dissolve** • Allow the vial to stand at room temperature for 30–60 minutes; some peptides dissolve slowly • Gently warm the vial to 37 °C in a water bath (do not exceed 37 °C) • Add bacteriostatic water in small increments (e.g., 0.5 mL at a time) • Some peptides (e.g., semaglutide, retatrutide) have fatty-diacid chains that reduce solubility; gentle warming and extended mixing may be required • Do not use organic solvents (acetonitrile, DMSO) unless specifically validated for the peptide **Solution is Cloudy or Precipitated** • Cloudiness may indicate peptide aggregation or poor solubility • Try gentle warming to 37 °C and slow cooling to room temperature • If precipitation persists, the peptide may be degraded or the concentration too high • Consider diluting to a lower concentration or using a different buffer (e.g., PBS with 0.1% BSA) **Foam Formation** • Foam is caused by vigorous shaking or forceful injection of water • Allow foam to settle naturally (do not shake to disperse) • If foam persists, briefly centrifuge the vial at low speed (e.g., 500 × g for 2 minutes) • To prevent foam: inject water slowly down the vial wall; do not shake; gently swirl to mix **pH Out of Range** • Measure pH and adjust with minimal volumes of dilute HCl or NaOH • For pH < 6.0: add 0.1 M NaOH dropwise until pH reaches 6.5–7.5 • For pH > 8.0: add 0.1 M HCl dropwise until pH reaches 6.5–7.5 • Recheck peptide integrity after pH adjustment using HPLC ## UK Research Sourcing Bacteriostatic water is classified as a sterile pharmaceutical accessory for laboratory use. It is not a controlled substance and is available for research laboratories without prescription requirements. For UK research laboratories, bacteriostatic water should be sourced from reputable suppliers with the following documentation: • Certificate of Analysis confirming sterility (USP <71> sterility test) • Endotoxin testing (LAL test, <0.5 EU/mL) • Benzyl alcohol concentration verification (0.9% w/v) • pH testing (4.5–7.0) • Osmolarity testing (isotonic) • Batch-specific manufacturing and expiry documentation • Sterile packaging verification Storage requirements: • Room temperature (15–30 °C) • Protected from light • Do not freeze • Use within 2–3 years of manufacture date (unopened) • Use within 28 days of first needle puncture (multi-dose vial) Researchers should ensure that bacteriostatic water is sourced from GMP-compliant manufacturers and that all documentation is retained for regulatory compliance and experimental reproducibility. ## FAQs ### What is bacteriostatic water and why is it used for peptide reconstitution? Bacteriostatic water is sterile water containing 0.9% benzyl alcohol as a preservative. It is used for peptide reconstitution because the benzyl alcohol inhibits bacterial growth, allowing reconstituted peptides to be stored for 7–14 days under refrigeration without significant microbial contamination. Unlike plain sterile water, bacteriostatic water enables multi-dose use and extends the stability of reconstituted solutions in research settings. ### How much bacteriostatic water should I use to reconstitute a peptide? The volume depends on the desired concentration. For a 10 mg peptide vial: 1 mL water = 10 mg/mL; 2 mL water = 5 mg/mL; 3 mL water = 3.33 mg/mL. Choose a concentration appropriate for your assay requirements. Standard practice is to use 1–2 mL for 10 mg peptides. The peptide should dissolve completely in the chosen volume; if not, allow the vial to stand at room temperature for 30–60 minutes or gently warm to 37°C. ### How long can reconstituted peptides be stored in bacteriostatic water? Reconstituted peptides in bacteriostatic water are generally stable for 7–14 days when stored at 2–8°C and protected from light. For extended storage, aliquot the solution into single-use portions and freeze at −20°C. Avoid repeated freeze-thaw cycles, as these cause peptide degradation and aggregation. Always inspect the solution for cloudiness, particles, or colour changes before use. ### Can I use sterile water instead of bacteriostatic water? Sterile water for injection (without benzyl alcohol) can be used for single-use preparations that will be consumed immediately. However, it does not contain a preservative, so reconstituted solutions must be used within hours or frozen immediately. For multi-day use or when aliquoting is impractical, bacteriostatic water is preferred. Some cellular assays may be sensitive to benzyl alcohol; in such cases, use sterile water and prepare fresh solutions for each assay. ### What are the signs that a reconstituted peptide has degraded? Signs of peptide degradation include: cloudiness or precipitation in the solution; colour change (e.g., yellowing, browning); visible particles or fibres; loss of biological activity in standard assays; changes in HPLC chromatographic profile (new peaks, broadening, or reduced main peak); and altered mass spectrometry profile (fragments, adducts). If any of these signs are observed, discard the solution and prepare fresh from a new lyophilised vial. ## References - [USP <71> Sterility Tests. United States Pharmacopeia. 2023.](https://www.usp.org/) - [FDA Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. 2004.](https://www.fda.gov/) - [WHO Good Manufacturing Practices for Pharmaceutical Products. 2022.](https://www.who.int/) - [Pharmaceutical Analysis: A Textbook for Pharmacy Students and Pharmaceutical Chemists. 4th Ed. 2020.](https://www.elsevier.com/) - [Remington: The Science and Practice of Pharmacy. 23rd Ed. 2020.](https://www.elsevier.com/) --- # Retatrutide vs Semaglutide: UK Research Comparison 2026 URL: https://hatipeptides.co.uk/research/retatrutide-vs-semaglutide Updated: 2026-06-05 Author: Hati Peptides Comparative research reference for Retatrutide and Semaglutide. Triple vs GLP-1 agonist mechanisms, receptor pharmacology, metabolic research, and UK sourcing standards. ## Overview Retatrutide and Semaglutide are both synthetic peptides used in metabolic research, but they differ fundamentally in receptor targets and mechanisms. Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors, while Semaglutide is a selective, long-acting GLP-1 receptor agonist. For UK research laboratories, the choice between these peptides depends on the research question: Retatrutide enables the study of multi-receptor metabolic integration, while Semaglutide provides a clean model for isolated GLP-1 receptor pharmacology and sustained incretin signalling. This comparison covers molecular structure, mechanism of action, research applications, cellular models, and sourcing standards for both compounds. ## Molecular Structure Comparison **Retatrutide** • Sequence: 39 amino acids with C20 fatty-diacid conjugate • Molecular weight: ~4,700 Da • Key modifications: N-terminal fatty-diacid via γ-Glu-2xAdo linker; triple receptor affinity • Half-life: ~5–7 days (albumin binding) **Semaglutide** • Sequence: 31 amino acids with C18 fatty-diacid chain • Molecular weight: ~4,114 Da • Key modifications: Aib at position 8 (DPP-4 resistance); C18 fatty-diacid at Lys26 (albumin binding) • Half-life: ~7 days (albumin binding + DPP-4 resistance) **Structural Differences** Retatrutide is 8 amino acids longer than Semaglutide and contains modifications conferring affinity for GIP and glucagon receptors in addition to GLP-1. Both peptides use fatty-diacid conjugation for albumin binding and extended half-life, but Retatrutide's C20 chain is longer than Semaglutide's C18 chain. The additional receptor targets in Retatrutide create a more complex pharmacological profile in research models. ## Mechanism of Action Comparison **Retatrutide: Triple Agonist Mechanism** Retatrutide activates three distinct receptor systems: 1. **GLP-1 receptor**: Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, activates satiety circuits 2. **GIP receptor**: Amplifies insulin secretion, promotes adipose lipid storage, supports bone formation 3. **Glucagon receptor**: Increases hepatic glucose output, stimulates lipolysis, raises energy expenditure The triple agonism creates a balanced metabolic profile where the glucagon component counteracts the insulinotropic effects of GLP-1 and GIP, producing unique research questions about metabolic signal integration. **Semaglutide: Selective GLP-1 Agonism** Semaglutide selectively activates the GLP-1 receptor with high affinity and sustained kinetics: 1. **GLP-1 receptor**: Produces sustained cAMP accumulation, enhanced insulin secretion, delayed gastric emptying, and central satiety signalling 2. **DPP-4 resistance**: The Aib8 substitution prevents enzymatic degradation, maintaining receptor occupancy for extended periods 3. **Albumin binding**: The C18 fatty-diacid chain creates a circulating reservoir, enabling continuous receptor activation **Key Research Differences** - Retatrutide produces multi-receptor metabolic effects with potential receptor crosstalk - Semaglutide provides a cleaner model for studying isolated GLP-1 receptor pharmacology - Retatrutide's glucagon activity adds energy expenditure and hepatic glucose output signals absent in Semaglutide - Semaglutide's sustained GLP-1 activation is ideal for studying receptor desensitisation and long-term signalling ## Research Applications Comparison **Retatrutide Research Applications** • Multi-receptor metabolic integration studies • Energy homeostasis and metabolic flexibility research • Comparative pharmacology with single and dual agonists • Receptor crosstalk and biased agonism studies • Class B GPCR oligomerisation research **Semaglutide Research Applications** • Sustained GLP-1 receptor activation studies • Appetite and satiety circuit research • Gastrointestinal motility and delayed gastric emptying studies • Receptor desensitisation and downregulation research • Comparative incretin pharmacology with shorter-acting analogues **When to Choose Retatrutide** • Research questions involve multi-receptor metabolic regulation • Studying the interplay between incretin and glucagon signalling • Examining receptor crosstalk and signal integration • Comparing triple agonism to single or dual agonist approaches **When to Choose Semaglutide** • Research questions require isolated GLP-1 receptor pharmacology • Studying sustained receptor activation and desensitisation • Examining central satiety mechanisms without confounding receptor signals • Comparing long-acting vs short-acting incretin agonists ## Cellular Models Comparison **Retatrutide Cellular Models** • Beta-cell lines (MIN6, INS-1) for insulin secretion with multi-receptor contributions • Primary hepatocytes for glucagon-mediated glucose output • 3T3-L1 adipocytes for GIP receptor-mediated lipid storage • Transfected cell lines expressing GLP-1, GIP, and glucagon receptors for binding affinity ratios • Multi-cellular co-culture systems for paracrine signalling studies **Semaglutide Cellular Models** • Beta-cell lines and isolated islets for sustained insulin secretion • Primary hepatocytes for glucagon suppression studies • Hypothalamic and brainstem neuronal cultures for satiety signalling • Gastric smooth muscle strips for motility studies • Transfected GLP-1 receptor cell lines for binding and desensitisation kinetics **Comparative Experimental Design** Researchers often use both peptides in parallel to compare: • Insulin secretion amplitude (Retatrutide's multi-receptor amplification vs Semaglutide's sustained GLP-1) • Glucagon dynamics (Retatrutide's stimulation vs Semaglutide's suppression) • Lipid metabolism (Retatrutide's GIP-mediated storage vs Semaglutide's lipolysis) • Receptor occupancy kinetics over extended incubations ## UK Sourcing and Purity Standards Both Retatrutide and Semaglutide require high-purity research-grade materials for valid experimental results. **Retatrutide Sourcing Requirements** • ≥98% purity (HPLC), ≥99% preferred • Mass spectrometry confirming 39-amino-acid sequence and C20 fatty-diacid conjugate • Molecular weight verification (~4,700 Da) • Batch-specific COA with endotoxin levels • Research-use-only labelling **Semaglutide Sourcing Requirements** • ≥98% purity (HPLC), ≥99% preferred • Mass spectrometry confirming 31-amino-acid sequence, Aib8 substitution, and C18 fatty-diacid chain • Molecular weight verification (~4,114 Da) • Batch-specific COA with endotoxin levels • Research-use-only labelling **UK Legal Status** Both peptides are not controlled substances under the Misuse of Drugs Act 1971 and are not scheduled under the Psychoactive Substances Act 2016. They are classified as research peptides and are not licensed as medicines by the MHRA. ## FAQs ### What is the main difference between Retatrutide and Semaglutide in research? The primary difference is receptor specificity. Retatrutide is a triple agonist activating GLP-1, GIP, and glucagon receptors, enabling research into multi-receptor metabolic integration. Semaglutide is a selective, long-acting GLP-1 receptor agonist, providing a clean model for isolated GLP-1 pharmacology and sustained incretin signalling. Retatrutide adds GIP-mediated insulin amplification and glucagon-mediated energy expenditure signals that are absent in Semaglutide. ### Which peptide is better for metabolic research? The choice depends on the research question. Retatrutide is preferable for studying multi-receptor metabolic regulation, energy homeostasis, and receptor crosstalk. Semaglutide is preferable for studying isolated GLP-1 receptor pharmacology, sustained receptor activation, and receptor desensitisation. Many researchers use both in parallel to compare single-receptor vs multi-receptor metabolic outcomes. ### Can Retatrutide and Semaglutide be used in the same study? Yes. In comparative study designs, researchers often run parallel treatment arms: one group receives Semaglutide (selective GLP-1 agonist), another receives Retatrutide (triple agonist), and a third receives vehicle. This enables direct comparison of triple agonism vs selective GLP-1 activation on metabolic endpoints such as insulin secretion, glucagon output, lipid metabolism, and cellular signalling. However, the two peptides are not typically co-administered or co-incubated in the same sample, as they compete for GLP-1 receptor binding. ### Do both peptides have the same half-life in research models? Both peptides have extended half-lives due to albumin binding, but the exact pharmacokinetics differ. Retatrutide has a half-life of approximately 5–7 days in research models, while Semaglutide's half-life is approximately 7 days. Both enable sustained receptor activation in cellular incubations and once-weekly dosing intervals in animal protocols. The extended half-life of both peptides requires researchers to account for sustained exposure when designing sequential studies. ### Are there differences in solubility between Retatrutide and Semaglutide? Both peptides are supplied as lyophilised powders and are generally soluble in aqueous solutions. Retatrutide's C20 fatty-diacid chain may reduce aqueous solubility slightly more than Semaglutide's C18 chain, but both require gentle handling: slow injection of water down the vial wall, no vigorous shaking, and brief warming (not exceeding 37°C) if needed. Both should be stored at −20°C as powder and 2–8°C as reconstituted solution. ## References - [Rosenstock J et al. Triple hormone receptor agonist retatrutide for obesity—A phase 2 trial. N Engl J Med 2023;389:138-151.](https://pubmed.ncbi.nlm.nih.gov/37389912/) - [Knudsen LB et al. The discovery and development of liraglutide and semaglutide. Front Endocrinol 2019;10:155.](https://pubmed.ncbi.nlm.nih.gov/30971904/) - [Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab 2022;34:1234-1247.](https://pubmed.ncbi.nlm.nih.gov/35809546/) - [Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018;27:740-756.](https://pubmed.ncbi.nlm.nih.gov/29617640/) - [Nauck MA et al. GLP-1 receptor agonists and GIP receptor agonists: Mechanisms and clinical applications. Nat Rev Endocrinol 2021;17:165-176.](https://pubmed.ncbi.nlm.nih.gov/33452483/) --- # BPC-157 vs TB-500: UK Regenerative Research Comparison 2026 URL: https://hatipeptides.co.uk/research/bpc-157-vs-tb-500 Updated: 2026-06-05 Author: Hati Peptides Comparative research reference for BPC-157 and TB-500. Pentadecapeptide vs thymosin beta-4 mechanisms, tissue repair applications, and sourcing standards for UK laboratories. ## Overview BPC-157 and TB-500 are both synthetic peptides studied in regenerative research, but they differ in origin, mechanism, and primary research applications. BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric protein, while TB-500 is a 43-amino-acid peptide representing the synthetic version of Thymosin Beta-4. For UK research laboratories, the choice between these peptides depends on the research model: BPC-157 is frequently studied for angiogenesis, fibroblast activation, and gastrointestinal protection, while TB-500 is primarily studied for actin regulation, cellular migration, and wound healing. This comparison covers molecular structure, mechanism of action, research applications, cellular models, and sourcing standards for both compounds. ## Molecular Structure Comparison **BPC-157** • Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids) • Molecular weight: ~1,419 Da • Origin: Synthetic partial sequence of human gastric Body Protection Compound • Structure: Linear peptide with multiple proline residues conferring rigidity **TB-500** • Sequence: 43 amino acids with N-terminal acetylated SDKP sequence • Molecular weight: ~4,963 Da • Origin: Synthetic version of endogenous Thymosin Beta-4 • Structure: Acetylated N-terminus with central actin-binding domain **Structural Differences** BPC-157 is significantly smaller than TB-500 (15 vs 43 amino acids) and lacks post-translational modifications. TB-500 contains an N-terminal acetylation and an actin-binding domain (residues 17–23) that is critical for its biological activity. The size difference influences cellular penetration, receptor interactions, and proteolytic susceptibility in research models. ## Mechanism of Action Comparison **BPC-157: Multi-Pathway Regenerative Mechanism** BPC-157 operates through several distinct mechanisms: 1. **Angiogenesis**: Upregulates VEGF and stimulates endothelial cell proliferation and migration 2. **Fibroblast activation**: Increases collagen synthesis and extracellular matrix deposition 3. **Gastrointestinal protection**: Maintains epithelial integrity and tight junction function 4. **Anti-inflammatory signalling**: Modulates NF-κB and reduces pro-inflammatory cytokines 5. **Nitric oxide pathway**: Enhances eNOS expression and NO production **TB-500: Actin-Regulation Mechanism** TB-500 primarily regulates the cytoskeleton: 1. **Actin sequestration**: Binds G-actin, preventing polymerisation into F-actin 2. **Cellular migration**: Promotes lamellipodia formation and directional cell movement 3. **Angiogenesis**: Stimulates endothelial cell migration and tube formation 4. **Anti-inflammatory effects**: N-terminal SDKP sequence reduces pro-inflammatory signalling 5. **Tissue regeneration**: Supports repair through enhanced cell migration and reduced inflammation **Key Research Differences** - BPC-157 produces multi-pathway regenerative effects with emphasis on angiogenesis and fibroblast activation - TB-500 primarily regulates actin dynamics and cell motility, with secondary angiogenic effects - BPC-157's gastric origin makes it relevant for gastrointestinal research - TB-500's actin regulation is central to wound healing and tissue repair models ## Research Applications Comparison **BPC-157 Research Applications** • Wound healing and angiogenesis studies • Tendon, ligament, and connective tissue repair • Gastrointestinal epithelial integrity and mucosal protection • Anti-inflammatory and NF-κB modulation research • Vascular regeneration and endothelial function **TB-500 Research Applications** • Wound healing and cellular migration studies • Musculoskeletal and cardiac tissue repair • Ocular and corneal epithelial healing • Actin cytoskeleton and cell motility research • Vascular repair and endothelial tube formation **When to Choose BPC-157** • Research questions involve angiogenesis and fibroblast activation • Studying gastrointestinal protective mechanisms • Examining multi-pathway tissue regeneration • Researching anti-inflammatory effects in wound healing **When to Choose TB-500** • Research questions involve actin regulation and cell migration • Studying wound healing through cytoskeletal remodelling • Examining endothelial cell motility and tube formation • Researching tissue repair in cardiac, ocular, or musculoskeletal models ## Cellular Models Comparison **BPC-157 Cellular Models** • Fibroblast scratch assays for wound closure and collagen deposition • HUVEC tube formation assays for angiogenesis • Ex vivo tendon and ligament explants for connective tissue repair • Caco-2 epithelial cells for barrier integrity and tight junctions • RAW 264.7 macrophages for inflammation and cytokine modulation **TB-500 Cellular Models** • Fibroblast scratch assays with time-lapse microscopy for migration dynamics • HUVEC Matrigel assays for tube formation and network complexity • Corneal epithelial cells for ocular wound healing • Primary cardiomyocytes for cardiac cell survival and migration • Fluorescent phalloidin staining for F-actin organisation **Comparative Experimental Design** Researchers often use both peptides in parallel to compare: • Wound closure rate (BPC-157's fibroblast activation vs TB-500's actin-regulated migration) • Angiogenic response (BPC-157's VEGF upregulation vs TB-500's endothelial motility) • Collagen synthesis (BPC-157's direct stimulation vs TB-500's indirect matrix remodelling) • Anti-inflammatory effects (BPC-157's NF-κB modulation vs TB-500's cytokine reduction) ## UK Sourcing and Purity Standards Both BPC-157 and TB-500 require high-purity research-grade materials for valid experimental results. **BPC-157 Sourcing Requirements** • ≥98% purity (HPLC), ≥99% preferred • Mass spectrometry confirming 15-amino-acid sequence • Molecular weight verification (~1,419 Da) • Batch-specific COA with endotoxin levels • Research-use-only labelling **TB-500 Sourcing Requirements** • ≥98% purity (HPLC), ≥99% preferred • Mass spectrometry confirming 43-amino-acid sequence and N-terminal acetylation • Molecular weight verification (~4,963 Da) • Batch-specific COA with endotoxin levels • Research-use-only labelling **UK Legal Status** Both peptides are not controlled substances under the Misuse of Drugs Act 1971 and are not scheduled under the Psychoactive Substances Act 2016. They are classified as research peptides and are not licensed as medicines by the MHRA. ## FAQs ### What is the main difference between BPC-157 and TB-500 in research? BPC-157 is a 15-amino-acid pentadecapeptide that promotes tissue regeneration through multiple pathways: angiogenesis (VEGF upregulation), fibroblast activation, collagen synthesis, and anti-inflammatory signalling. TB-500 is a 43-amino-acid peptide that primarily regulates the actin cytoskeleton, promoting cell migration and wound healing through actin sequestration. BPC-157 is often studied for gastrointestinal protection and connective tissue repair, while TB-500 is frequently studied for musculoskeletal and cardiac tissue repair. ### Which peptide is better for wound healing research? Both peptides are effective in wound healing models, but through different mechanisms. BPC-157 excels in angiogenesis and fibroblast activation, making it ideal for studies requiring new blood vessel formation and collagen deposition. TB-500 excels in cellular migration and actin remodelling, making it ideal for studies requiring rapid cell movement and tissue reorganization. Many researchers use both peptides in combination to examine synergistic effects on wound healing. ### Can BPC-157 and TB-500 be used together in research? Yes. Many researchers use both peptides in combination to examine synergistic regenerative effects. BPC-157's angiogenic and fibroblast-activating properties complement TB-500's actin-regulating and migration-promoting properties. Combined use is studied in wound healing, tissue repair, and regenerative medicine models. Researchers should design appropriate controls (BPC-157 alone, TB-500 alone, combined, and vehicle) to isolate additive or synergistic effects. ### Are there differences in stability between BPC-157 and TB-500? Both peptides are supplied as lyophilised powders and have similar storage requirements. BPC-157's multiple proline residues confer structural rigidity and resistance to proteolytic degradation. TB-500's N-terminal acetylation provides some protection against degradation. Both should be stored at −20°C as lyophilised powder and 2–8°C as reconstituted solution. BPC-157 shows resistance to pepsin degradation in vitro, which may be relevant for gastrointestinal research models. ### Which peptide is more suitable for gastrointestinal research? BPC-157 is more suitable for gastrointestinal research due to its origin from a gastric protein (Body Protection Compound). The peptide has been studied in intestinal epithelial cell models (Caco-2) for barrier integrity, tight junction maintenance, and mucosal protection. TB-500 is not specifically derived from gastrointestinal tissue and is less commonly studied in GI models. For gastrointestinal research, BPC-157 is the preferred reference compound. ## References - [Sikiric P et al. Stable gastric pentadecapeptide BPC 157: multiple organoprotection and therapeutic possibilities. Curr Pharm Des 2020;26:3947-3957.](https://pubmed.ncbi.nlm.nih.gov/32697396/) - [Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012;12:37-51.](https://pubmed.ncbi.nlm.nih.gov/22074294/) - [Sikiric P et al. BPC 157 and its effects on healing. Life Sci 2020;259:118198.](https://pubmed.ncbi.nlm.nih.gov/32721584/) - [Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999;113:364-368.](https://pubmed.ncbi.nlm.nih.gov/10469315/) - [Gwyer D et al. The stable gastric pentadecapeptide BPC 157: an overview of the current status. Curr Pharm Des 2020;26:3967-3978.](https://pubmed.ncbi.nlm.nih.gov/32571150/) --- # Beginner's Guide to Research Peptides: 2026 Edition URL: https://hatipeptides.co.uk/research/beginners-guide-research-peptides-2026 Updated: 2026-06-06 Author: Hati Peptides Starter guide for researchers new to peptides: what they are, choosing a first compound, purity standards, reconstitution basics, UK legality, common mistakes. ## What Are Research Peptides? Research peptides are short chains of amino acids (typically 2–50 residues) synthesised in laboratories for scientific investigation. Unlike pharmaceutical drugs, they are manufactured as **reference materials** for in vitro and laboratory animal studies — not for human consumption or clinical use. Peptides occur naturally in the body as signalling molecules: insulin, growth hormone, and glucagon are all peptides. Synthetic research peptides mimic or modulate these natural pathways, allowing scientists to study cellular signalling, metabolic regulation, tissue repair, and ageing mechanisms in controlled settings. For UK buyers, research peptides are legal to purchase for legitimate laboratory use. They are not controlled substances under the Misuse of Drugs Act 1971, nor are they licensed medicines under the MHRA. This guide explains everything a first-time buyer needs to know to make informed, safe decisions. ## The Four Main Research Areas Research peptides are generally grouped into four categories based on their primary research applications. Understanding these categories helps you choose the right compound for your model. **1. Metabolic & Weight Loss Research** Peptides in this category target glucose regulation, insulin secretion, appetite signalling, and energy expenditure. Common examples include: • **Semaglutide** — GLP-1 receptor agonist for sustained incretin signalling • **[Tirzepatide](/product/tirzepatide)** — Dual agonist (GLP-1 / GIP) for glucose-dependent insulin secretion and energy homeostasis • **Retatrutide** — Triple agonist (GLP-1 / GIP / glucagon) for multi-receptor metabolic studies • **MOTS-C** — Mitochondrial-derived peptide for AMPK activation and metabolic flexibility • **Tesamorelin** — GHRH analogue for growth hormone axis studies **2. Recovery & Healing Research** These peptides are studied in tissue regeneration, wound healing, and connective tissue repair models: • **BPC-157** — Pentadecapeptide investigated for angiogenesis and fibroblast activation • **TB-500** — Thymosin Beta-4 fragment for actin regulation and cell migration • **GHK-Cu** — Copper tripeptide for extracellular matrix remodelling and collagen synthesis **3. Longevity & Anti-Aging Research** Longevity peptides examine cellular senescence, telomere maintenance, and mitochondrial function: • **Epithalon** — Tetrapeptide studied for telomerase activation • **NAD+** — Coenzyme for redox metabolism and sirtuin activation **4. Cognitive & Neuro Research** These compounds are used in neuroimmune, stress-response, and synaptic plasticity models: • **Selank** — Synthetic heptapeptide for neuroimmune modulation and BDNF expression Most first-time researchers start with either **metabolic** or **regenerative** peptides, as these have the most published literature and established cellular models. ## How to Choose Your First Peptide Selecting your first peptide depends on three factors: your research model, your budget, and the depth of available literature. **Step 1: Define Your Research Question** • Are you studying metabolic pathways? → Consider [Semaglutide](/product/semaglutide), [Tirzepatide](/product/tirzepatide), or [Retatrutide](/product/retatrutide) • Are you studying tissue repair or wound healing? → Consider BPC-157 or GHK-Cu • Are you studying cellular ageing? → Consider Epithalon or NAD+ • Are you studying neuroimmune signalling? → Consider Selank **Step 2: Check Published Literature** Before ordering, search PubMed for your peptide + your cell type. For example: • "BPC-157 fibroblast" → 50+ studies • "Semaglutide MIN6" → 30+ studies • "GHK-Cu collagen synthesis" → 40+ studies A well-studied peptide gives you established protocols, positive controls, and reproducible endpoints. **Step 3: Start with a Single Compound** Beginners should avoid multi-peptide stacks until they are comfortable with reconstitution, storage, and assay design. Order one peptide, master the basics, then expand. **Step 4: Order the Right Size** • **10 mg** is the standard starter size for most peptides • **5 mg** is available for some compounds if you want to test before scaling up • **Bacteriostatic water** is essential for reconstitution — add a 3 ml vial to your order **Recommended First-Time Orders** | Research Focus | Peptide | Size | Why Start Here | |----------------|---------|------|----------------| | Metabolic | Semaglutide | 10 mg | Well-documented, extensive cellular models | | Metabolic | [Tirzepatide](/product/tirzepatide) | 5 mg | Dual agonist with unique GLP-1/GIP crosstalk data | | Regenerative | BPC-157 | 10 mg | High purity, robust fibroblast literature | | Skin / Matrix | GHK-Cu | 50 mg | Affordable, stable, visual confirmation (blue-violet) | | Longevity | NAD+ | 500 mg | Simple reconstitution, clear enzymatic assays | ## Understanding Purity and Quality Purity is the most important parameter for reproducible research. Impurities can confound results, alter cellular responses, and invalidate your conclusions. **What the Numbers Mean** • **≥95%**: Acceptable for preliminary screening and high-throughput assays • **≥98%**: Standard for most published research and cell culture work • **≥99%**: Preferred for sensitive assays (receptor binding, crystallography, NMR) **How Purity Is Measured** • **HPLC (High-Performance Liquid Chromatography)**: Separates the target peptide from synthesis by-products. The area-under-curve percentage is the purity value. • **Mass Spectrometry (MS)**: Confirms the molecular weight and sequence identity. Always verify that the observed mass matches the theoretical mass within ±1 Da. **What to Demand from Your Supplier** 1. **Certificate of Analysis (CoA)** per batch, showing HPLC chromatogram and MS data 2. **Batch-specific testing** — not a generic template 3. **Endotoxin levels** <0.5 EU/mL for cell culture safety 4. **Molecular weight confirmation** matching the theoretical value **Red Flags** • No batch number on the CoA • No analytical method details (e.g., "purity >95%" without HPLC method) • No mass spectrometry data • Outdated analysis date relative to the batch • No analyst signature or reviewer stamp **Best Practice**: Retain the CoA for every batch. If you publish results, include the batch number, supplier, and purity grade in your methods section. ## Reconstitution Basics Reconstitution is the process of dissolving lyophilised (freeze-dried) peptide powder into a liquid solution for laboratory use. It is simpler than it sounds, but precision matters. **What You Need** • Bacteriostatic water (BAC water) — sterile water with 0.9% benzyl alcohol • Sterile syringe (1–3 ml) with 25G or 27G needle • Alcohol wipes (70% isopropyl) • Vial stand or rack **Basic Steps** 1. Allow the peptide vial and BAC water to reach room temperature 2. Wipe both stoppers with an alcohol wipe; let dry 3. Draw the required volume of BAC water into the syringe 4. Inject the water **slowly down the inside wall** of the peptide vial — do not spray directly onto the powder 5. Gently swirl the vial until the powder dissolves. **Do not shake vigorously** 6. Inspect the solution: it should be clear and free of particles **Concentration Quick Reference** For a 10 mg vial: • 1 ml water = 10 mg/ml • 2 ml water = 5 mg/ml • 5 ml water = 2 mg/ml Choose a concentration appropriate for your assay. Higher concentrations are not always better — some peptides become less soluble above 5 mg/ml. **Troubleshooting** • **Won't dissolve?** Gently warm to 25–30°C (never exceed 37°C) or add water in smaller increments • **Cloudy solution?** The concentration may be too high; dilute with more BAC water • **Foam formed?** Caused by shaking or forceful injection. Let it settle; do not shake to disperse For a detailed protocol, see our [Peptide Reconstitution Guide](/guides/reconstitution). ## Storage and Handling Proper storage preserves peptide integrity and ensures reproducible results. **Lyophilised Powder (Unopened)** • Store at **−20°C** in a desiccated container • Protect from light (amber vials or foil wrapping) • Shelf life: **24–36 months** when properly stored • Avoid frost-free freezers (temperature cycling degrades peptides) **Reconstituted Solution** • Store at **2–8°C** (refrigerator) • Use **bacteriostatic water** for multi-day storage (prevents bacterial growth) • Shelf life: **7–14 days** under refrigeration • Protect from light • **Never freeze-thaw repeatedly** — causes aggregation and pH shifts **Critical Precautions** • Wear powder-free gloves when handling vials • Wipe the stopper with alcohol before every needle insertion • Use a new sterile needle for each access • Label the vial with peptide name, concentration, and reconstitution date • Document all handling in your laboratory notebook **Light-Sensitive Peptides** • **GHK-Cu**: The copper complex is photoreduced by visible light; store in amber vials or wrapped in foil • **Tryptophan-containing peptides**: Oxidise under UV light • **Methionine-containing peptides**: Susceptible to photo-oxidation For comprehensive storage guidance, see our [Storage and Handling Guide](/guides/storage). ## UK Legal Status and Compliance Research peptides operate in a specific regulatory framework in the UK. Understanding this framework protects you and ensures your research remains compliant. **Legal Status** • **Not controlled substances** under the Misuse of Drugs Act 1971 • **Not scheduled** under the Psychoactive Substances Act 2016 • **Not licensed as medicines** by the MHRA • Classified as **research reference materials** for laboratory use **What This Means for Buyers** • You do **not** need a prescription or licence to purchase research peptides • You must use them for **in vitro and laboratory research only** • You must **not** consume them, administer them to animals without ethical approval, or market them as medicines **For Animal Research** If you plan to use peptides in animal studies, you must obtain: • Institutional Animal Care and Use Committee (IACUC) or equivalent approval • Compliance with the **Animals (Scientific Procedures) Act 1986** • Veterinary oversight and appropriate dosing protocols **Importing Peptides** Importing research peptides for laboratory use is permitted under UK customs regulations, provided: • The peptides are for genuine research • The quantity is appropriate for research (not commercial resale) • The materials are properly declared • You retain all import documentation (invoices, CoAs, batch records) **Research-Use-Only Labelling** All legitimate UK suppliers label peptides explicitly for research use. If a supplier markets peptides for human consumption, cosmetic use, or as dietary supplements, they are operating outside UK regulations and should be avoided. ## Common Beginner Mistakes Avoiding these common errors will save you money, time, and failed experiments. **1. Buying from Unverified Suppliers** The UK peptide market includes vendors with questionable quality control. Always verify: • Batch-specific CoAs with HPLC and MS data • UK-based testing or clear traceability • Responsive customer support • Transparent pricing (no hidden fees) If a price seems too good to be true, the purity probably is too. **2. Choosing the Wrong Purity Grade** • **Mistake**: Buying 95% purity for a sensitive cell culture assay • **Fix**: Use ≥98% for cell culture, ≥99% for receptor binding or crystallography • **Exception**: Screening and antibody generation can tolerate 95% **3. Using the Wrong Solvent** • **Mistake**: Reconstituting with tap water or distilled water • **Fix**: Use bacteriostatic water for multi-day storage; sterile water only for same-day use • **Mistake**: Using PBS for long-term storage (no preservative) **4. Storing Improperly** • **Mistake**: Leaving reconstituted peptides at room temperature for days • **Fix**: Refrigerate at 2–8°C immediately after reconstitution • **Mistake**: Repeated freeze-thaw of reconstituted solutions • **Fix**: Aliquot into single-use vials before freezing **5. Skipping Documentation** • **Mistake**: Not recording batch numbers, reconstitution dates, or storage conditions • **Fix**: Maintain a laboratory notebook. This is essential for reproducibility and regulatory compliance. **6. Ordering Without a Clear Research Plan** • **Mistake**: Buying a peptide because it is popular, not because it fits your model • **Fix**: Search PubMed for your cell type + peptide before ordering. Confirm that published protocols exist. **7. Ignoring the CoA** • **Mistake**: Throwing away the Certificate of Analysis • **Fix**: Retain the CoA for every batch. Verify the molecular weight and purity independently if publishing results. ## FAQs ### Are research peptides legal to buy in the UK? Yes. Research peptides are not controlled substances under UK law. They are classified as laboratory reference materials and are legal to purchase for legitimate research. No prescription or licence is required. They must be sold for research use only and are not licensed as medicines by the MHRA. ### How much should I spend on my first peptide order? A sensible first order includes one 10 mg peptide (£15–£30) plus bacteriostatic water (£3–£4). With the 10% sitewide discount applied at checkout, most first orders total £20–£35. Start with a single compound, master reconstitution and storage, then expand your catalog once you are confident. ### Do I need a university laboratory to buy research peptides? No. You do not need institutional affiliation to purchase research peptides in the UK. However, you must use them for legitimate research purposes. If you plan animal studies, you will need institutional ethics approval under the Animals (Scientific Procedures) Act 1986. For in vitro research, standard laboratory safety precautions apply. ### What is the difference between 98% and 99% purity? The difference is 1% of impurities. For most cell culture and biochemical assays, ≥98% is perfectly adequate. ≥99% is preferred for highly sensitive assays such as receptor binding, crystallography, or mass spectrometry quantification. The price difference is typically 30–50% more for 99% vs 98%. For a beginner's first experiments, 98% is the standard and cost-effective choice. ### How do I know if a peptide supplier is trustworthy? Trustworthy suppliers provide: (1) batch-specific Certificates of Analysis with HPLC and MS data, (2) clear contact information and UK-based support, (3) transparent pricing with no hidden fees, (4) research-use-only labelling and compliance disclaimers, (5) secure payment options, and (6) responsive customer service. Avoid suppliers who make health claims, omit CoAs, or pressure you into large orders. ## References - [Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 1963;85:2149-2154.](https://pubmed.ncbi.nlm.nih.gov/1400950/) - [Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 1990;35:161-214.](https://pubmed.ncbi.nlm.nih.gov/2191921/) - [UK Home Office. Misuse of Drugs Act 1971. Legislation.gov.uk.](https://www.legislation.gov.uk/ukpga/1971/38) - [Medicines and Healthcare products Regulatory Agency (MHRA). Human Medicines Regulations 2012.](https://www.legislation.gov.uk/uksi/2012/1916) - [Animals (Scientific Procedures) Act 1986. Legislation.gov.uk.](https://www.legislation.gov.uk/ukpga/1986/14) --- # Recovery Stack: BPC-157 + TB-500 Research Guide 2026 URL: https://hatipeptides.co.uk/research/recovery-stack Updated: 2026-06-06 Author: Hati Peptides Research guide for the Recovery Stack combining BPC-157 and TB-500. Complementary mechanisms in tissue regeneration, wound healing, and musculoskeletal repair models. ## Overview The Recovery Stack combines two of the most studied regenerative peptides in research: BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4). While both peptides are investigated in tissue repair and wound healing models, they operate through distinct mechanisms that create complementary research outcomes when studied together. BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric protein, primarily studied for angiogenesis, fibroblast activation, and gastrointestinal protection. TB-500 is a 43-amino-acid peptide representing the synthetic version of Thymosin Beta-4, primarily studied for actin regulation, cellular migration, and cytoskeletal remodelling. For UK research laboratories, the Recovery Stack offers a dual-mechanism model for studying tissue regeneration: BPC-157 provides the angiogenic and fibroblast-activating signals, while TB-500 provides the actin-regulated cellular migration and structural reorganisation. This combination enables researchers to examine whether distinct regenerative pathways produce additive or synergistic effects in wound healing and tissue repair models. ## Molecular Structure **BPC-157** • Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids) • Molecular weight: ~1,419 Da • Structure: Linear pentadecapeptide with multiple proline residues conferring rigidity • Origin: Synthetic partial sequence of human gastric Body Protection Compound **TB-500** • Sequence: 43 amino acids with N-terminal acetylated SDKP sequence • Molecular weight: ~4,963 Da • Structure: Acetylated N-terminus with central actin-binding domain (residues 17–23) • Origin: Synthetic version of endogenous Thymosin Beta-4 **Structural Differences** BPC-157 is significantly smaller and lacks post-translational modifications, while TB-500 contains N-terminal acetylation and a dedicated actin-binding domain. The size difference influences cellular penetration, receptor interactions, and proteolytic susceptibility. Both peptides are supplied as lyophilised powders and are soluble in aqueous solutions. ## Mechanism of Action **BPC-157 Mechanisms** BPC-157 operates through multiple regenerative pathways in cellular models: 1. **Angiogenesis**: Upregulates vascular endothelial growth factor (VEGF) and stimulates endothelial cell proliferation and migration 2. **Fibroblast activation**: Increases collagen synthesis and extracellular matrix deposition 3. **Nitric oxide pathway**: Enhances endothelial nitric oxide synthase (eNOS) expression and NO production 4. **Anti-inflammatory signalling**: Modulates NF-κB and reduces pro-inflammatory cytokine production 5. **Gastrointestinal protection**: Maintains epithelial integrity and tight junction function **TB-500 Mechanisms** TB-500 primarily regulates cytoskeletal dynamics: 1. **Actin sequestration**: Binds G-actin, preventing polymerisation into F-actin 2. **Cellular migration**: Promotes lamellipodia formation and directional cell movement 3. **Angiogenesis**: Stimulates endothelial cell migration and tube formation 4. **Anti-inflammatory effects**: N-terminal SDKP sequence reduces pro-inflammatory signalling 5. **Tissue regeneration**: Supports repair through enhanced cell migration and reduced inflammation **Complementary Mechanism** In combined research models, BPC-157 provides the vascular and matrix-building signals (angiogenesis, collagen, NO), while TB-500 provides the cellular motility required for tissue reorganisation (actin regulation, migration). The angiogenic signal from BPC-157 creates the vascular infrastructure needed for tissue repair, while TB-500's actin regulation enables cells to migrate into the repair zone and restructure the extracellular matrix. ## Research Applications The Recovery Stack is employed across multiple research domains in UK laboratories: **Wound Healing Research** In vitro studies examine the combined effects of BPC-157 and TB-500 on wound closure rates, cellular migration, and tissue regeneration. Researchers use scratch assays, organotypic cultures, and tissue explants to model wound healing and examine whether the dual-mechanism approach produces faster or more complete repair compared to single-peptide models. **Musculoskeletal Research** Tendon, ligament, and muscle cell cultures are used to examine the stack's effects on connective tissue repair. BPC-157's fibroblast activation and collagen synthesis complement TB-500's actin-regulated cellular migration in tendon explant and tenocyte cultures. **Vascular Regeneration** Endothelial cell models examine the combined angiogenic effects of both peptides. BPC-157's VEGF upregulation and TB-500's endothelial cell motility create a dual-angiogenic model for studying vessel formation and tissue perfusion. **Comparative Regenerative Studies** The stack is compared to single-peptide treatments and other regenerative compounds in cellular studies. Research questions examine whether the complementary mechanisms produce additive, synergistic, or sequential effects in tissue repair models. **Anti-Inflammatory Research** Macrophage and fibroblast co-cultures examine the combined anti-inflammatory effects of both peptides. BPC-157's NF-κB modulation and TB-500's cytokine reduction create a dual anti-inflammatory signal that is studied in chronic inflammation and tissue repair models. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for Recovery Stack studies: **Fibroblast Co-Culture Assays** Primary fibroblasts are cultured with both peptides simultaneously or sequentially to measure wound closure, collagen deposition, and matrix reorganisation. Endpoints include scratch closure rate, collagen I/III production, α-SMA expression, and extracellular matrix stiffness. Parallel single-peptide controls isolate additive effects. **Endothelial Tube Formation** HUVEC cultures are treated with both peptides in Matrigel assays to examine combined angiogenic effects. Endpoints include tube length, branch points, network complexity, and VEGF production. The dual treatment is compared to BPC-157 alone and TB-500 alone. **Tendon Explant Cultures** Ex vivo tendon and ligament explants are maintained in culture with the stack to examine tissue-level healing. Endpoints include tissue strength, collagen organisation, cell viability, and matrix deposition. The combination is compared to individual treatments and vehicle controls. **Macrophage Inflammation Models** RAW 264.7 and primary macrophages are activated with LPS, then treated with the stack to examine combined anti-inflammatory effects. Endpoints include TNF-α, IL-6, and IL-10 production, as well as NF-κB activation. **Epithelial Wound Healing** Corneal epithelial cells and skin keratinocytes are used in scratch assays to examine combined effects on epithelial migration and wound closure. Time-lapse microscopy tracks cell migration dynamics in response to dual-peptide treatment. ## Safety and Sourcing Standards Both peptides in the Recovery Stack require high-purity research-grade materials for valid experimental results. **BPC-157 Sourcing Requirements** • ≥98% purity (HPLC), ≥99% preferred • Mass spectrometry confirming 15-amino-acid sequence • Molecular weight verification (~1,419 Da) • Batch-specific COA with endotoxin levels • Research-use-only labelling **TB-500 Sourcing Requirements** • ≥98% purity (HPLC), ≥99% preferred • Mass spectrometry confirming 43-amino-acid sequence and N-terminal acetylation • Molecular weight verification (~4,963 Da) • Batch-specific COA with endotoxin levels • Research-use-only labelling **Safety Profile** Both peptides have favourable safety profiles in preclinical cellular and animal studies. In vitro toxicology screens have not identified significant cytotoxicity at research-relevant concentrations. No organ-specific toxicity has been reported at standard research doses for either peptide. **UK Legal Status** Both peptides are not controlled substances under the Misuse of Drugs Act 1971 and are not scheduled under the Psychoactive Substances Act 2016. They are classified as research peptides and are not licensed as medicines by the MHRA. ## FAQs ### How do BPC-157 and TB-500 complement each other in research? BPC-157 and TB-500 operate through distinct but complementary mechanisms in tissue repair models. BPC-157 primarily promotes angiogenesis (VEGF upregulation), fibroblast activation, and collagen synthesis. TB-500 primarily regulates actin cytoskeleton dynamics and promotes cellular migration. In combined research models, BPC-157 provides the vascular and matrix-building infrastructure, while TB-500 enables the cellular motility required for tissue reorganisation. This dual-mechanism approach is studied in wound healing, tendon repair, and tissue regeneration models. ### Can BPC-157 and TB-500 be used together in cellular assays? Yes. Researchers often use both peptides in combination to examine synergistic or additive regenerative effects. Standard experimental designs include parallel treatment arms: BPC-157 alone, TB-500 alone, combined treatment, and vehicle control. Endpoints such as wound closure rate, collagen deposition, and angiogenic response are compared across all groups to isolate combined effects. Both peptides are soluble in aqueous solutions and are compatible in standard cell culture media. ### What is the best cellular model for studying the Recovery Stack? The most common model is the fibroblast scratch assay, which measures wound closure rate, collagen synthesis, and matrix deposition. HUVEC tube formation assays are used for angiogenic studies, and ex vivo tendon explants are used for connective tissue repair. For inflammatory studies, LPS-activated macrophages treated with the stack measure combined anti-inflammatory effects. Time-lapse microscopy is recommended for tracking cell migration dynamics in response to dual-peptide treatment. ### Is the Recovery Stack legal for research in the UK? Yes. Both BPC-157 and TB-500 are not controlled substances under UK law. They are classified as research peptides and are legal to purchase and possess for legitimate laboratory research. They are not licensed as medicines by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for Recovery Stack research? Both peptides should be ≥98% pure by HPLC, with ≥99% being the preferred standard for sensitive assays. Mass spectrometry identity confirmation is essential for both peptides: BPC-157 requires verification of the 15-amino-acid sequence (~1,419 Da), and TB-500 requires verification of the 43-amino-acid sequence and N-terminal acetylation (~4,963 Da). Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels for both compounds. ## References - [Sikiric P et al. Stable gastric pentadecapeptide BPC 157: multiple organoprotection and therapeutic possibilities. Curr Pharm Des 2020;26:3947-3957.](https://pubmed.ncbi.nlm.nih.gov/32697396/) - [Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012;12:37-51.](https://pubmed.ncbi.nlm.nih.gov/22074294/) - [Sikiric P et al. BPC 157 and its effects on healing. Life Sci 2020;259:118198.](https://pubmed.ncbi.nlm.nih.gov/32721584/) - [Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999;113:364-368.](https://pubmed.ncbi.nlm.nih.gov/10469315/) - [Gwyer D et al. The stable gastric pentadecapeptide BPC 157: an overview of the current status. Curr Pharm Des 2020;26:3967-3978.](https://pubmed.ncbi.nlm.nih.gov/32571150/) --- # Metabolic Stack: Retatrutide + MOTS-C Research Guide 2026 URL: https://hatipeptides.co.uk/research/metabolic-stack Updated: 2026-06-06 Author: Hati Peptides Research guide for the Metabolic Stack combining Retatrutide and MOTS-C. Multi-receptor metabolic regulation and mitochondrial signalling for energy homeostasis research. ## Overview The Metabolic Stack combines Retatrutide, a triple agonist at GLP-1, GIP, and glucagon receptors, with MOTS-C, a mitochondrial-derived peptide that activates AMP-activated protein kinase (AMPK). This combination creates a dual-layer metabolic research model: Retatrutide provides the hormonal signalling layer, while MOTS-C provides the cellular energy-sensing layer. Retatrutide (LY3437943) is a 39-amino-acid peptide with a C20 fatty-diacid conjugate, enabling extended half-life through albumin binding. It activates three distinct metabolic receptors simultaneously, producing integrated metabolic regulation in cellular and in vitro models. MOTS-C is a 16-amino-acid peptide encoded within the mitochondrial genome. It activates AMPK, regulates glucose uptake, and communicates mitochondrial status to the nucleus through retrograde signalling. For UK research laboratories, the Metabolic Stack offers a comprehensive model for studying the relationship between hormonal metabolic regulation and mitochondrial energy sensing. Retatrutide's receptor-level signalling is studied in combination with MOTS-C's cellular-level energy regulation to examine how multi-scale metabolic signals interact. Researchers also compare this stack to dual-agonist approaches such as [Tirzepatide](/product/tirzepatide) for GLP-1/GIP-focused metabolic studies. ## Molecular Structure **Retatrutide** • Sequence: 39 amino acids with C20 fatty-diacid conjugate • Molecular weight: ~4,700 Da • Key modifications: N-terminal fatty-diacid via γ-Glu-2xAdo linker; triple receptor affinity • Half-life: ~5–7 days (albumin binding) **MOTS-C** • Sequence: MRWQEMGYIFYPRKLN (16 amino acids) • Molecular weight: ~2,099 Da • Origin: Encoded by mitochondrial 12S rRNA gene • Processing: Cleaved from mitochondrial ORF; exported to cytosol and extracellular space **Structural Differences** Retatrutide is a large, modified peptide with lipid conjugation for extended pharmacokinetics. MOTS-C is a small, unmodified peptide with rapid cellular uptake and short half-life. The size difference reflects their distinct modes of action: Retatrutide acts as a receptor ligand requiring sustained plasma exposure, while MOTS-C acts as an intracellular signalling molecule with rapid nuclear translocation. ## Mechanism of Action **Retatrutide Mechanisms** Retatrutide activates three distinct receptor systems in metabolic research models: 1. **GLP-1 receptor agonism**: Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, activates satiety circuits 2. **GIP receptor agonism**: Amplifies insulin secretion, promotes adipose lipid storage, supports bone formation 3. **Glucagon receptor agonism**: Increases hepatic glucose output, stimulates lipolysis, raises energy expenditure The triple agonism creates a balanced metabolic profile where the glucagon component counteracts the insulinotropic effects of GLP-1 and GIP, producing unique research questions about metabolic signal integration. **MOTS-C Mechanisms** MOTS-C operates through several distinct pathways: 1. **AMPK activation**: Increases AMPK phosphorylation, leading to enhanced glucose uptake, fatty acid oxidation, and mitochondrial biogenesis 2. **Mitochondrial-nuclear communication**: Translocates to the nucleus and modulates gene expression programmes related to metabolism and stress resistance 3. **Cellular stress response**: Upregulated in response to metabolic stress, conferring resistance through enhanced glucose uptake and mitochondrial optimisation 4. **Insulin sensitivity**: Enhances glucose uptake in skeletal muscle cells and adipocytes, reduces hepatic glucose production **Complementary Mechanism** In combined research models, Retatrutide provides the hormonal metabolic signals (insulin secretion, glucagon suppression, satiety), while MOTS-C provides the cellular energy-sensing response (AMPK activation, metabolic gene expression, mitochondrial adaptation). The combination enables researchers to study how hormonal inputs interact with intracellular energy-sensing pathways to coordinate metabolic homeostasis. ## Research Applications The Metabolic Stack is employed across multiple research domains in UK laboratories: **Metabolic Flexibility Research** Cellular models examine how Retatrutide's multi-receptor metabolic regulation interacts with MOTS-C's AMPK activation to coordinate fuel switching between glucose and fatty acids. Researchers use hepatocyte and myocyte cultures to study metabolic flexibility under dual-peptide treatment. **Energy Homeostasis Studies** In vitro studies examine the combined effects on energy balance, examining whether the hormonal signals from Retatrutide and the cellular energy signals from MOTS-C produce coordinated or competing effects on ATP production, oxygen consumption, and metabolic flux. **Insulin Sensitivity Research** Adipocyte and myocyte cultures are used to examine combined effects on insulin signalling, glucose uptake, and GLUT4 translocation. Retatrutide's incretin-mediated insulin secretion is studied alongside MOTS-C's AMPK-mediated glucose uptake to examine multi-pathway insulin sensitivity. **Mitochondrial Function Studies** Seahorse respirometry and isolated mitochondrial assays measure the combined effects on oxygen consumption rate, ATP synthesis, and reactive oxygen species production. The interaction between receptor-level hormonal regulation and mitochondrial bioenergetics is a key research question. **Comparative Metabolic Pharmacology** The stack is compared to single-peptide treatments and other metabolic compounds in cellular studies. Research questions examine whether the combination of hormonal and mitochondrial metabolic regulation produces additive or synergistic effects on metabolic endpoints. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for Metabolic Stack studies: **Beta-Cell Insulin Secretion** MIN6 and INS-1 beta-cell lines are used to measure glucose-stimulated insulin secretion in response to Retatrutide, with MOTS-C added to examine mitochondrial contributions to insulin secretion. Endpoints include insulin release, intracellular calcium flux, and cAMP accumulation. **Hepatocyte Glucose Metabolism** Primary hepatocytes and hepatoma cell lines are used to examine combined effects on hepatic glucose output, gluconeogenic gene expression, and glucagon receptor signalling. Retatrutide's glucagon activity is studied alongside MOTS-C's effects on hepatic glucose production. **Adipocyte Metabolism** 3T3-L1 adipocytes and primary human adipocytes are used to examine lipid storage, lipolysis, and adipokine secretion. Retatrutide's GIP-mediated lipid storage is compared to MOTS-C's AMPK-mediated fatty acid oxidation. **Myocyte Glucose Uptake** C2C12 myotubes are used to measure 2-deoxyglucose uptake and GLUT4 translocation in response to the stack. The combination of Retatrutide's insulinotropic effects and MOTS-C's AMPK activation creates a dual-pathway glucose uptake model. **Mitochondrial Respiration** Seahorse respirometry is used to measure oxygen consumption rate, spare respiratory capacity, and ATP production in cells treated with both peptides. The combined effects on mitochondrial function are compared to individual treatments. ## Safety and Sourcing Standards Both peptides in the Metabolic Stack require high-purity research-grade materials for valid experimental results. **Retatrutide Sourcing Requirements** • ≥98% purity (HPLC), ≥99% preferred • Mass spectrometry confirming 39-amino-acid sequence and C20 fatty-diacid conjugate • Molecular weight verification (~4,700 Da) • Batch-specific COA with endotoxin levels • Research-use-only labelling **MOTS-C Sourcing Requirements** • ≥98% purity (HPLC), ≥99% preferred • Mass spectrometry confirming 16-amino-acid sequence • Molecular weight verification (~2,099 Da) • Batch-specific COA with endotoxin levels • Research-use-only labelling **Safety Profile** Both peptides have favourable safety profiles in preclinical cellular and animal studies. In vitro toxicology screens have not identified significant cytotoxicity at research-relevant concentrations. No organ-specific toxicity has been reported at standard research doses. **UK Legal Status** Both peptides are not controlled substances under the Misuse of Drugs Act 1971 and are not scheduled under the Psychoactive Substances Act 2016. They are classified as research peptides and are not licensed as medicines by the MHRA. ## FAQs ### How do Retatrutide and MOTS-C complement each other in metabolic research? Retatrutide and MOTS-C operate at different scales of metabolic regulation. Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors, providing hormonal-level metabolic signals (insulin secretion, glucagon suppression, satiety). MOTS-C is a mitochondrial-derived peptide that activates AMPK, providing cellular-level energy sensing (glucose uptake, fatty acid oxidation, mitochondrial biogenesis). In combined research models, the hormonal signals from Retatrutide interact with the intracellular energy responses from MOTS-C, creating a multi-scale metabolic research model for studying metabolic homeostasis. ### Can Retatrutide and MOTS-C be used together in cellular assays? Yes. Researchers often use both peptides in combination to examine multi-scale metabolic regulation. Standard experimental designs include parallel treatment arms: Retatrutide alone, MOTS-C alone, combined treatment, and vehicle control. Endpoints such as insulin secretion, glucose uptake, lipid metabolism, and mitochondrial respiration are compared across all groups. Both peptides are soluble in aqueous solutions and are compatible in standard cell culture media, though Retatrutide's fatty-diacid chain may require brief warming for complete dissolution. ### What is the best cellular model for studying the Metabolic Stack? The most common models are beta-cell lines (MIN6, INS-1) for insulin secretion studies, primary hepatocytes for hepatic glucose metabolism, 3T3-L1 adipocytes for lipid metabolism, and C2C12 myotubes for glucose uptake. For mitochondrial studies, Seahorse respirometry is used to measure oxygen consumption rate and ATP production. Multi-cellular co-culture systems are also used to study paracrine signalling between different metabolic cell types in response to the stack. ### Is the Metabolic Stack legal for research in the UK? Yes. Both Retatrutide and MOTS-C are not controlled substances under UK law. They are classified as research peptides and are legal to purchase and possess for legitimate laboratory research. They are not licensed as medicines by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for Metabolic Stack research? Both peptides should be ≥98% pure by HPLC, with ≥99% being the preferred standard for sensitive metabolic assays. Mass spectrometry identity confirmation is essential: Retatrutide requires verification of the 39-amino-acid sequence and C20 fatty-diacid conjugate (~4,700 Da), while MOTS-C requires verification of the 16-amino-acid sequence (~2,099 Da). Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels for both compounds. ## References - [Rosenstock J et al. Triple hormone receptor agonist retatrutide for obesity—A phase 2 trial. N Engl J Med 2023;389:138-151.](https://pubmed.ncbi.nlm.nih.gov/37389912/) - [Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21:443-454.](https://pubmed.ncbi.nlm.nih.gov/25738462/) - [Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab 2022;34:1234-1247.](https://pubmed.ncbi.nlm.nih.gov/35809546/) - [Reynolds JC et al. MOTS-c is an exercise-mimetic peptide. Cell Metab 2021;33:1862-1875.](https://pubmed.ncbi.nlm.nih.gov/34610280/) - [Nauck MA et al. GLP-1 receptor agonists and GIP receptor agonists: Mechanisms and clinical applications. Nat Rev Endocrinol 2021;17:165-176.](https://pubmed.ncbi.nlm.nih.gov/33452483/) --- # Longevity Stack: Epithalon + NAD+ Research Guide 2026 URL: https://hatipeptides.co.uk/research/longevity-stack Updated: 2026-06-06 Author: Hati Peptides Research guide for the Longevity Stack combining Epithalon and NAD+. Telomerase activation and cellular metabolism for ageing and cellular senescence research. ## Overview The Longevity Stack combines Epithalon, a synthetic tetrapeptide studied for telomerase activation and pineal axis regulation, with NAD+ (nicotinamide adenine dinucleotide), a coenzyme central to cellular metabolism, redox reactions, and sirtuin activation. This combination creates a dual-mechanism model for ageing research: Epithalon provides the telomere maintenance and cellular senescence layer, while NAD+ provides the metabolic and epigenetic regulation layer. Epithalon (Ala-Glu-Asp-Gly) is a 4-amino-acid peptide originally isolated from the pineal gland. It is studied for its effects on telomerase activity, cellular replicative lifespan, and pineal hormone regulation. NAD+ is a dinucleotide found in all living cells, serving as an essential electron carrier and substrate for sirtuins, PARPs, and other enzymes involved in DNA repair and metabolic regulation. For UK research laboratories, the Longevity Stack offers a comprehensive model for studying cellular ageing mechanisms. Epithalon's telomerase-mediated effects are studied alongside NAD+'s metabolic and epigenetic regulation to examine how telomere maintenance and cellular energy status interact in ageing models. ## Molecular Structure **Epithalon** • Sequence: Ala-Glu-Asp-Gly (4 amino acids) • Molecular weight: ~390.4 Da • Origin: Synthetic version of a pineal gland peptide • Size: One of the smallest bioactive peptides in research use **NAD+** • Formula: C21H27N7O14P2 • Molecular weight: 663.4 Da (oxidised form) • Structure: Adenine + ribose + pyrophosphate + nicotinamide + ribose • Redox centre: Nicotinamide ring (accepts/donates hydride ion) **Structural Differences** Epithalon is a small linear peptide with rapid cellular uptake and direct nuclear localisation. NAD+ is a dinucleotide with negatively charged phosphate groups and a bulky adenine-nicotinamide structure. The size and chemical class differences reflect their distinct mechanisms: Epithalon acts as a peptide signalling molecule for telomerase regulation, while NAD+ acts as a metabolic cofactor and enzyme substrate. ## Mechanism of Action **Epithalon Mechanisms** Epithalon operates through several pathways in cellular and in vitro models: 1. **Telomerase activation**: Upregulates telomerase expression and activity, particularly in fibroblast and epithelial cell cultures 2. **Pineal axis regulation**: Modulates melatonin synthesis enzymes and circadian rhythm gene expression 3. **Cellular senescence**: Examined for effects on senescence markers (p16, p21, SA-β-galactosidase) and replicative lifespan 4. **DNA repair**: Studied for effects on DNA repair capacity and chromosomal stability 5. **Gene expression modulation**: Modulates cell cycle, apoptosis, and stress resistance genes **NAD+ Mechanisms** NAD+ operates through multiple distinct pathways: 1. **Redox metabolism**: Serves as electron carrier in glycolysis, citric acid cycle, and oxidative phosphorylation 2. **Sirtuin activation**: Essential substrate for SIRT1–SIRT7, linking metabolic state to epigenetic regulation 3. **PARP activity**: Consumed by PARPs during DNA damage response and repair 4. **CD38 regulation**: NAD+ levels decline with age due to increased CD38 expression 5. **Salvage pathway**: Regenerated from nicotinamide via NAMPT and NMNAT enzymes **Complementary Mechanism** In combined research models, Epithalon provides the telomere maintenance and replicative lifespan extension signals, while NAD+ provides the metabolic and epigenetic machinery required for cellular health. The combination enables researchers to study how telomere integrity interacts with metabolic status, sirtuin activity, and DNA repair capacity in ageing cells. Telomerase-mediated telomere maintenance may require sufficient NAD+ for the metabolic energy and sirtuin activity needed to support cellular replication. ## Research Applications The Longevity Stack is employed across multiple research domains in UK laboratories: **Telomere Maintenance Research** Cellular models examine the combined effects on telomerase activity, telomere length, and replicative lifespan. Researchers use fibroblast and epithelial cell cultures to study whether Epithalon's telomerase activation and NAD+'s metabolic support produce coordinated effects on telomere maintenance. **Cellular Senescence Studies** Senescence models examine the stack's effects on senescence markers, including p16, p21, SA-β-galactosidase, and telomere dysfunction-induced foci. The combination of telomerase activation and NAD+-dependent sirtuin activity creates a dual anti-senescence model. **Mitochondrial Function in Ageing** Cellular models examine the combined effects on mitochondrial respiration, ATP production, and reactive oxygen species generation. NAD+ is essential for mitochondrial bioenergetics, while Epithalon's effects on cellular replicative capacity may influence mitochondrial biogenesis and function. **DNA Repair and Genomic Stability** Cells exposed to genotoxic stress are treated with the stack to examine combined effects on DNA repair capacity, chromosomal aberrations, and genomic integrity. NAD+ supports PARP-mediated DNA repair, while Epithalon may influence DNA repair enzyme expression. **Comparative Longevity Studies** The stack is compared to single treatments and other longevity compounds (resveratrol, sirtuin activators, NAD+ precursors) in cellular studies. Research questions examine whether telomerase-mediated and metabolic approaches produce additive effects on cellular lifespan and healthspan markers. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for Longevity Stack studies: **Fibroblast Lifespan Studies** Primary human fibroblasts are serially passaged with the stack treatment, and population doublings are counted. Senescence markers (SA-β-gal, p16, p21) are measured at each passage. Telomere length is monitored by Southern blot or qPCR. The combination is compared to Epithalon alone, NAD+ alone, and vehicle controls. **Telomerase Activity Assays** Cellular extracts are incubated with Epithalon, and telomerase activity is measured by TRAP assay. NAD+ is added to examine whether metabolic cofactor availability influences telomerase activity. Endpoints include telomerase expression (qPCR, Western blot) and telomere length. **NAD+/NADH Ratio Assays** Cellular lysates are assayed for NAD+ and NADH content using enzymatic cycling assays or fluorescent probes. The NAD+/NADH ratio is calculated as a metabolic indicator. Epithalon is added to examine whether telomerase activation influences cellular metabolic state. **Sirtuin Activity Assays** Cellular extracts or recombinant sirtuins are incubated with NAD+ and acetylated substrate peptides. Deacetylation is measured by fluorescence or luminescence. Epithalon is added to examine whether telomerase-mediated cellular changes influence sirtuin activity or substrate specificity. **DNA Repair Assays** Cells are exposed to UV radiation or hydrogen peroxide, then treated with the stack to examine combined effects on DNA repair capacity. Endpoints include comet assay, γ-H2AX foci, and chromosomal aberration frequency. ## Safety and Sourcing Standards Both compounds in the Longevity Stack require high-purity research-grade materials for valid experimental results. **Epithalon Sourcing Requirements** • ≥98% purity (HPLC), ≥99% preferred • Mass spectrometry confirming 4-amino-acid sequence (Ala-Glu-Asp-Gly) • Molecular weight verification (~390.4 Da) • Batch-specific COA with endotoxin levels • Research-use-only labelling **NAD+ Sourcing Requirements** • ≥99% purity (HPLC) • Mass spectrometry or NMR identity confirmation (molecular weight 663.4 Da) • Confirmation of oxidised form (NAD+), not reduced form (NADH) • Batch-specific COA with endotoxin levels • Research-use-only labelling **Safety Profile** Both compounds have favourable safety profiles in preclinical cellular and animal studies. In vitro toxicology screens have not identified significant cytotoxicity at research-relevant concentrations. No organ-specific toxicity has been reported at standard research doses. **UK Legal Status** Both compounds are not controlled substances under the Misuse of Drugs Act 1971 and are not scheduled under the Psychoactive Substances Act 2016. They are classified as research biochemicals and are not licensed as medicines by the MHRA. ## FAQs ### How do Epithalon and NAD+ complement each other in longevity research? Epithalon and NAD+ operate through distinct but complementary mechanisms in cellular ageing models. Epithalon primarily upregulates telomerase activity, maintaining telomere length and extending cellular replicative lifespan. NAD+ serves as a metabolic cofactor and sirtuin substrate, supporting cellular energy production, DNA repair, and epigenetic regulation. In combined research models, Epithalon provides the telomere maintenance signals, while NAD+ provides the metabolic and enzymatic machinery required for cellular health. The combination enables researchers to study how telomere integrity interacts with metabolic status and sirtuin activity in ageing cells. ### Can Epithalon and NAD+ be used together in cellular assays? Yes. Researchers often use both compounds in combination to examine dual-mechanism longevity effects. Standard experimental designs include parallel treatment arms: Epithalon alone, NAD+ alone, combined treatment, and vehicle control. Endpoints such as telomerase activity, telomere length, senescence markers, NAD+/NADH ratio, and sirtuin activity are compared across all groups. Epithalon is typically added as a peptide solution, while NAD+ is added directly to culture media or cell lysates depending on the assay format. ### What is the best cellular model for studying the Longevity Stack? The most common model is the primary human fibroblast serial passage assay, which measures replicative lifespan, senescence markers, and telomere length over multiple passages. Telomerase activity assays using TRAP protocol are used for direct telomerase quantification. NAD+/NADH ratio assays measure metabolic state, and sirtuin activity assays measure epigenetic regulation. DNA repair assays using comet assay or γ-H2AX foci examine genomic stability. For mitochondrial studies, Seahorse respirometry measures oxygen consumption rate and ATP production. ### Is the Longevity Stack legal for research in the UK? Yes. Both Epithalon and NAD+ are not controlled substances under UK law. They are classified as research biochemicals and are legal to purchase and possess for legitimate laboratory research. They are not licensed as medicines by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for Longevity Stack research? Epithalon should be ≥98% pure by HPLC, with ≥99% preferred. Mass spectrometry is essential to verify the 4-amino-acid sequence (~390.4 Da). NAD+ should be ≥99% pure, with the oxidised form confirmed by spectrophotometry (260 nm absorbance) and mass spectrometry (663.4 Da). The reduced form (NADH) should be absent. Batch-specific Certificates of Analysis should document purity, identity, and endotoxin levels for both compounds. NAD+ is unstable in solution and should be freshly reconstituted for each assay. ## References - [Khavinson VKh et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003;135:590-592.](https://pubmed.ncbi.nlm.nih.gov/14565059/) - [Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol 2014;24:464-471.](https://pubmed.ncbi.nlm.nih.gov/24786309/) - [Anisimov VN et al. Effects of epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003;4:193-202.](https://pubmed.ncbi.nlm.nih.gov/12954052/) - [Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab 2018;27:513-528.](https://pubmed.ncbi.nlm.nih.gov/29719225/) - [Khavinson VKh et al. The effects of short peptides on gene expression. Bull Exp Biol Med 2009;147:248-251.](https://pubmed.ncbi.nlm.nih.gov/19513388/) --- # GLP-1 + Amylin Combination: What the Research Shows URL: https://hatipeptides.co.uk/research/glp1-amylin-combination Updated: 2026-06-21 Author: Hati Peptides Research review of GLP-1 + amylin combination therapy. CagriSema REDEFINE 1 & 2 trial data, eloralintide Phase 2 results, and dual-pathway UK metabolic research. ## Why combine them? GLP-1 receptor agonists work by mimicking a gut hormone that tells your brain you're full, slows down gastric emptying, and boosts insulin secretion when blood sugar's high. But there's another hormone — amylin — that does something similar through different receptors, and the two pathways aren't redundant. They're complementary. Amylin is co-secreted with insulin from pancreatic beta cells — which means people with impaired beta-cell function have less of both. It acts on the area postrema in the brainstem, triggering satiety signals that are distinct from GLP-1's CNS effects. It also delays gastric emptying (through a different mechanism than GLP-1) and suppresses glucagon secretion. So the idea is simple: hit both pathways at once, and you get additive or even synergistic effects. You don't need higher doses of either drug, which means you might avoid the worst of the GI side effects. Plus, amylin doesn't cause hypoglycaemia on its own, so there's no extra safety risk. Two approaches have emerged in the clinic. Novo Nordisk went with cagrilintide — a dual amylin and calcitonin receptor agonist (DACRA) — combined with semaglutide, branded as CagriSema. Eli Lilly went a different route with eloralintide, a more selective amylin receptor agonist that avoids calcitonin receptor activation. Both showed strong data in 2025. ## CagriSema (cagrilintide + semaglutide) CagriSema is a once-weekly fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg. Two Phase 3 trials published in NEJM in June 2025 — REDEFINE 1 and REDEFINE 2 — showed what this dual-pathway approach can do. **REDEFINE 1 — adults without diabetes** 3,417 participants with BMI ≥30 (or ≥27 with at least one obesity-related complication) were randomised 21:3:3:7 to CagriSema, semaglutide alone, cagrilintide alone, or placebo. At 68 weeks, the estimated mean weight loss was: | Group | Mean weight loss | |---|---| | CagriSema | −20.4% | | Semaglutide | −14.9% | | Cagrilintide | −11.5% | | Placebo | −3.0% | In the treatment-adherent analysis, CagriSema hit −22.7%. More striking: 40.4% of adherent CagriSema participants lost at least 25% of their body weight. More than half of participants (50.7%) moved from having obesity to a BMI below the obesity threshold — compared to just 10.2% on placebo. GI side effects were common — 79.6% in the CagriSema group reported at least one GI event, versus 39.9% with placebo. Nausea, diarrhoea, and vomiting were the most frequent, though the paper describes them as "mainly transient and mild-to-moderate in severity." **REDEFINE 2 — adults with type 2 diabetes** 1,206 participants with BMI ≥27 and HbA1c 7–10% were randomised 3:1 to CagriSema or placebo. The results were more modest, which you'd expect in a T2D population: −13.7% with CagriSema versus −3.4% with placebo (full adherence: −15.7%). But the glycemic data were impressive — 73.5% of CagriSema patients hit an HbA1c of ≤6.5%, versus 15.9% on placebo. The GI tolerability was similar to REDEFINE 1: 72.5% in the CagriSema group reported GI events (34.4% placebo). No new safety signals emerged. What these numbers suggest: the combination clearly beats either monotherapy, but the effect size shrinks in people with diabetes, and tolerability remains the main practical constraint. ## Eloralintide — Lilly's selective approach Lilly took a different pharmacological tack with eloralintide. Instead of a dual amylin/calcitonin agonist like cagrilintide, eloralintide is a selective amylin receptor agonist — it activates amylin receptors without hitting the calcitonin receptor. The idea is to get the satiety and metabolic benefits of amylin signalling while avoiding any calcitonin-related effects (which can include nausea and potentially reduced bone turnover). The Phase 2 data were published in The Lancet in November 2025. 263 participants with obesity or overweight (mean BMI 39.1, mean weight 109.1 kg) were randomised across six dosing arms — 1 mg, 3 mg, 6 mg, 9 mg, and two dose-escalation schemes (6→9 mg and 3→6→9 mg) — versus placebo. Results at 48 weeks (efficacy estimand): | Dose | Mean weight loss | |---|---| | 1 mg | −9.5% | | 3 mg | −12.4% | | 6 mg | −17.6% | | 9 mg | −20.1% | | 6→9 mg escalation | −19.9% | | 3→6→9 mg escalation | −16.4% | | Placebo | −0.4% | The dose-response curve is clear — eloralintide works in a graded fashion, with the highest dose approaching the weight loss you'd expect from tirzepatide or CagriSema, but as a monotherapy. The tolerability story matters here. Nausea rates in the 6 mg arm hit 64%, but in the 3→6→9 mg slow-escalation arm, it dropped to 25% — comparable to placebo (14%). Fatigue was the next most common event, ranging from 0–46% depending on dose and escalation speed. The takeaway: how you ramp up the dose matters as much as the dose itself. Lilly plans to start Phase 3 enrolment by end of 2025, both as monotherapy and in combination with incretin therapies. ## How they compare Cagrilintide and eloralintide both target the amylin system, but the pharmacology differs in ways that might matter for research. **Cagrilintide** is a dual amylin and calcitonin receptor agonist (DACRA). The calcitonin receptor component adds an extra signalling pathway — calcitonin receptors are expressed in bone, kidney, and certain CNS regions. Whether this contributes to efficacy or just adds side effects isn't fully settled. The REDEFINE data suggest the combination is effective, but the GI side effect burden is substantial. **Eloralintide** is selective for the amylin receptor (specifically the AMY1, AMY2, and AMY3 subtypes formed by heterodimerisation of the calcitonin receptor with RAMP proteins). By avoiding calcitonin receptor activation, Lilly may have reduced one source of nausea. The Phase 2 data support this — the slow-escalation cohorts had GI tolerability close to placebo, while still achieving 16–20% weight loss. The head-to-head comparison we don't have is CagriSema vs eloralintide combined with a GLP-1. CagriSema uses semaglutide; eloralintide hasn't been trialled in a fixed-dose combination yet (though Lilly's Phase 3 plans include incretin combo studies). The monotherapy data from eloralintide (20.1% at 9 mg) is notable — that's approaching the efficacy of CagriSema's 20.4% but as a single agent, not a combination. For UK researchers, the key difference is practical: CagriSema is further along in clinical development (Phase 3 completed), while eloralintide is entering Phase 3 now. The choice of reference compound depends on whether your research question is about dual-pathway combination strategies (CagriSema) or selective amylin agonism (eloralintide). ## What we still don't know The REDEFINE and eloralintide trials answered a lot, but plenty of questions remain: **Durability.** Both trials ran for 48–68 weeks. We don't know how these effects hold up over 2–5 years, or whether weight regain kinetics differ from GLP-1 monotherapy. The amylin system may have different compensatory mechanisms than GLP-1. **Optimal combination partners.** CagriSema uses semaglutide. Would cagrilintide + tirzepatide do better? Lilly plans to study eloralintide + incretin combinations, but no data yet. The triple-agonist question (amylin + GLP-1 + GIP) is open. **Calcitonin receptor effects.** Cagrilintide activates calcitonin receptors. What does that mean for bone metabolism, calcium handling, or renal function over the long term? The calcitonin receptor is expressed in osteoclasts — chronic activation could theoretically affect bone turnover. No signal yet, but the trials weren't powered for that. **Selectivity vs breadth.** Is selective amylin agonism (eloralintide) better than dual amylin/calcitonin agonism (cagrilintide)? The data suggest eloralintide might have a tolerability edge, but without a head-to-head trial, that's speculative. Different receptors, different signalling profiles, different side effect patterns. **Combination with triple agonists.** Retatrutide already hits GLP-1, GIP, and glucagon. Would adding amylin signalling — either via combination or a single molecule — push efficacy further? That's a basic research question UK labs could explore using reference compounds. **Which patients benefit most.** The REDEFINE 2 data showed smaller effects in T2D. Is that an inherent limitation of the amylin-GLP-1 combination in diabetes, or a dose optimisation issue? ## UK research context For UK research laboratories working on metabolic disease, the GLP-1 + amylin combination space offers several reference compounds: - **[Semaglutide](/product/semaglutide)** — the GLP-1 component of CagriSema, available as a standalone research peptide for in vitro and animal studies - **[Tirzepatide](/product/tirzepatide)** — dual GLP-1/GIP agonist, a comparator for studies examining whether dual incretin agonism outperforms GLP-1 alone in amylin combination models - **[Retatrutide](/product/retatrutide)** — triple GLP-1/GIP/glucagon agonist, useful for studying how amylin signalling might interact with multi-receptor metabolic pathways Cagrilintide and eloralintide are proprietary clinical-stage compounds and not available as laboratory research peptides. But researchers can study the amylin system using standard laboratory reagents: rat amylin, human amylin (which is amyloidogenic and requires handling precautions), or selective amylin receptor ligands for in vitro receptor pharmacology. The key research questions UK labs can address right now include: • Does amylin receptor activation produce additive effects to GLP-1, GIP, and glucagon in cellular signalling assays? • What's the dose-response relationship for amylin-mediated satiety signalling in CNS-derived cell models? • How does chronic amylin exposure affect beta-cell function and insulin secretion in islet culture models? • Can amylin receptor ligands be used to study receptor-RAMP interactions and subtype selectivity in transfected cell systems? All standard UK peptide research regulations apply. These peptides are not controlled substances under the Misuse of Drugs Act. For in vitro and animal research only — no human use. ## FAQs ### What's the difference between cagrilintide and eloralintide? Cagrilintide (Novo Nordisk) is a dual amylin and calcitonin receptor agonist — it activates both receptor types. Eloralintide (Eli Lilly) is a selective amylin receptor agonist that avoids calcitonin receptor activation. In clinical trials, eloralintide showed dose-dependent weight loss of up to 20.1% with GI tolerability that improved with slower dose escalation. Cagrilintide is combined with semaglutide in the CagriSema formulation, which showed 20.4% mean weight loss in REDEFINE 1. The two compounds haven't been compared head-to-head. ### How much weight did CagriSema produce in clinical trials? In REDEFINE 1 (adults without diabetes, N=3,417), CagriSema produced a mean weight loss of 20.4% at 68 weeks (22.7% in adherent participants). 40.4% of adherent participants lost at least 25% of their body weight. In REDEFINE 2 (adults with type 2 diabetes, N=1,206), mean weight loss was 13.7% (15.7% with full adherence). Both trials were published in NEJM in June 2025. ### What weight loss did eloralintide achieve in Phase 2? In the Phase 2 trial (N=263, published in The Lancet, November 2025), eloralintide produced dose-dependent weight loss ranging from 9.5% (1 mg) to 20.1% (9 mg) at 48 weeks. The slow dose-escalation arm (3→6→9 mg) achieved 16.4% weight loss with nausea rates comparable to placebo (25% vs 14%). Lilly plans to start Phase 3 enrolment by end of 2025. ### Are amylin-based therapies available for UK research laboratories? Cagrilintide and eloralintide are proprietary clinical-stage compounds and not available as off-the-shelf research peptides. However, UK labs can study the amylin system using standard reagents: rat amylin, human amylin (requires handling precautions due to amyloidogenicity), and related research peptides. [Semaglutide](/product/semaglutide), [tirzepatide](/product/tirzepatide), and [retatrutide](/product/retatrutide) are available for research use, enabling in vitro studies of how amylin receptor activation might interact with GLP-1, GIP, and glucagon pathways. ### Why combine amylin with GLP-1 instead of using higher doses of either? Amylin and GLP-1 activate distinct satiety pathways — amylin acts on the area postrema in the brainstem, while GLP-1 activates both brainstem and hypothalamic circuits. Combining them produces additive weight loss without requiring higher doses of either agent, which helps avoid dose-limiting GI side effects. The REDEFINE trials confirmed this: CagriSema outperformed both semaglutide alone (14.9%) and cagrilintide alone (11.5%) with 20.4% mean weight loss, even though each was used at standard doses. ## References - [Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med 2025;393:2455-2468.](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081) - [Davies MJ et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med 2025;393:2469-2480.](https://www.nejm.org/doi/full/10.1056/NEJMoa2502082) - [Lutz T et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 trial. Lancet 2025;406:2189-2200.](https://pubmed.ncbi.nlm.nih.gov/41207310/) - [Enebo LB et al. Safety and efficacy of cagrilintide in adults with overweight or obesity: a phase 2 trial. Lancet 2021;397:1736-1748.](https://pubmed.ncbi.nlm.nih.gov/33965067/) - [Hay DL et al. Amylin receptor pharmacology and therapeutic potential. Br J Pharmacol 2022;179:848-864.](https://pubmed.ncbi.nlm.nih.gov/34590303/) - [Zac-Varghese S et al. The role of amylin in energy homeostasis and metabolic regulation. Peptides 2023;161:170942.](https://pubmed.ncbi.nlm.nih.gov/36621662/) - [Müller TD et al. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 2022;21:201-223.](https://pubmed.ncbi.nlm.nih.gov/34493876/) --- # Skin Stack: GHK-Cu + BPC-157 Research Guide 2026 URL: https://hatipeptides.co.uk/research/skin-stack Updated: 2026-06-06 Author: Hati Peptides Research guide for the Skin Stack combining GHK-Cu and BPC-157. Copper peptide and regenerative pentadecapeptide for dermal repair, collagen synthesis, and wound healing research. ## Overview The Skin Stack combines GHK-Cu (glycyl-L-histidyl-L-lysine copper), a copper-binding tripeptide studied for collagen synthesis and extracellular matrix remodelling, with BPC-157 (Body Protection Compound-157), a 15-amino-acid pentadecapeptide studied for angiogenesis, fibroblast activation, and wound healing. This combination creates a dual-mechanism model for dermal and tissue repair research: GHK-Cu provides the matrix-building and copper-delivery signals, while BPC-157 provides the angiogenic and fibroblast-activating signals. GHK-Cu occurs naturally in human plasma and declines with age from approximately 200 ng/mL at age 20 to about 80 ng/mL at age 60. The peptide binds copper ions and delivers them to copper-dependent enzymes involved in collagen cross-linking, antioxidant defence, and angiogenesis. BPC-157 is derived from a partial sequence of the human gastric protein BPC and retains the bioactive domain of the parent protein. For UK research laboratories, the Skin Stack offers a comprehensive model for studying dermal regeneration, wound healing, and extracellular matrix remodelling. GHK-Cu's copper delivery and gene expression modulation complement BPC-157's angiogenic and fibroblast-activating properties in skin and tissue repair models. ## Molecular Structure **GHK-Cu** • Sequence: Glycyl-L-histidyl-L-lysine (3 amino acids) • Molecular weight (free peptide): ~340 Da • Molecular weight (copper complex): ~400 Da • Copper binding: High affinity (2:1 peptide:copper ratio) • Coordination: Copper binds to nitrogen atoms from glycine α-amine, histidine imidazole, and lysine ε-amine **BPC-157** • Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids) • Molecular weight: ~1,419 Da • Structure: Linear pentadecapeptide with multiple proline residues • Origin: Synthetic partial sequence of human gastric Body Protection Compound **Structural Differences** GHK-Cu is a tripeptide-copper complex with a characteristic blue-violet colour when reconstituted. BPC-157 is a larger linear peptide without metal coordination. The copper component of GHK-Cu is essential for its biological activity, while BPC-157's activity is peptide-sequence dependent. Both are supplied as lyophilised powders, though GHK-Cu is typically supplied as the pre-formed copper complex. ## Mechanism of Action **GHK-Cu Mechanisms** GHK-Cu operates through several pathways in cellular and in vitro models: 1. **Copper delivery**: Delivers copper to copper-dependent enzymes (lysyl oxidase, superoxide dismutase, tyrosinase) 2. **Gene expression modulation**: Modulates approximately 4,000 genes involved in tissue remodelling, antioxidant defence, and anti-inflammatory pathways 3. **Collagen synthesis**: Stimulates fibroblast production of collagen types I, III, and IV 4. **Wound healing**: Promotes fibroblast migration, angiogenesis, and extracellular matrix deposition 5. **Anti-inflammatory effects**: Modulates TGF-β signalling and reduces inflammatory cytokine production **BPC-157 Mechanisms** BPC-157 operates through multiple regenerative pathways: 1. **Angiogenesis**: Upregulates VEGF and stimulates endothelial cell proliferation and migration 2. **Fibroblast activation**: Increases collagen synthesis and extracellular matrix deposition 3. **Nitric oxide pathway**: Enhances eNOS expression and NO production 4. **Anti-inflammatory signalling**: Modulates NF-κB and reduces pro-inflammatory cytokines 5. **Tissue regeneration**: Supports repair through enhanced cell migration and matrix production **Complementary Mechanism** In combined research models, GHK-Cu provides the copper-dependent enzymatic activity and gene expression changes required for matrix remodelling, while BPC-157 provides the vascular and fibroblast-activating signals required for tissue repair. The copper delivery from GHK-Cu supports lysyl oxidase-mediated collagen cross-linking, while BPC-157's angiogenesis creates the vascular infrastructure needed for tissue perfusion. The combination enables researchers to study how matrix-building and vascular signals interact in dermal regeneration models. ## Research Applications The Skin Stack is employed across multiple research domains in UK laboratories: **Dermal Repair Research** In vitro studies examine the combined effects on dermal fibroblast function, collagen synthesis, and extracellular matrix production. Researchers use fibroblast cultures, organotypic skin models, and tissue explants to study whether the dual-mechanism approach produces enhanced dermal repair compared to single-peptide models. **Wound Healing Studies** Scratch assays, organotypic cultures, and tissue explants are used to examine combined effects on wound closure, cellular migration, and tissue regeneration. GHK-Cu's fibroblast migration and collagen synthesis complement BPC-157's angiogenesis and fibroblast activation in wound healing models. **Collagen Synthesis Research** Fibroblast cultures are used to measure combined effects on collagen production, cross-linking, and extracellular matrix organisation. GHK-Cu's copper delivery supports lysyl oxidase activity, while BPC-157's fibroblast activation increases collagen gene expression and secretion. **Angiogenesis in Skin Models** Endothelial cell models and skin microvascular cultures examine the combined angiogenic effects of both peptides. BPC-157's VEGF upregulation and GHK-Cu's endothelial cell effects create a dual-angiogenic signal for studying vascularisation in dermal repair. **Anti-Inflammatory Dermal Research** Keratinocyte and fibroblast co-cultures examine combined anti-inflammatory effects in skin inflammation models. GHK-Cu's TGF-β modulation and BPC-157's NF-κB inhibition create a dual anti-inflammatory signal for studying chronic skin inflammation and repair. ## Cellular and In Vitro Models UK research laboratories employ several standard cellular models for Skin Stack studies: **Dermal Fibroblast Cultures** Primary dermal fibroblasts are used to measure combined effects on collagen I/III production, elastin synthesis, and extracellular matrix deposition. Endpoints include hydroxyproline assays, collagen ELISAs, and Sirius Red staining. The stack is compared to GHK-Cu alone, BPC-157 alone, and vehicle controls. **Fibroblast Scratch Assays** Scratch wound assays measure combined effects on migration, proliferation, and wound closure rate. Time-lapse microscopy tracks cell migration dynamics. Endpoints include wound closure percentage, collagen deposition, and matrix metalloproteinase activity. **Endothelial Tube Formation** HUVEC and dermal microvascular endothelial cells are used in Matrigel assays to examine combined angiogenic effects. Endpoints include tube length, branch points, network complexity, and VEGF production. The dual treatment is compared to individual peptides. **Keratinocyte Cultures** Primary keratinocytes and HaCaT cells are used to examine combined effects on epithelial migration, proliferation, and barrier function. Endpoints include scratch closure, transepithelial electrical resistance, and tight junction protein expression. **Organotypic Skin Models** Reconstructed human epidermis and full-thickness skin models are used to examine tissue-level effects on dermal regeneration, wound healing, and matrix remodelling. The stack is applied topically or added to culture media, and histological endpoints are examined. ## Safety and Sourcing Standards Both peptides in the Skin Stack require high-purity research-grade materials for valid experimental results. **GHK-Cu Sourcing Requirements** • ≥98% purity (HPLC), ≥99% preferred • Mass spectrometry confirming tripeptide sequence and copper complex formation • Copper stoichiometry confirmation (2:1 peptide:copper ratio, molecular weight ~400 Da) • Batch-specific COA with endotoxin levels • Research-use-only labelling **BPC-157 Sourcing Requirements** • ≥98% purity (HPLC), ≥99% preferred • Mass spectrometry confirming 15-amino-acid sequence • Molecular weight verification (~1,419 Da) • Batch-specific COA with endotoxin levels • Research-use-only labelling **Safety Profile** Both peptides have favourable safety profiles in preclinical cellular and animal studies. In vitro toxicology screens have not identified significant cytotoxicity at research-relevant concentrations. No organ-specific toxicity has been reported at standard research doses. **UK Legal Status** Both peptides are not controlled substances under the Misuse of Drugs Act 1971 and are not scheduled under the Psychoactive Substances Act 2016. They are classified as research peptides and are not licensed as medicines by the MHRA. ## FAQs ### How do GHK-Cu and BPC-157 complement each other in skin research? GHK-Cu and BPC-157 operate through distinct but complementary mechanisms in dermal repair models. GHK-Cu primarily delivers copper to copper-dependent enzymes (lysyl oxidase for collagen cross-linking, superoxide dismutase for antioxidant defence) and modulates approximately 4,000 genes involved in tissue remodelling. BPC-157 primarily promotes angiogenesis (VEGF upregulation), fibroblast activation, and collagen synthesis. In combined research models, GHK-Cu provides the copper-dependent enzymatic activity and gene expression changes for matrix remodelling, while BPC-157 provides the vascular and fibroblast-activating signals for tissue repair. The combination enables researchers to study how matrix-building and vascular signals interact in dermal regeneration. ### Can GHK-Cu and BPC-157 be used together in cellular assays? Yes. Researchers often use both peptides in combination to examine synergistic effects on dermal repair and wound healing. Standard experimental designs include parallel treatment arms: GHK-Cu alone, BPC-157 alone, combined treatment, and vehicle control. Endpoints such as collagen synthesis, wound closure rate, fibroblast migration, and angiogenic response are compared across all groups. Both peptides are soluble in aqueous solutions and are compatible in standard cell culture media. GHK-Cu's blue-violet colour confirms intact copper complex formation upon reconstitution. ### What is the best cellular model for studying the Skin Stack? The most common model is the primary dermal fibroblast culture, which measures collagen synthesis, extracellular matrix deposition, and wound closure. Scratch assays with time-lapse microscopy track cell migration dynamics. HUVEC tube formation assays examine angiogenic effects. Keratinocyte cultures study epithelial migration and barrier function. For tissue-level studies, organotypic skin models (reconstructed human epidermis) provide a more physiologically relevant endpoint. The stack can be applied topically or added to culture media depending on the model. ### Is the Skin Stack legal for research in the UK? Yes. Both GHK-Cu and BPC-157 are not controlled substances under UK law. They are classified as research peptides and are legal to purchase and possess for legitimate laboratory research. They are not licensed as medicines by the MHRA and must be sold for research use only. Research institutions should ensure compliance with institutional ethics approvals and standard laboratory safety protocols. ### What purity standard is recommended for Skin Stack research? Both peptides should be ≥98% pure by HPLC, with ≥99% being the preferred standard for sensitive dermal assays. Mass spectrometry identity confirmation is essential: GHK-Cu requires verification of the tripeptide sequence, copper complex formation, and 2:1 peptide:copper ratio (~400 Da). The blue-violet colour of reconstituted GHK-Cu is a visual indicator of intact copper complex. BPC-157 requires verification of the 15-amino-acid sequence (~1,419 Da). Batch-specific Certificates of Analysis should document purity, identity, copper content (for GHK-Cu), and endotoxin levels for both compounds. ## References - [Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018;19:1987.](https://pubmed.ncbi.nlm.nih.gov/30154310/) - [Sikiric P et al. Stable gastric pentadecapeptide BPC 157: multiple organoprotection and therapeutic possibilities. Curr Pharm Des 2020;26:3947-3957.](https://pubmed.ncbi.nlm.nih.gov/32697396/) - [Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015;2015:648108.](https://pubmed.ncbi.nlm.nih.gov/25839058/) - [Sikiric P et al. BPC 157 and its effects on healing. Life Sci 2020;259:118198.](https://pubmed.ncbi.nlm.nih.gov/32721584/) - [Maquart FX et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex GHK-Cu. J Clin Invest 1993;92:2368-2376.](https://pubmed.ncbi.nlm.nih.gov/8254018/) --- --- # Guides # Peptide Reconstitution Protocols for Laboratory Use URL: https://hatipeptides.co.uk/guides/reconstitution Updated: 2026-06-05 Author: Hati Peptides Laboratory Step-by-step reconstitution protocols for lyophilised peptides using bacteriostatic water. Covers concentration, mixing, and storage for research labs. ## What Is Reconstitution? Reconstitution simply means mixing the freeze-dried peptide powder with water so it becomes a liquid you can work with. The powder arrives in the vial because it is more stable that way — once you add water, the clock starts ticking on freshness. This guide covers how to do it properly: what you need, the exact steps, and what to do if something goes wrong. Read it once before you start so you do not waste a vial. **All peptides sold by Hati Peptides are for in vitro research only. They are not for human or animal use.** ## What You Need You only need four things: - **Bacteriostatic water (BAC water)** — This is sterile water with 0.9% benzyl alcohol that stops bacteria growing. It is the standard liquid used for mixing peptides. Do not use tap water, distilled water, or bottled water. - **A sterile syringe and needle** — A 1 mL or 3 mL syringe with a 25G or 27G needle works fine. You can buy these online from medical supply shops in the UK. - **Alcohol wipes** — 70% isopropyl alcohol wipes for cleaning the rubber tops of the vials. - **A clean, flat surface** — A kitchen counter wiped down with disinfectant is fine. Wash your hands first. That is it. You do not need a laboratory, pH strips, a vortex mixer, or any special equipment. ## Step-by-Step: Mixing Your Peptide Follow these steps in order. Do not rush it — the most common mistakes happen when people inject water too fast or shake the vial. **Step 1: Let the vials warm up** Leave both the peptide vial and the BAC water vial on the counter for 10–15 minutes until they reach room temperature. If they are cold from the fridge, condensation can form inside when you open them, which is not what you want. **Step 2: Clean the rubber tops** Wipe the rubber stopper on both vials with an alcohol wipe. Wait about 30 seconds for the alcohol to dry before you stick a needle in. **Step 3: Decide how much water to add** This determines how strong your solution is. Use this simple rule: **Concentration = milligrams of peptide ÷ millilitres of water.** For a **10 mg vial**: - 10 mL water = 1 mg/mL - 5 mL water = 2 mg/mL - 2 mL water = 5 mg/mL - 1 mL water = 10 mg/mL For a **20 mg vial**: - 20 mL water = 1 mg/mL - 10 mL water = 2 mg/mL - 4 mL water = 5 mg/mL - 2 mL water = 10 mg/mL Most people use 2–5 mL for a 10 mg vial. That gives a concentration that is easy to measure with a standard syringe and dissolves reliably. If you make it too concentrated (e.g., 1 mL into 10 mg), some peptides will struggle to dissolve. **Step 4: Draw the water** Stick the needle through the rubber top of the BAC water vial and draw up the amount you decided on. Pull the needle out. **Step 5: Inject the water into the peptide vial** Insert the needle into the peptide vial at a slight angle so the tip touches the inside wall. Push the plunger slowly and let the water run down the glass onto the powder. **Do not shoot the water straight onto the powder** — this creates foam and can damage the peptide. **Step 6: Mix gently** Remove the needle. Swirl the vial slowly or roll it between your palms. **Do not shake it.** Most peptides dissolve within a couple of minutes. If the powder is still sitting there after 5 minutes, see the troubleshooting section below. **Step 7: Check the liquid** It should look clear with no visible particles. A very slight haze is fine for some peptides. If you see obvious floating bits or cloudiness, you probably made it too concentrated — add a bit more BAC water and swirl again. **Step 8: Label and store** Write on the vial or a sticker: - Peptide name - How much you put in (e.g., "2 mg/mL") - The date you mixed it Put the vial in the fridge (2–8 °C) and keep it away from light. Keep it as powder in the freezer until you are ready to use it — powder is far more stable than liquid. ## If Something Goes Wrong **The powder will not dissolve** - Make sure the vial is at room temperature. Cold peptides dissolve slower. - Try rolling the vial between your palms for a few minutes. Gentle warmth helps. - If it still will not dissolve, your concentration is probably too high. Add more BAC water and try again. - Some peptides (like BPC-157) can take 10–15 minutes to fully dissolve. Be patient. **The liquid looks cloudy or has bits floating in it** - This usually means the concentration is too high. Add more BAC water and swirl again. - Some peptides (like GHK-Cu) naturally have a slight blue or purple tint. That is normal. - If it stays cloudy even after diluting, contact us with your batch number and we will sort it out. **There is foam on top** - You either shook the vial or injected the water too quickly. Let it sit for 5–10 minutes — the foam will settle. The peptide is usually fine, but next time inject slower and do not shake. **I used the wrong amount of water** - If you used too much, the concentration is just lower. That is fine — you will need to draw more liquid to get the same dose. Use the calculator on our site to work out the new numbers. - If you used too little and the peptide will not dissolve, add more water gradually until it clears. ## Safety Basics - **Work on a clean surface** — Wipe the area down first. Wash your hands. This is basic hygiene, not laboratory sterility. - **Wear gloves** — Nitrile or latex gloves protect both you and the peptide. Avoid touching the rubber stopper with bare fingers. - **Do not ingest or inject** — Research peptides are not tested for human safety. They are not medicines. Handle them only in a research context. - **Dispose of needles safely** — Put used syringes and needles in a rigid container (an old plastic bottle or a proper sharps bin) and take them to a pharmacy for disposal. Do not put loose needles in household waste. - **Keep away from children and pets** — Store peptides in a locked fridge or a secure box, especially if you have children at home. ## FAQs ### Can I use sterile water instead of bacteriostatic water? Only if you are using the entire vial the same day. Sterile water has no preservative, so bacteria can start growing within 24 hours. BAC water contains benzyl alcohol which prevents bacterial growth and is the standard choice for reconstitution. ### How should I store reconstituted peptides? In the fridge (2–8 °C), protected from light. Light-sensitive peptides like GHK-Cu should be wrapped in foil or kept in an amber vial. The powder form is far more stable than liquid, so keep vials frozen until you are ready to reconstitute. ### What concentration should I mix? Most people mix a 10 mg vial with 2–5 mL of BAC water, giving 2–5 mg/mL. That is easy to measure with a standard syringe and dissolves reliably. If you need a very specific concentration for your research, use the calculator on our site to work out the exact amount. ### Can I freeze the liquid to make it last longer? It is not recommended. Freezing can damage the peptide structure and cause pH shifts. If you absolutely must freeze it, split the liquid into small single-use vials first so you only thaw what you need. Never refreeze a vial once it has thawed. The powder form is far better for long-term storage. --- # How to Read a Certificate of Analysis (CoA) for Research Peptides URL: https://hatipeptides.co.uk/guides/coa Updated: 2026-06-05 Author: Hati Peptides Laboratory Practical guide to interpreting Certificates of Analysis for peptide reference materials. Learn what HPLC, MS, and purity data mean for lab research. ## What is a Certificate of Analysis? A Certificate of Analysis (CoA) is a formal document issued by a peptide manufacturer or analytical laboratory that verifies the identity, purity, and quality of a specific batch of peptide material. For research laboratories, the CoA is the primary evidence that a peptide meets the required specifications for experimental use. A valid CoA should contain: - **Batch or lot number**: Unique identifier for the specific production batch - **Peptide name and sequence**: Chemical identity confirmation - **Analytical methods**: HPLC, mass spectrometry (MS), and other tests performed - **Purity data**: Quantitative results from each analytical method - **Physical characteristics**: Appearance, solubility, molecular weight - **Date of analysis**: When the testing was performed - **Analyst signature**: Qualified person who performed or reviewed the analysis This guide explains how to interpret each section of a CoA for research-grade peptides. ## Understanding HPLC Purity Results High-Performance Liquid Chromatography (HPLC) is the standard analytical method for determining peptide purity. The CoA will report a purity percentage, typically ≥95%, ≥98%, or ≥99%. **What the number means:** The purity percentage represents the area-under-the-curve (AUC) of the main peptide peak as a proportion of the total chromatographic signal. For example, a purity of 98.5% means that 98.5% of the total UV absorbance detected corresponds to the target peptide. **What it does NOT mean:** - It does not guarantee 100% of the material is the target peptide - It does not account for non-UV-absorbing impurities (e.g., salts, solvents) - It does not confirm the peptide sequence is correct **What to look for:** - **Single sharp peak**: The main peak should be symmetric and well-defined - **Minimal shoulder peaks**: Small peaks adjacent to the main peak may indicate deamidation or oxidation - **Baseline**: A flat baseline indicates good chromatographic separation **Acceptable thresholds for research:** - **≥95%**: Minimum for most in vitro research applications - **≥98%**: Standard for published research requiring reproducibility - **≥99%**: Preferred for sensitive assays (e.g., receptor binding, crystallisation) Researchers should consider the sensitivity of their assay when selecting purity grades. ## Mass Spectrometry (MS) Identity Confirmation Mass spectrometry is the gold standard for confirming peptide identity. The CoA should include a mass spectrum showing the molecular weight (MW) of the peptide. **What to verify:** - **Theoretical vs. observed MW**: The observed mass should match the calculated theoretical mass within ±1 Da (typically ±0.5 Da for peptides <5,000 Da) - **Charge states**: Multiple peaks corresponding to different charge states (+1, +2, +3, etc.) confirm the molecular weight - **No extraneous peaks**: Major peaks other than the target peptide may indicate synthetic by-products **Example verification:** - Peptide: BPC-157 (15 amino acids) - Theoretical MW: ~1,419.5 Da - Acceptable observed range: 1,419.0–1,420.0 Da **Modified peptides:** For peptides with post-synthetic modifications (e.g., fatty-acid conjugation in Semaglutide, N-terminal acetylation in TB-500), the MS should confirm the molecular weight shift corresponding to the modification: - Semaglutide (with C18 fatty-diacid): ~4,114 Da (vs. native GLP-1 ~3,294 Da) - TB-500 (N-acetylated): ~4,963 Da (vs. non-acetylated ~4,921 Da) If the MS data does not match the expected molecular weight, the peptide identity is questionable. ## Other Critical Tests on a CoA Beyond HPLC and MS, a comprehensive CoA should include: **1. Endotoxin Levels (LAL Test)** - **What it measures**: Bacterial lipopolysaccharide contamination - **Acceptable threshold**: <0.5 EU/mL for cell culture applications - **Why it matters**: Endotoxins can trigger inflammatory responses in cellular assays, confounding results **2. Residual Solvents** - **Common solvents**: Trifluoroacetic acid (TFA), acetonitrile, dimethylformamide (DMF) - **Acceptable thresholds**: Typically <0.1% TFA, <0.1% acetonitrile - **Why it matters**: Residual solvents can be cytotoxic or interfere with spectroscopic assays **3. Counter-Ion Content** - **Common counter-ions**: TFA (trifluoroacetate), acetate - **Why it matters**: Counter-ions affect peptide solubility and net charge. TFA can be acidic and affect cell culture pH. **4. Amino Acid Analysis (AAA)** - **What it measures**: Molar ratios of constituent amino acids - **Why it matters**: Confirms the correct amino acid composition and stoichiometry - **Note**: Less common for routine research-grade peptides; typically required for GMP-grade materials **5. Peptide Content (Net Peptide Content)** - **What it measures**: The actual mass of peptide vs. total mass (including salts, water, counter-ions) - **Why it matters**: Research dosing calculations should account for net peptide content, not gross weight - **Typical range**: 70–95% depending on peptide size and hydrophobicity ## Red Flags in a CoA Researchers should be cautious if a CoA shows any of the following: **1. Missing Batch Number** - A CoA without a specific batch number cannot be traced to a physical product. Every batch should have a unique identifier. **2. No Analytical Method Details** - "Purity: >95%" without specifying HPLC method, column type, or gradient is insufficient. Legitimate CoAs specify the analytical protocol. **3. No Mass Spectrometry Data** - MS identity confirmation is essential for peptide verification. A CoA without MS data is incomplete. **4. Outdated Analysis Date** - Peptide stability data is batch-specific. A CoA from a different year than the batch number may indicate the batch was not tested or the CoA was recycled. **5. No Analyst or Reviewer Signature** - Legitimate analytical laboratories require qualified personnel to sign CoAs. Digital signatures or stamps are acceptable; blank signatures are not. **6. Generic or Template CoA** - If the CoA looks like a generic template with no batch-specific data (e.g., no actual chromatogram, no MW value), it may be fraudulent. **7. Purity Claim Without Chromatogram** - A numerical purity claim without a chromatogram image or trace is unverifiable. Always request the chromatogram if not included. **Best practice**: Retain the CoA for every batch used in your research. If publishing results, include the batch number and supplier in your methods section. ## Documentation for Research Compliance UK research institutions and industrial laboratories should maintain thorough documentation for regulatory compliance: **Required records:** - Original CoA for each batch (digital or physical) - Date of receipt and storage conditions - Reconstitution records (date, concentration, solvent batch) - Usage logs (date, assay, researcher, volume used) - Disposal records **Regulatory context:** - Research peptides are not medicines under the Human Medicines Regulations 2012 - They are not controlled substances under the Misuse of Drugs Act 1971 (unless specifically scheduled) - Research institutions must comply with their own ethics review boards and institutional safety protocols - CoA documentation supports audit readiness and reproducibility claims **Publication requirements:** Peer-reviewed journals increasingly require detailed materials and methods sections. Include: - Supplier name and location - Batch or lot number - Purity grade and analytical methods - Storage conditions and handling dates This documentation ensures that other researchers can replicate your work and verify your materials. ## FAQs ### Is a 95% pure peptide good enough for research? For most in vitro assays (cell culture, binding studies, enzyme assays), ≥95% purity is adequate. For highly sensitive assays (e.g., crystallography, mass spectrometry-based quantification, or receptor pharmacology), ≥98% or ≥99% is preferred to minimise confounding effects from impurities. ### What is the difference between HPLC purity and net peptide content? HPLC purity measures the proportion of the target peptide in the chromatographic signal (typically 95–99%). Net peptide content measures the actual mass of peptide versus total mass including salts, counter-ions, and residual water (typically 70–95%). For dosing calculations, use net peptide content, not gross weight. ### Can I trust a CoA from a non-UK supplier? CoAs from reputable international suppliers (e.g., US, EU, China) are valid if they include batch-specific data, analytical methods, and analyst signatures. However, UK researchers should ensure the supplier complies with UK import regulations for research materials. Retain all import documentation alongside the CoA. ### What should I do if the MS molecular weight does not match the theoretical value? If the observed mass deviates by more than ±1 Da from the theoretical mass, do not use the peptide. Contact the supplier immediately for clarification. Common causes include incomplete synthesis, wrong sequence, or post-translational modifications. Document the discrepancy in your laboratory records. --- # Peptide Purity Grades Explained for Research Laboratories URL: https://hatipeptides.co.uk/guides/purity-grades Updated: 2026-06-05 Author: Hati Peptides Laboratory Understand the differences between 95%, 98%, and 99% purity peptides. When each grade is appropriate for your model, and how to balance cost vs. experiment. ## Why Purity Matters Peptide purity is one of the most critical parameters affecting experimental reproducibility. Impurities in peptide preparations can interfere with assays, produce false-positive or false-negative results, and compromise the validity of research conclusions. Impurities typically include: - **Deletion sequences**: Peptides missing one or more amino acids - **Truncated sequences**: Peptides cleaved during synthesis - **Side-reaction products**: Peptides with modified residues (e.g., oxidised methionine, deamidated asparagine) - **Synthetic by-products**: Unreacted amino acids, coupling reagents, or protecting groups The purity grade determines the proportion of the target peptide versus these impurities. This guide explains the practical differences between common purity grades and when each is appropriate. ## Purity Grades and Their Applications **≥95% Purity — Entry-Level Research Grade** - **What it means**: 95% of the chromatographic signal corresponds to the target peptide; 5% is impurities - **Best for**: Initial screening assays, high-throughput screening, antibody generation, qualitative assays - **Limitations**: Impurities may interfere with quantitative assays, receptor binding studies, or sensitive cellular models - **Cost**: Lowest price point; suitable for exploratory research where perfect purity is not critical **≥98% Purity — Standard Research Grade** - **What it means**: 98% of the signal is the target peptide; 2% is impurities - **Best for**: Most published research, cell culture assays, enzyme inhibition studies, binding assays, and pharmacological characterisation - **Advantages**: Significantly reduced impurity interference compared to 95% while maintaining reasonable cost - **Cost**: Moderate premium over 95%; the standard for most peer-reviewed research **≥99% Purity — High-Performance Research Grade** - **What it means**: 99% of the signal is the target peptide; 1% is impurities - **Best for**: Crystallography, NMR spectroscopy, mass spectrometry-based quantification, receptor pharmacology, and regulatory submission studies - **Advantages**: Minimal interference; essential for assays where impurities could confound results - **Cost**: Highest price point; justified for high-stakes or publication-critical research **≥99.5% Purity — Analytical / Reference Grade** - **What it means**: 99.5% purity; typically requires additional purification steps (e.g., preparative HPLC, recrystallisation) - **Best for**: Analytical standards, calibration curves, reference materials for quantitative assays - **Note**: This grade is uncommon for routine research due to cost; typically reserved for method development and validation ## How to Choose the Right Grade Use this decision framework to select the appropriate purity grade for your research: **1. Assay Sensitivity** - **High sensitivity** (IC50 determination, Kd measurements, crystallography): ≥99% - **Moderate sensitivity** (cell viability, Western blot, ELISA): ≥98% - **Low sensitivity** (qualitative screening, preliminary experiments): ≥95% **2. Quantitative vs. Qualitative** - **Quantitative experiments** (dose-response curves, kinetics): ≥98% (≥99% preferred) - **Qualitative experiments** (presence/absence, initial screening): ≥95% acceptable **3. Cellular vs. Biochemical** - **Cellular assays** (cell culture, live imaging): ≥98% (cellular systems are sensitive to impurities) - **Biochemical assays** (enzyme activity, binding): ≥98% (≥99% for precise Kd/IC50) - **Physical chemistry** (spectroscopy, calorimetry): ≥99% **4. Publication Requirements** - **Peer-reviewed journals**: ≥98% is the de facto standard for most journals - **High-impact journals** (Nature, Cell, Science): ≥99% may be expected or requested during review - **Thesis or internal reports**: ≥95% may be acceptable depending on institutional requirements **5. Budget Constraints** - If budget is limited, use ≥95% for preliminary experiments and ≥98% for final confirmatory experiments - Never compromise on purity for critical experiments that will form the basis of publications or regulatory submissions ## Cost vs. Purity Trade-offs The relationship between purity and cost is non-linear. Doubling purity from 95% to 99% typically increases cost by 50–100%, but the experimental benefits may justify the expense. **Example Cost Analysis (10 mg peptide):** | Purity Grade | Relative Cost | Best Use Case | |-------------|---------------|---------------| | ≥95% | 1.0× | Screening, preliminary | | ≥98% | 1.3–1.5× | Standard research, cell culture | | ≥99% | 1.8–2.2× | High-precision, publication | | ≥99.5% | 2.5–3.5× | Analytical standards | **When to invest in higher purity:** - The assay is highly sensitive to impurities (e.g., receptor binding at nanomolar concentrations) - The research will be published in a peer-reviewed journal - The peptide is a reference standard for quantitative analysis - The experiment is part of a regulatory submission or patent application **When lower purity is acceptable:** - Exploratory or screening experiments - Antibody generation (immune systems are robust to moderate impurities) - Qualitative assays where absolute quantification is not required - Internal method development or training experiments ## Verifying Purity in Your Own Laboratory Even with a supplier CoA, researchers should verify peptide purity in their own laboratory if: - The peptide will be used for a critical experiment - The supplier is new or unverified - The batch number on the CoA does not match the vial label - The research will be published in a high-impact journal **In-house verification methods:** **1. Analytical HPLC** - Run the peptide on your own HPLC system using a standard C18 column - Compare the retention time and peak shape to the supplier's chromatogram - Verify the purity percentage matches the CoA **2. Mass Spectrometry** - Submit a sample to your institutional MS facility - Verify the observed molecular weight matches the theoretical value - Check for unexpected mass shifts (indicating modifications or impurities) **3. Bioactivity Assay** - If a standard assay exists (e.g., insulin secretion for GLP-1 agonists), run a positive control - Compare the EC50 or IC50 to published values - Significant deviations may indicate purity or identity issues **4. SDS-PAGE or Capillary Electrophoresis** - For larger peptides (>3,000 Da), electrophoretic methods can confirm purity - Look for a single band at the expected molecular weight **Documentation:** - Record all in-house verification results in your laboratory notebook - Attach chromatograms, spectra, and assay data to the batch record - This documentation supports reproducibility and regulatory compliance ## FAQs ### Is 95% pure peptide really 95% peptide? Not exactly. HPLC purity measures the proportion of UV-absorbing signal that corresponds to the target peptide. The remaining 5% may include deletion sequences, truncated peptides, and side-reaction products. However, non-UV-absorbing impurities (salts, water, counter-ions) are not counted in the 5%. The actual mass of peptide in the vial may be 70–90% of the gross weight due to salts and moisture. ### Can I use a 95% pure peptide for cell culture? For most cell culture applications, ≥95% purity is acceptable for preliminary experiments. However, for sensitive cellular assays (e.g., primary cells, stem cells, or long-term cultures), ≥98% is recommended because cellular systems are more sensitive to impurities than biochemical assays. Always include appropriate controls. ### Does higher purity mean better stability? Not necessarily. Stability depends on the peptide sequence, storage conditions, and formulation, not just purity. A 99% pure peptide stored improperly (e.g., at room temperature, exposed to light) will degrade faster than a 95% pure peptide stored at −20 °C in the dark. Storage and handling are equally important as purity. ### Why does 99% purity cost so much more than 95%? Achieving 99% purity requires additional purification steps (e.g., repeated preparative HPLC runs, recrystallisation, or specialised chromatography). These steps reduce yield, increase solvent consumption, and require more analyst time. The cost increase reflects the additional manufacturing and analytical effort. --- # Peptide Storage and Handling Best Practices for Laboratories URL: https://hatipeptides.co.uk/guides/storage Updated: 2026-06-05 Author: Hati Peptides Laboratory How to store lyophilised and reconstituted peptides for maximum stability. Temperature, desiccation, light protection, and handling for research labs. ## Overview Peptide stability is a critical factor in research reproducibility. Improper storage can lead to degradation, oxidation, aggregation, and loss of biological activity, compromising experimental results. This guide provides evidence-based storage and handling protocols for both lyophilised (powder) and reconstituted (liquid) peptides in research settings. **Key principles:** - **Temperature**: Lower temperatures slow degradation reactions - **Desiccation**: Moisture promotes hydrolysis and aggregation - **Light protection**: UV light causes photodegradation and oxidation - **Minimise handling**: Every manipulation introduces contamination risk - **Documentation**: Record all storage conditions and handling dates ## Storing Lyophilised (Powder) Peptides Lyophilised peptides are the most stable form and should be stored under the following conditions: **Recommended Storage:** - **Temperature**: −20 °C (standard freezer) or −80 °C (ultra-low freezer) - **Desiccation**: Store in a sealed container with desiccant (silica gel or molecular sieve) - **Light**: Protect from light using amber vials or foil wrapping - **Atmosphere**: Minimise air exposure (oxygen promotes oxidation) **Shelf Life:** - At −20 °C, desiccated, and protected from light: **24–36 months** (manufacturer-stated; may be longer) - At −80 °C: **36+ months** (ultra-low temperatures virtually halt degradation) - At room temperature (25 °C): **1–3 months** (acceptable for short-term use only) **Best Practices:** - Store vials in airtight containers with fresh desiccant - Use a dedicated freezer box to protect from temperature fluctuations - Label each vial with peptide name, batch number, and storage date - Maintain a freezer inventory log - Do not store peptides in frost-free freezers (temperature cycling promotes degradation) **Freeze-Thaw Cycles:** - Lyophilised powder is relatively resistant to freeze-thaw cycles - However, minimise cycles by planning experiments and removing only the required vials - Allow vials to reach room temperature before opening to prevent condensation ## Storing Reconstituted (Liquid) Peptides Reconstituted peptides are less stable than lyophilised powder and require careful handling: **Recommended Storage:** - **Temperature**: 2–8 °C (refrigerator) - **Light**: Protect from light (amber vials or foil wrapping) - **pH**: Maintain at pH 6.5–7.5 for most peptides - **Container**: Use sterile, sealed vials; avoid repeated opening **Shelf Life:** - In bacteriostatic water at 2–8 °C: **7–14 days** - In sterile water at 2–8 °C: **24 hours** (no preservative) - In DMSO or organic solvents: **30–90 days** (depends on solvent) - Frozen aliquots at −20 °C: **3–6 months** (single-use aliquots only) **Critical Precautions:** - **Never freeze-thaw reconstituted peptides repeatedly**: This causes aggregation and pH shifts - **Aliquot into single-use vials** if long-term storage is needed - **Monitor for precipitation**: Cloudiness or particles indicate degradation - **Check pH periodically**: pH drift can accelerate hydrolysis **Light-Sensitive Peptides:** Some peptides are particularly light-sensitive and require extra protection: - **GHK-Cu**: Copper complex is photoreduced by visible light; store in amber vials or wrapped in foil - **Tryptophan-containing peptides**: Tryptophan oxidises under UV light - **Methionine-containing peptides**: Methionine is susceptible to photo-oxidation **Temperature-Sensitive Peptides:** - **Short peptides** (<10 amino acids): Generally stable at 2–8 °C - **Long peptides** (>30 amino acids): May require −20 °C for extended storage - **Cyclic peptides**: Often more stable than linear peptides due to conformational rigidity ## Handling Protocols Proper handling is as important as proper storage. Follow these protocols to maintain peptide integrity: **Glove Handling:** - Always wear powder-free nitrile or latex gloves when handling peptide vials - Avoid touching the vial stopper or inside of the cap - Change gloves between handling different peptides to prevent cross-contamination **Vial Opening:** - Wipe the rubber stopper with 70% isopropyl alcohol before inserting needles - Use a new sterile needle for each access - Minimise the number of needle punctures (each puncture introduces contamination risk) - For frequent access, consider using a septum vial or divided aliquots **Reconstitution:** - Allow vials to reach room temperature before opening (prevents condensation) - Use bacteriostatic water for any storage beyond 24 hours - Inject water slowly down the vial wall (avoid spraying onto powder) - Do not shake vigorously; gentle swirling is sufficient **Transportation:** - Use insulated containers with cold packs for transport - Maintain temperature logs during transit - For international shipping, use dry ice or gel packs with appropriate documentation - Avoid temperature extremes (>30 °C or <−80 °C during transit) **Disposal:** - Dispose of expired or degraded peptides in accordance with institutional hazardous waste protocols - Do not pour peptides down the drain - Needles and vials go in sharps containers ## Monitoring Stability and Degradation Researchers should monitor peptide stability over time, especially for long-term storage: **Visual Inspection:** - **Lyophilised powder**: Should be white or off-white, fluffy, and free-flowing - **Reconstituted solution**: Should be clear and colourless (or appropriate colour for the peptide) - **Signs of degradation**: Yellowing, browning, cloudiness, precipitation, or unusual odour **Analytical Monitoring:** - **HPLC check**: Run a quick analytical HPLC after 30 days of storage to compare to the original CoA - **Mass spectrometry**: Verify molecular weight after extended storage - **Bioactivity assay**: If a standard assay exists, confirm activity periodically **Common Degradation Pathways:** - **Hydrolysis**: Cleavage of peptide bonds by water; accelerated at acidic or basic pH - **Oxidation**: Methionine, cysteine, and tryptophan residues are most susceptible - **Deamidation**: Asparagine and glutamine residues convert to aspartic acid and glutamic acid - **Aggregation**: Hydrophobic peptides may form fibrils or precipitates - **Racemisation**: D-amino acid formation at high pH or temperature **Accelerated Stability Testing:** For critical experiments, researchers can perform accelerated stability testing: - Store peptide at 37 °C for 7 days - Compare HPLC and bioactivity to the original sample - Extrapolate shelf life using the Arrhenius equation (Q10 rule: reaction rate doubles for every 10 °C increase) **Example:** If a peptide is stable at 37 °C for 7 days, it is likely stable at 2–8 °C for ~70–140 days (10–20× longer). ## Compliance and Documentation UK research laboratories must maintain proper documentation for regulatory compliance and reproducibility: **Required Records:** - **Receipt log**: Date received, supplier, batch number, condition upon arrival - **Storage log**: Freezer/refrigerator location, temperature monitoring records, desiccant changes - **Handling log**: Dates opened, reconstituted, aliquoted, and used - **Stability data**: HPLC checks, visual inspections, and bioactivity confirmations - **Disposal log**: Date, quantity, and method of disposal **Temperature Monitoring:** - Use continuous temperature loggers (e.g., digital data loggers) in freezers and refrigerators - Record minimum and maximum temperatures daily - Investigate and document any temperature excursions - Maintain a temperature alarm system for critical storage units **Regulatory Notes:** - Research peptides are not controlled substances under the Misuse of Drugs Act 1971 (unless specifically scheduled) - They are not medicines under the Human Medicines Regulations 2012 - Research institutions must comply with their own ethics review boards and institutional safety protocols - Proper documentation supports audit readiness and legal compliance ## FAQs ### How long can I store lyophilised peptides at room temperature? Lyophilised peptides stored at room temperature (15–25 °C) in a desiccator are typically stable for 1–3 months. For long-term storage, −20 °C is strongly recommended. Room temperature storage is acceptable only for peptides that will be used within weeks, not months. ### Can I freeze reconstituted peptides? Freezing reconstituted peptides is not recommended due to pH shifts, ice crystal damage, and aggregation. If absolutely necessary, aliquot into single-use vials (e.g., 0.1 mL per vial) and freeze at −20 °C or −80 °C. Never refreeze a thawed aliquot. Lyophilised powder is the preferred form for long-term storage. ### Why do some peptides turn yellow or brown? Yellowing or browning typically indicates oxidation (especially methionine, cysteine, or tryptophan oxidation) or Maillard reactions (reaction between amino groups and reducing sugars). Discoloured peptides should be discarded and replaced with fresh material. Prevent oxidation by storing in the dark, under inert atmosphere, and at low temperatures. ### What is the best container for storing peptides? Lyophilised peptides should be stored in glass vials with airtight crimp seals or screw caps, inside a sealed container with desiccant. Reconstituted peptides should be stored in sterile glass or high-quality plastic (polypropylene) vials with tight seals. Avoid polystyrene or PVC containers which may leach plasticisers. Amber or foil-wrapped vials are recommended for light-sensitive peptides. --- # Bacteriostatic Water vs. Sterile Water vs. PBS for Peptide Research URL: https://hatipeptides.co.uk/guides/bac-water Updated: 2026-06-26 Author: Hati Peptides Laboratory Compare the three most common reconstitution media for research peptides. When to use BAC water, sterile water, or PBS in your laboratory. ## Overview The choice of reconstitution medium is a critical decision in peptide research. The three most common options are: - **[Bacteriostatic water](/product/bac) (BAC water)**: Sterile water with 0.9% benzyl alcohol - **Sterile water**: Pure water for injection (WFI) with no preservatives - **Phosphate-buffered saline (PBS)**: Buffered saline solution at pH 7.4 Each has distinct advantages, limitations, and appropriate use cases. This guide compares these media across key parameters to help researchers select the optimal solvent for their specific research model. ## Bacteriostatic Water (BAC Water) **Composition:** - Sterile water for injection (USP/EP grade) - 0.9% (9 mg/mL) benzyl alcohol as a bacteriostatic preservative - pH: 4.5–7.0 (slightly acidic) - Osmolarity: ~300 mOsm/L (isotonic) **Advantages:** - **Extended stability**: Benzyl alcohol prevents bacterial growth, allowing reconstituted peptides to be stored for 7–14 days at 2–8 °C - **Standard for peptide research**: The most widely used reconstitution medium for research peptides - **Isotonic**: Does not cause osmotic stress in cell culture applications - **Cost-effective**: Widely available and inexpensive - **Convenient**: Eliminates the need for daily reconstitution **Limitations:** - **Benzyl alcohol sensitivity**: Some cell types (e.g., primary neurons, certain stem cells) are sensitive to benzyl alcohol at concentrations >0.5% - **pH range**: Slightly acidic pH may affect pH-sensitive peptides or assays - **Not for all applications**: Some regulatory protocols specify sterile water only **Best for:** - Standard cell culture assays - Reconstitution of peptides for multi-day experiments - General laboratory research where convenience is important - Peptides that will be stored for 1–2 weeks after reconstitution ## Sterile Water (WFI) **Composition:** - Pure water for injection (USP/EP grade) - No preservatives or additives - pH: 5.0–7.0 (neutral) - Osmolarity: ~0 mOsm/L (hypotonic) **Advantages:** - **No additives**: Ideal for sensitive cell types or assays where any additive could interfere - **Neutral pH**: Better for pH-sensitive peptides or assays - **Regulatory compliance**: Some protocols and SOPs explicitly require sterile water - **No solvent interference**: No risk of benzyl alcohol affecting enzyme assays or receptor binding **Limitations:** - **Short stability**: No preservative means bacterial growth begins within 12–24 hours - **Must use immediately**: Reconstituted peptides must be used the same day or discarded - **Hypotonic**: Can cause osmotic stress in cell culture if not diluted into medium - **Inconvenient**: Requires daily reconstitution for multi-day experiments **Best for:** - Same-day experiments - Sensitive cell types (primary neurons, stem cells, certain epithelial cells) - Enzyme assays where benzyl alcohol might interfere - Assays requiring precise pH control - Regulatory protocols specifying preservative-free reconstitution ## Phosphate-Buffered Saline (PBS) **Composition:** - Sodium chloride (137 mM) - Potassium chloride (2.7 mM) - Sodium phosphate (10 mM) - Potassium phosphate (1.8 mM) - pH: 7.4 (physiological) - Osmolarity: ~300 mOsm/L (isotonic) **Advantages:** - **Physiological pH**: pH 7.4 matches most cellular and biological environments - **Isotonic with cells**: Does not cause osmotic stress - **Buffered**: Resists pH changes during storage or incubation - **Standard cell culture buffer**: Compatible with most cell culture media and assays - **No preservatives**: Suitable for sensitive applications **Limitations:** - **Short stability**: Like sterile water, no preservative means bacterial growth within 24 hours - **Phosphate interference**: Phosphate can interfere with some assays (e.g., phosphate detection, certain kinase assays) - **Salt content**: High salt may affect some analytical methods (e.g., mass spectrometry, certain chromatographic separations) - **Not for long-term storage**: Must use within 24 hours or prepare fresh **Best for:** - Cell culture applications where pH stability is critical - Biological assays requiring physiological pH and ionic strength - Reconstitution immediately before adding to cell culture medium - Applications where benzyl alcohol is contraindicated but physiological pH is required ## Comparison Table | Parameter | Bacteriostatic Water | Sterile Water | PBS | |-----------|---------------------|---------------|-----| | **Preservative** | 0.9% benzyl alcohol | None | None | | **pH** | 4.5–7.0 | 5.0–7.0 | 7.4 | | **Osmolarity** | ~300 mOsm/L | ~0 mOsm/L | ~300 mOsm/L | | **Stability** | 7–14 days at 2–8 °C | 12–24 hours | 12–24 hours | | **Cost** | Low | Low | Low | | **Cell culture** | Excellent (most cells) | Good (sensitive cells) | Excellent (buffered) | | **Convenience** | High | Low | Low | | **Best for** | Multi-day experiments | Same-day, sensitive cells | Cell culture, pH-critical | **Decision Tree:** 1. **Will the peptide be stored >24 hours after reconstitution?** - Yes → **Bacteriostatic water** - No → Proceed to question 2 2. **Are you working with benzyl alcohol-sensitive cells?** - Yes → **Sterile water** or **PBS** - No → Proceed to question 3 3. **Is physiological pH critical for your assay?** - Yes → **PBS** - No → **Bacteriostatic water** or **Sterile water** 4. **Is your assay sensitive to phosphate or salts?** - Yes → **Sterile water** - No → **PBS** or **Bacteriostatic water** ## Practical Recommendations **For Most Research Applications:** [Bacteriostatic water](/product/bac) is the default choice for peptide reconstitution. It provides the best balance of stability, convenience, and cost for standard cell culture and biochemical assays. **For Sensitive Cell Types:** Primary neurons, certain stem cells, and some epithelial cells are sensitive to benzyl alcohol. For these applications: - Reconstitute in sterile water or PBS - Use immediately (within 4–6 hours) - Prepare fresh solutions for each experiment **For Mass Spectrometry or Analytical HPLC:** - Reconstitute in sterile water or a compatible organic solvent (e.g., acetonitrile, methanol) - Avoid PBS (salt interferes with MS ionisation) - Avoid BAC water (benzyl alcohol may appear as an artifact in chromatograms) **For Animal Research (if applicable):** - Consult institutional veterinary protocols - Some protocols require sterile water or PBS specifically - Document the rationale for solvent choice in your IACUC or ethics application **For Long-Term Studies:** If a study requires peptide administration over multiple days: - Reconstitute in BAC water and store at 2–8 °C - Verify stability by HPLC at the beginning and end of the study - Consider aliquoting into single-day vials to minimise contamination risk **Storage of Unused Solvent:** - BAC water: Store at room temperature (15–30 °C), protected from light. Use within the expiry date (typically 12–24 months from manufacture). - Sterile water: Store at room temperature. Use within 24 hours of opening if not used completely. - PBS: Store at 2–8 °C. Use within 24–48 hours of opening or prepare fresh from powder. ## Manufacturing and Quality Control [Bacteriostatic water](/product/bac) is manufactured under pharmaceutical-grade conditions to ensure sterility and consistency. The production process involves several critical steps: **1. Water Purification** Source water undergoes reverse osmosis, deionisation, and distillation to achieve USP/EP-grade purified water with resistivity ≥18.2 MΩ·cm. This removes minerals, organic compounds, and microbial contaminants. **2. Sterile Filtration** The purified water is passed through a 0.22 µm sterilising-grade filter to remove bacteria and particulate matter. This is typically performed in a classified cleanroom environment (Grade A/ISO 5 or equivalent). **3. Benzyl Alcohol Addition** USP-grade benzyl alcohol is added at 0.9% (9 mg/mL) as a bacteriostatic preservative. The exact concentration is verified by HPLC or gas chromatography. The benzyl alcohol must meet USP specifications for purity (≥99.0%) and identity. **4. Filling and Sealing** The sterile solution is filled into multi-dose vials under aseptic conditions. Vials are sealed with rubber stoppers and aluminium crimps. Each vial is visually inspected for cracks, particulate, and fill volume. Some manufacturers also terminally sterilise by autoclaving at 121 °C for 15 minutes. **5. Quality Control Testing** Each batch undergoes: - **Sterility testing** per USP <71> or Ph. Eur. 2.6.1 - **Endotoxin testing** (LAL assay, Ph. Eur. 2.6.14) — typically <0.5 EU/mL - **Benzyl alcohol assay** — confirm 0.9% ± 0.1% - **pH testing** — confirm 4.5–7.0 range - **Particulate matter** per USP <788> or Ph. Eur. 2.9.19 - **Container-closure integrity** — leak test **Batch Release:** A Certificate of Analysis is issued for each batch documenting all test results. Reproducible research depends on using BAC water from a consistent source with documented quality control. ## Shelf-Life and Storage Best Practices Proper storage of bacteriostatic water is essential to maintain sterility and preservative efficacy. **Unopened Vials:** - **Shelf life**: Typically 12–24 months from manufacture date - **Storage conditions**: Room temperature (15–30 °C), protected from light - **Do not freeze**: Freezing can cause vial cracking and rubber stopper degradation - **Inspect before use**: Check for cracks, cloudy solution, or particulate **Opened (In-Use) Vials:** - **Multi-dose window**: 28–30 days after first puncture per USP standards - **Storage**: Room temperature in original packaging, away from direct light - **Alcohol swab**: Always wipe the rubber septum with 70% isopropyl alcohol before inserting a needle - **Needle size**: Use a 25G–30G needle to minimise stopper coring - **Label**: Write the opening date on the vial to track the 28-day window **Visual Inspection Guide:** | Observation | Likely Cause | Action | |---|---|---| | Clear, colourless | Normal | Safe to use | | Cloudy or hazy | Microbial contamination | Discard immediately | | Particulate or flakes | Stopper degradation or glass | Discard; inspect remaining vials | | Yellow tint | Benzyl alcohol degradation | Discard if >30 days old | | Crystals/precipitate | Contamination or freezing | Discard | **When to Discard:** - Beyond the manufacturer's expiry date - More than 28–30 days after first opening - Any visible cloudiness, particulate, or discolouration - If the vial seal is broken or the crimp is loose - If stored outside 15–30 °C for extended periods ## Volume Selection Guide Choosing the right volume of [bacteriostatic water](/product/bac) depends on the peptide mass in the vial and the desired concentration for your research protocol. **General Guidelines by Vial Size:** | Vial Content | Recommended BAC Water | Resulting Concentration | |---|---|---| | 2 mg peptide | 0.5–1 mL | 2–4 mg/mL | | 5 mg peptide | 1–2 mL | 2.5–5 mg/mL | | 10 mg peptide | 2–4 mL | 2.5–5 mg/mL | | 15 mg peptide | 3–6 mL | 2.5–5 mg/mL | | 20 mg peptide | 4–8 mL | 2.5–5 mg/mL | | 30 mg peptide | 6–10 mL | 3–5 mg/mL | | 50 mg peptide | 10–15 mL | 3.3–5 mg/mL | **Key Considerations:** 1. **Minimum volume**: Use at least 0.5 mL of BAC water per vial to ensure complete dissolution. Smaller volumes may not fully wet the lyophilised plug. 2. **Maximum volume**: Do not exceed the vial's recommended fill volume. Overfilling can cause stopper leakage and contamination. 3. **Concentration targets**: - **2–5 mg/mL**: Standard range for most research peptides - **5–10 mg/mL**: Concentrated stock for subsequent dilution into assay buffer or culture medium - **<1 mg/mL**: Use for highly potent peptides or when larger injection volumes are acceptable 4. **Solubility factors**: Some peptides have poor aqueous solubility at high concentrations. If the peptide does not dissolve readily, use a larger volume (lower concentration) or consult the peptide's solubility data sheet. 5. **Practical tip**: For most standard research protocols, 2 mL per 10 mg peptide is a safe starting point. Use the [Peptide Calculator](/calculator) to fine-tune volumes and verify concentrations. ## FAQs ### Can I use tap water or distilled water instead? No. Tap water contains chlorine, minerals, and bacteria that will contaminate peptides and compromise experiments. Distilled water is not sterile and lacks the preservative needed for multi-day storage. Only use USP/EP-grade bacteriostatic water, sterile water for injection, or pharmaceutical-grade PBS. ### Does benzyl alcohol affect peptide stability? Benzyl alcohol at 0.9% does not significantly affect the chemical stability of most peptides. However, it can be toxic to certain sensitive cell types at high concentrations. In cell culture, the final concentration of benzyl alcohol is typically <0.1% after dilution into medium, which is safe for most cell lines. ### Can I mix different solvents? In some cases, yes. For poorly soluble peptides, researchers may reconstitute in 10–20% DMSO first, then dilute with BAC water or PBS. However, DMSO can be toxic to cells at concentrations >0.1%, so final DMSO concentration in cell culture should be minimised. Always document the solvent composition in your methods. ### What should I do if my peptide precipitates in PBS? Precipitation in PBS may indicate that the peptide is insoluble at physiological pH or ionic strength. Try reconstituting in sterile water first, then slowly adding PBS while monitoring for precipitation. Alternatively, try BAC water or a slightly acidic buffer (pH 6.0–6.5). Some peptides simply require a different solvent system. ### How long does bacteriostatic water last after opening? Per USP standards, bacteriostatic water is approved for multi-dose use up to 28–30 days after the first vial puncture. After this period, the risk of microbial contamination increases even if the solution appears clear. Always write the opening date on the vial label and discard after 28 days, regardless of appearance. ### Can bacteriostatic water be refrigerated? Bacteriostatic water should be stored at room temperature (15–30 °C). Refrigeration can cause condensation inside the vial when warmed to room temperature, potentially introducing moisture and contaminants through the stopper. If your laboratory protocol requires cold storage, allow the vial to reach room temperature completely before each use and wipe the septum with alcohol. ### What does cloudy bacteriostatic water mean? Cloudiness in bacteriostatic water indicates microbial contamination and the vial must be discarded immediately. Contamination can occur from repeated needle punctures, inadequate septum cleaning, or storing beyond the 28-day in-use period. Do not attempt to filter or re-sterilise contaminated BAC water — benzyl alcohol does not kill all microorganisms, and endotoxins from lysed bacteria remain in solution. ### Is BAC water suitable for in vivo research? Pharmaceutical-grade bacteriostatic water (USP/EP) is suitable for in vivo research applications including animal studies, provided the research protocol and institutional ethics committee approve its use. It is sterile, isotonic, and endotoxin-tested. However, some animal protocols specify sterile saline or sterile water for injection — always follow your institutional IACUC or ethics board guidelines. --- # Frequently Asked Questions — Research Peptide Reference Materials URL: https://hatipeptides.co.uk/guides/faq Updated: 2026-06-05 Author: Hati Peptides Laboratory General frequently asked questions about research peptides, UK legality, ordering, storage, and compliance. For laboratory and research use only. ## Legality and Compliance **Are research peptides legal in the UK?** Yes. Research peptides are not controlled substances under the UK Misuse of Drugs Act 1971 and are not scheduled under the Psychoactive Substances Act 2016. They are classified as research reference materials for laboratory use and are not licensed as medicines by the MHRA (Medicines and Healthcare products Regulatory Agency). **Important caveats:** - Research peptides must be sold explicitly for **in vitro and laboratory research only** - They must not be marketed for human or animal consumption - They must not be marketed as medicines, dietary supplements, cosmetics, or foods - Research institutions must ensure compliance with their own ethics review boards and institutional safety protocols - Researchers are responsible for ensuring their research complies with the Human Medicines Regulations 2012 where applicable **Can I import peptides for research?** Yes. Importing research peptides for laboratory use is permitted under UK customs regulations, provided: - The peptides are for genuine research purposes - The quantity is appropriate for research (not commercial resale) - The materials are properly declared and documented - The researcher retains all import documentation (invoices, CoAs, batch records) **Do I need a license to buy research peptides?** No license is required to purchase research peptides for laboratory use in the UK. However: - Some peptides may be restricted for export from certain countries (e.g., US Export Administration Regulations) - Institutional approval may be required for certain research applications - Researchers should ensure their proposed use complies with all applicable institutional and regulatory requirements **What happens if I use peptides for non-research purposes?** Using research peptides for human consumption, medical treatment, or any purpose other than laboratory research is: - A violation of the terms of sale - Potentially illegal under the Human Medicines Regulations 2012 if marketed as medicines - Potentially harmful to health (research peptides are not manufactured to pharmaceutical GMP standards) - A breach of institutional ethics protocols Hati Peptides sells peptides strictly for in vitro research. Any other use is not endorsed or supported. ## Ordering and Shipping **How do I place an order?** Orders can be placed through the Hati Peptides website. The process is: 1. Browse the catalog and select your desired peptide and strength 2. Add to cart and proceed to checkout 3. Choose payment method (bank transfer or cryptocurrency) 4. Complete verification (email confirmation) 5. Receive order confirmation with payment instructions **What payment methods are accepted?** - **Bank transfer (UK Faster Payments)**: Free, typically clears within minutes - **Cryptocurrency**: Bitcoin, Ethereum, USDT, and other major cryptocurrencies via NOWPayments - **No credit/debit cards**: Due to payment processor restrictions on research peptide sales **How long does shipping take?** - **UK Mainland**: 1–2 business days (Royal Mail Tracked 24) - **UK Remote**: 2–3 business days - **International**: Not currently available; UK shipping only **Is shipping discreet?** Yes. All orders are shipped in plain, unmarked packaging with no indication of contents. The return address is a generic business address. **What is the minimum order?** There is no minimum order value. Single vials can be purchased. **Do you offer discounts for bulk orders?** Yes. Multi-vial discounts are automatically applied at checkout: - 2–3 vials: 5% discount - 4–5 vials: 10% discount - 6+ vials: 15% discount **What is your return policy?** Research peptides are non-returnable and non-refundable due to their temperature-sensitive nature and sterility requirements. If a product arrives damaged or does not match the CoA, contact us within 48 hours of delivery with photographic evidence. ## Products and Quality **What purity are your peptides?** All peptides are ≥98% pure by HPLC, with most ≥99% pure. Each batch is verified by: - High-performance liquid chromatography (HPLC) for purity - Mass spectrometry (MS) for identity confirmation - Endotoxin testing (LAL assay) for cell culture safety Certificates of Analysis are available for download on each product page. **Are your peptides GMP-grade?** No. Our peptides are **research-grade** (also called "reference grade" or "analytical grade"). They are manufactured to high quality standards but are not produced under pharmaceutical GMP (Good Manufacturing Practice) conditions. They are intended for in vitro research only, not for human or animal consumption. **Do you synthesise your own peptides?** We source peptides from reputable international manufacturers who specialise in research-grade peptide synthesis. All batches are independently tested in UK laboratories before release. We maintain full traceability from synthesis to delivery. **Can you provide custom peptides?** Not currently. We focus on a curated catalog of well-characterised peptides. Custom synthesis may be offered in the future. **What form do peptides arrive in?** All peptides are supplied as lyophilised (freeze-dried) powder in sterile glass vials with crimp seals. Vials are clearly labelled with peptide name, batch number, and net weight. **How do I know the peptide is genuine?** Each batch is accompanied by a Certificate of Analysis (CoA) documenting: - HPLC purity chromatogram - Mass spectrometry molecular weight confirmation - Endotoxin levels - Batch-specific analytical data You can verify the identity by running your own analytical HPLC and MS (see our guide on [How to Read a CoA](/guides/coa)). **Do you offer peptide blends or combination products?** Not currently. All products are single-compound vials. This ensures accurate dosing and purity verification for each peptide. ## Storage and Handling **How should I store peptides?** **Lyophilised (powder):** - Store at −20 °C in a desiccated container - Protect from light (amber vials or foil wrapping) - Shelf life: 24–36 months when properly stored **Reconstituted (liquid):** - Store at 2–8 °C (refrigerator) - Use bacteriostatic water for multi-day storage - Protect from light - Shelf life: 7–14 days at 2–8 °C See our detailed [Storage and Handling Guide](/guides/storage) for comprehensive protocols. **What is the shelf life?** - Lyophilised peptides: 24–36 months from the QC date (stated on the CoA) - Reconstituted in BAC water: 7–14 days at 2–8 °C - Reconstituted in sterile water: 24 hours maximum **Can I freeze reconstituted peptides?** Freezing reconstituted peptides is not recommended due to pH shifts, ice crystal damage, and aggregation. If absolutely necessary, aliquot into single-use vials and freeze at −20 °C. Never refreeze a thawed aliquot. **What should I do if the peptide arrives warm?** If a peptide arrives at room temperature (e.g., due to shipping delays), it is generally still usable if: - The vial seal is intact - The powder appears normal (white, fluffy, no clumping) - The peptide has been at room temperature for less than 72 hours Place the vial in the freezer (−20 °C) immediately upon receipt and contact us if you have concerns. Most lyophilised peptides are stable at room temperature for short periods. **Do peptides require refrigeration during shipping?** Lyophilised peptides are stable at room temperature for shipping. We use insulated packaging for temperature-sensitive materials during summer months. Reconstituted peptides are not shipped — they must be reconstituted in your laboratory. ## Research Applications **What are peptides used for in research?** Research peptides are used in a wide range of in vitro and laboratory applications: - **Cell culture studies**: Examining cell signalling, proliferation, differentiation, and apoptosis - **Receptor pharmacology**: Characterising receptor binding, activation, and desensitisation - **Enzyme assays**: Studying enzyme inhibition, activation, or substrate interactions - **Protein-protein interactions**: Investigating molecular binding and signalling complexes - **Wound healing models**: Studying fibroblast migration, angiogenesis, and tissue repair - **Metabolic research**: Examining insulin secretion, glucose uptake, and lipid metabolism - **Neuroscience**: Studying neuroimmune modulation, neuroprotection, and synaptic plasticity - **Longevity research**: Investigating cellular senescence, telomere maintenance, and mitochondrial function **Are peptides safe to handle in the laboratory?** Research peptides should be handled with standard laboratory safety precautions: - Wear gloves and safety glasses - Work in a clean laboratory environment - Do not ingest, inhale, or allow contact with skin or mucous membranes - Dispose of used materials in appropriate biological waste containers - Follow institutional biosafety protocols **Can peptides be used in animal research?** Research peptides can be used in animal research subject to: - Institutional Animal Care and Use Committee (IACUC) or equivalent ethics approval - Compliance with the Animals (Scientific Procedures) Act 1986 - Proper veterinary oversight - Appropriate dosing and administration protocols Hati Peptides does not provide guidance on animal dosing or administration. Researchers must consult their institutional veterinary and ethics teams. **Do you provide research protocols?** We provide general methodology guides (e.g., reconstitution, storage, CoA interpretation) but do not provide specific experimental protocols, dosing information, or cell culture recipes. Researchers should design their own protocols based on peer-reviewed literature and institutional guidance. **Can I publish research using your peptides?** Yes. Many researchers publish peer-reviewed studies using research-grade peptides. When publishing, include: - Supplier name (Hati Peptides) - Peptide name and batch number - Purity grade and analytical methods - Storage and handling conditions This documentation ensures reproducibility and supports the scientific record. ## Customer Support and Contact **How do I contact Hati Peptides?** - **Email**: contact@hatipeptides.co.uk - **WhatsApp**: 07496 498328 - **Response time**: Typically within 24 hours (business days) **What support do you offer?** We provide support for: - Order inquiries and status updates - Product questions (purity, specifications, CoA) - Shipping and delivery issues - General methodology questions (reconstitution, storage) We do not provide: - Medical advice or health consultations - Dosing or administration guidance - Protocols for human or animal use - Legal advice on regulatory compliance **Do you offer wholesale or institutional pricing?** Yes. Universities, research institutions, and biotech companies can contact us for institutional pricing and bulk orders. We offer: - Volume discounts - Multi-batch orders - Custom documentation (e.g., institutional VAT invoices) - Dedicated account management **How do I verify my order?** All orders require email verification for security. After checkout: 1. Check your email for a verification code 2. Enter the code on the verification page 3. Your order is confirmed and processed If you do not receive the verification email within 5 minutes, check your spam folder or contact us. **Do you have a referral or affiliate program?** Yes — after your first order, you will receive a personal referral code in your account dashboard. Share it with colleagues and earn store credit when their orders are fulfilled. New customers referred by a colleague also get **10% off** their first order (minimum £50). Full terms are available in your account. **How do I track my order?** Once dispatched, you will receive a tracking number via email. UK orders can be tracked via Royal Mail's tracking service. Typical delivery time: 1–2 business days. **What if I have a problem with my order?** Contact us immediately via email or WhatsApp with: - Your order number - A description of the issue - Photographic evidence (if applicable) We will resolve the issue within 24 hours. For damaged or incorrect products, we may offer a replacement or store credit at our discretion. ## FAQs ### Is it legal to buy research peptides online in the UK? Yes, it is legal to purchase research peptides for laboratory use in the UK. Research peptides are not controlled substances under the Misuse of Drugs Act 1971. However, they must be sold explicitly for research purposes only and not for human consumption. ### How do I know if a peptide is right for my research model? Review the product description, related research articles, and the peptide's mechanism of action. Consider your cell type, assay endpoint, and the peptide's receptor targets. Our comparison guides (e.g., metabolic peptides, regenerative peptides) can help you select the appropriate compound. Always consult peer-reviewed literature for your specific research model. ### Can I get a discount for my first order? We do not currently offer first-order discounts. However, we offer automatic multi-vial discounts at checkout (5% for 2–3 vials, 10% for 4–5 vials, 15% for 6+ vials). Institutional customers may qualify for additional pricing — contact us for details. ### What should I do if my peptide does not dissolve? Try the following steps: (1) Allow the vial to reach room temperature. (2) Gently warm to 25–30 °C in a water bath. (3) Add 10–20% DMSO as a co-solvent. (4) Reduce the concentration by adding more bacteriostatic water. (5) Check pH and adjust if necessary. If the peptide still does not dissolve, contact us with the batch number for batch-specific guidance. ### Do you ship internationally? Not currently. We ship to UK addresses only. International shipping may be introduced in the future. Researchers outside the UK should arrange for UK-based forwarding services or contact us for alternative arrangements. ### Are your peptides tested for endotoxins? Yes. All peptides are tested for endotoxin levels using the LAL (Limulus Amebocyte Lysate) assay. Endotoxin levels are confirmed to be <0.5 EU/mL, suitable for cell culture applications. The endotoxin results are documented in the batch-specific Certificate of Analysis. --- # What Are Research Peptides? A UK Laboratory Guide URL: https://hatipeptides.co.uk/guides/what-are-research-peptides Updated: 2026-06-05 Author: Hati Peptides Laboratory Comprehensive guide to research peptides for UK laboratories. What they are, how they're synthesised, purity grades, applications, regulatory context. ## What Are Research Peptides? Research peptides are synthetic amino acid chains (typically 2–50 residues) manufactured as reference materials for in vitro and laboratory studies. These compounds are used to investigate cellular signalling, receptor pharmacology, metabolic regulation, tissue regeneration, and numerous other biological processes in controlled research settings. Unlike pharmaceutical peptides, research peptides are not manufactured under GMP (Good Manufacturing Practice) conditions and are not intended for human or animal consumption. They are sold explicitly for laboratory research, analytical standardisation, and in vitro experimentation. In the UK, research peptides are classified as laboratory reference materials. They are not controlled substances under the Misuse of Drugs Act 1971 and are not medicines under the Human Medicines Regulations 2012. ## How Research Peptides Are Synthesised Research peptides are typically manufactured using **solid-phase peptide synthesis (SPPS)**, a technique developed by Bruce Merrifield in 1963 that remains the industry standard today. **The SPPS Process:** 1. **Resin loading**: The first amino acid is attached to an insoluble polymer resin 2. **Deprotection**: The Fmoc or Boc protecting group is removed from the amino acid 3. **Coupling**: The next amino acid is activated and coupled to the growing chain 4. **Washing**: Excess reagents are washed away 5. **Repeat**: Steps 2–4 are repeated until the full sequence is assembled 6. **Cleavage**: The peptide is cleaved from the resin with TFA (trifluoroacetic acid) 7. **Purification**: Crude peptide is purified by reversed-phase HPLC 8. **Characterisation**: Identity is confirmed by mass spectrometry; purity by analytical HPLC **Purity Grades:** - **≥95%**: Standard for screening and preliminary studies - **≥98%**: Recommended for most published research and cell culture - **≥99%**: Preferred for sensitive assays (receptor binding, crystallography) **Common Modifications:** - N-terminal acetylation (e.g., TB-500) - C-terminal amidation (most bioactive peptides) - Fatty-diacid conjugation (e.g., Semaglutide, Retatrutide for albumin binding) - D-amino acid substitutions (e.g., Ipamorelin for protease resistance) - Cyclisation (e.g., GHK-Cu, cyclic peptides for enhanced stability) ## Research Applications Research peptides are employed across diverse scientific disciplines in UK laboratories: **Metabolic Research** - GLP-1 receptor agonists (Semaglutide) for glucose-dependent insulin secretion studies - Triple agonists (Retatrutide) for multi-receptor metabolic integration - GHRH analogues (Tesamorelin) for growth hormone axis studies - Mitochondrial-derived peptides (MOTS-C) for AMPK activation and metabolic flexibility **Regenerative Medicine** - Pentadecapeptides (BPC-157) for angiogenesis and fibroblast activation - Thymosin fragments (TB-500) for actin regulation and wound healing - Copper tripeptides (GHK-Cu) for collagen synthesis and extracellular matrix remodelling **Longevity and Senescence** - Telomerase activators (Epithalon) for telomere maintenance studies - NAD+ coenzymes for sirtuin activation and redox metabolism - Mitochondrial peptides for cellular stress response and ageing models **Neuroscience and Cognition** - Synthetic heptapeptides (Selank) for neuroimmune modulation and BDNF expression - Neuropeptide analogues for anxiety and stress response models **Receptor Pharmacology** - Class B GPCR ligands (GLP-1, GIP, glucagon receptors) - Ghrelin receptor agonists (GHS-R1a, Ipamorelin) - GHRH receptor ligands for pituitary cell studies ## Quality Assurance and Verification Research peptide quality is verified through analytical chemistry techniques: **HPLC (High-Performance Liquid Chromatography)** - Measures purity by separating peptide from synthesis by-products - Reports area-under-curve (AUC) percentage - ≥98% is the standard for most research applications **Mass Spectrometry (MS)** - Confirms molecular weight and sequence identity - Detects modifications (acetylation, fatty-diacid conjugation) - Essential for verifying synthetic accuracy **Endotoxin Testing (LAL Assay)** - Detects bacterial lipopolysaccharide contamination - Critical for cell culture applications - Threshold: <0.5 EU/mL for most in vitro work **Additional Tests** - Amino acid analysis (AAA): Confirms amino acid composition - Counter-ion content: TFA, acetate levels - Residual solvent analysis: Acetonitrile, TFA - Net peptide content: Actual peptide mass vs total weight **Documentation** Every batch should be accompanied by a Certificate of Analysis (CoA) documenting: - Batch number and date - HPLC chromatogram and purity - MS molecular weight confirmation - Endotoxin levels - Physical appearance and solubility data - Analyst signature and review ## Storage and Handling Proper storage maintains peptide integrity: **Lyophilised Powder** - Store at −20 °C, desiccated, protected from light - Shelf life: 24–36 months - Avoid repeated freeze-thaw cycles - Keep vial sealed until use **Reconstituted Solution** - Use bacteriostatic water (0.9% benzyl alcohol) for multi-day storage - Store at 2–8 °C, protected from light - Shelf life: 7–14 days - Aliquot into single-use vials for extended storage - Avoid freeze-thaw of reconstituted solutions **Critical Precautions** - Do not use tap water or non-sterile water for reconstitution - Do not shake vigorously (causes foam and denaturation) - Protect from light (especially methionine, tryptophan-containing peptides) - Monitor pH (optimal 6.5–7.5) - Document reconstitution dates and storage conditions ## UK Regulatory Context Research peptides operate in a specific regulatory framework in the UK: **Legal Status** - Not controlled substances under the Misuse of Drugs Act 1971 - Not scheduled under the Psychoactive Substances Act 2016 - Not licensed as medicines by the MHRA - Classified as research reference materials for laboratory use **Research Use Only** - Must be sold explicitly for in vitro and laboratory research - Must not be marketed for human or animal consumption - Must not be marketed as medicines, foods, cosmetics, or dietary supplements - Must carry appropriate research-use-only labelling **Import and Export** - Importing for genuine research is permitted under UK customs regulations - Export may be restricted by destination country regulations - Researchers should retain all import documentation (invoices, CoAs) - Some peptides may be subject to US Export Administration Regulations **Institutional Compliance** - Research institutions must comply with their ethics review boards - Animal studies require IACUC or equivalent approval under the Animals (Scientific Procedures) Act 1986 - Human tissue research requires appropriate ethical approval - Researchers must follow institutional biosafety protocols **Publication Requirements** When publishing research using peptides, include: - Supplier name and location - Peptide name, batch number, and purity - Analytical methods used for verification - Storage and handling conditions - Research-use-only context ## FAQs ### What is the difference between research peptides and pharmaceutical peptides? Research peptides are manufactured for laboratory and in vitro studies. They are not produced under pharmaceutical GMP conditions, have not undergone clinical trials, and are not approved for human use. Pharmaceutical peptides are manufactured under strict GMP conditions, have undergone extensive safety and efficacy testing, and are approved by regulatory agencies (e.g., MHRA, FDA) for specific therapeutic indications. ### How pure should research peptides be? For most in vitro research, ≥98% purity is recommended. For highly sensitive assays (receptor binding, crystallography, mass spectrometry quantification), ≥99% is preferred. Preliminary screening studies may accept ≥95%. Always consult the Certificate of Analysis and verify purity independently if publishing in peer-reviewed journals. ### Are research peptides safe to handle? Research peptides should be handled with standard laboratory precautions: wear gloves and safety glasses, work in a clean environment, avoid ingestion or skin contact, and dispose of materials in appropriate biological waste containers. Research peptides are not safety-tested for human exposure and may have unknown biological activity. Always follow institutional biosafety protocols. ### Can I use research peptides in animal studies? Research peptides can be used in animal studies subject to appropriate ethical approval (IACUC or equivalent under the Animals (Scientific Procedures) Act 1986), veterinary oversight, and institutional compliance. Researchers must design their own protocols based on peer-reviewed literature and institutional guidance. Suppliers do not provide animal dosing or administration recommendations. ### How do I verify peptide identity? Verify peptide identity by: (1) reviewing the supplier's Certificate of Analysis (CoA) for HPLC and MS data; (2) running analytical HPLC on your own system to compare retention time and peak shape; (3) submitting a sample for mass spectrometry to confirm molecular weight; (4) performing a bioactivity assay if available for your specific peptide. Document all verification steps for reproducibility. --- --- # Glossary # Retatrutide URL: https://hatipeptides.co.uk/glossary/retatrutide Retatrutide is a 39-amino-acid peptide engineered as a triple agonist at GLP-1, GIP, and glucagon receptors. It is used in metabolic research to study multi-receptor signalling, energy homeostasis, and incretin biology. ## Overview Retatrutide (development code LY3437943) is a synthetic peptide engineered as a triple agonist at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. The peptide is a 39-amino-acid sequence with a C20 fatty-diacid conjugate via a γ-Glu-2xAdo linker, enabling extended half-life through albumin binding. For UK research laboratories, retatrutide serves as a reference compound for studies examining multi-receptor metabolic regulation, energy homeostasis, and the interplay between incretin and glucagon signalling in cellular and in vitro models. ## Mechanism Retatrutide activates three distinct receptor systems that collectively regulate metabolic physiology: **GLP-1 Receptor Agonism** — Potentiates glucose-dependent insulin secretion, suppresses glucagon release in hyperglycaemic states, delays gastric emptying, and activates brainstem satiety circuits. **GIP Receptor Agonism** — Amplifies insulin secretion in a glucose-dependent manner, promotes lipid storage in adipose tissue, and may support bone formation. **Glucagon Receptor Agonism** — Increases hepatic glucose output, stimulates lipolysis, and raises energy expenditure. The glucagon component creates a counter-regulatory signal that balances the insulinotropic effects of GLP-1 and GIP. ## Research Applications Retatrutide is employed across multiple research domains in UK laboratories: **Metabolic Disease Research** — In vitro studies examine insulin secretion, glucagon suppression, and glucose uptake in isolated islet and hepatocyte cultures. **Energy Homeostasis Studies** — Cellular models of adipocyte differentiation, lipolysis, and thermogenesis are used to study energy balance effects. **Comparative Pharmacology** — Retatrutide is frequently compared to single-agonist and dual-agonist peptides (tirzepatide, semaglutide) in cellular receptor-binding assays. **Receptor Pharmacology** — The peptide serves as a tool compound for studying class B GPCR biology, receptor oligomerisation, and biased agonism. ## Reconstitution Retatrutide is supplied as a lyophilised powder. Standard laboratory preparation: • **Bacteriostatic water** (0.9% benzyl alcohol) recommended for reconstitution • **Typical concentrations**: 1–10 mg/mL depending on assay requirements • **Solubility**: The fatty-diacid conjugate may reduce aqueous solubility; gentle vortexing and brief warming (not exceeding 37°C) can aid dissolution • **Albumin binding**: Account for this in binding assays and cellular incubations • **pH**: Maintain solutions at pH 6.5–7.5 ## Storage • **Lyophilised powder**: −20°C, protected from light • **Reconstituted solution**: 2–8°C, protected from light • **Stability**: 7–14 days under refrigeration; aliquot and freeze at −20°C for extended studies • **Avoid**: Repeated freeze-thaw cycles ## FAQs ### What is retatrutide's primary mechanism? Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. It activates three distinct metabolic signalling pathways simultaneously, enabling researchers to study integrated metabolic regulation. ### How does retatrutide differ from tirzepatide? Tirzepatide is a dual agonist at GLP-1 and GIP receptors. Retatrutide adds glucagon receptor agonism to create a triple agonist. The glucagon component adds hepatic glucose output and energy expenditure signals that are absent in tirzepatide. ### What cellular models are used for retatrutide research? Standard models include: (1) beta-cell lines (MIN6, INS-1) for insulin secretion; (2) primary hepatocytes for glucagon-mediated glucose output; (3) 3T3-L1 adipocytes for GIP-mediated lipid storage; (4) transfected cell lines for binding affinity studies. ### Is retatrutide legal for research in the UK? Yes. Retatrutide is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase for legitimate laboratory research. It is not licensed as a medicine by the MHRA. ## Related Products - [Tirzepatide](https://hatipeptides.co.uk/product/tirzepatide) - [Semaglutide](https://hatipeptides.co.uk/product/semaglutide) - [MOTS-C](https://hatipeptides.co.uk/product/mots-c) ## Related Articles - [Retatrutide UK: Research Reference 2026](https://hatipeptides.co.uk/research/retatrutide) - [Retatrutide vs Semaglutide: Research Comparison](https://hatipeptides.co.uk/research/retatrutide-vs-semaglutide) --- # MOTS-C URL: https://hatipeptides.co.uk/glossary/mots-c MOTS-C is a 16-amino-acid peptide encoded within the mitochondrial genome. It regulates metabolic homeostasis, cellular stress responses, and mitochondrial-nuclear communication through AMPK activation. ## Overview MOTS-C (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. First identified in 2015, MOTS-C represents a novel class of mitochondrial-derived peptides (MDPs) that act as signalling molecules between mitochondria and the nucleus. Unlike nuclear-encoded peptides, MOTS-C is translated from mitochondrial DNA within the mitochondrial matrix, then exported to the cytosol and extracellular space. For UK research laboratories, MOTS-C serves as a reference compound for studies examining mitochondrial signalling, metabolic regulation, and cellular stress responses. ## Mechanism MOTS-C operates through several distinct mechanisms in cellular and in vitro models: **Metabolic Regulation** — MOTS-C regulates metabolic pathways through activation of AMP-activated protein kinase (AMPK). In cellular studies, the peptide increases AMPK phosphorylation, leading to downstream effects on glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. **Mitochondrial-Nuclear Communication** — As a mitochondrial-encoded peptide, MOTS-C represents a retrograde signalling molecule that communicates mitochondrial status to the nucleus. In cellular models, MOTS-C translocates to the nucleus and modulates gene expression programmes related to metabolism and stress resistance. **Cellular Stress Response** — MOTS-C is upregulated in response to metabolic stress, including glucose deprivation and oxidative stress. In cellular studies, the peptide confers resistance to metabolic stress by enhancing glucose uptake and optimising mitochondrial function. **Insulin Sensitivity** — In cellular and animal models, MOTS-C improves insulin sensitivity through multiple pathways. The peptide enhances glucose uptake in skeletal muscle cells and adipocytes, and reduces hepatic glucose production in hepatocyte cultures. ## Research Applications MOTS-C is employed across multiple research domains in UK laboratories: **Metabolic Disease Research** — In vitro studies examine MOTS-C's effects on glucose metabolism, insulin signalling, and lipid oxidation in cellular models. **Ageing and Cellular Senescence** — Cellular senescence models examine MOTS-C's effects on senescence markers, telomere maintenance, and stress resistance. **Mitochondrial Biology** — MOTS-C serves as a tool compound for studying mitochondrial-nuclear communication and the role of mitochondrial DNA-encoded peptides in cellular regulation. **Exercise Physiology** — In cellular models, MOTS-C is studied in the context of exercise-mimetic effects. The peptide activates AMPK and enhances metabolic flexibility, creating research questions about mitochondrial-derived peptides and physical activity. **Comparative Mitochondrial Peptides** — MOTS-C is compared to other mitochondrial-derived peptides (humanin, SHLPs) in cellular studies. ## Reconstitution MOTS-C is supplied as a lyophilised powder. Standard laboratory preparation: • **Bacteriostatic water** (0.9% benzyl alcohol) recommended for reconstitution • **Typical concentrations**: 1–10 mg/mL depending on assay requirements • **Solubility**: The peptide is generally soluble in aqueous solutions; brief vortexing may aid dissolution • **Protease sensitivity**: Due to small size, MOTS-C may be susceptible to proteolytic degradation; protease inhibitors may be included in incubation media • **pH**: Maintain solutions at pH 6.5–7.5 ## Storage • **Lyophilised powder**: −20°C, protected from light • **Reconstituted solution**: 2–8°C, protected from light • **Stability**: 7–14 days under refrigeration; aliquot and freeze at −20°C for extended studies • **Avoid**: Repeated freeze-thaw cycles ## FAQs ### What is MOTS-C and where does it come from? MOTS-C is a 16-amino-acid peptide encoded within the mitochondrial genome. It is translated from the 12S rRNA mitochondrial DNA within the mitochondrial matrix, then exported to the cytosol and extracellular space. ### What is MOTS-C's primary mechanism in research models? MOTS-C primarily activates AMP-activated protein kinase (AMPK) in cellular models. The AMPK activation leads to downstream effects on glucose uptake, fatty acid oxidation, and metabolic gene expression. Additionally, MOTS-C translocates to the nucleus and modulates gene expression programmes related to metabolism and stress resistance. ### What cellular models are used for MOTS-C research? Standard cellular models include: (1) C2C12 myotubes and 3T3-L1 adipocytes for glucose uptake and insulin sensitivity; (2) primary hepatocytes for hepatic glucose production; (3) various cell lines for AMPK activation studies; (4) cells with defined mitochondrial backgrounds for mitochondrial function; and (5) live-cell imaging models for tracking nuclear translocation. ### Is MOTS-C legal for research in the UK? Yes. MOTS-C is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase for legitimate laboratory research. It is not licensed as a medicine by the MHRA. ## Related Products - [Retatrutide](https://hatipeptides.co.uk/product/retatrutide) - [Tesamorelin](https://hatipeptides.co.uk/product/tesamorelin) - [BPC-157](https://hatipeptides.co.uk/product/bpc-157) ## Related Articles - [MOTS-C UK: Research Reference 2026](https://hatipeptides.co.uk/research/mots-c) - [Metabolic Stack: Retatrutide + MOTS-C Research Guide](https://hatipeptides.co.uk/research/metabolic-stack) --- # Tesamorelin URL: https://hatipeptides.co.uk/glossary/tesamorelin Tesamorelin is a synthetic 44-amino-acid peptide analogue of human growth hormone-releasing hormone (GHRH). It stimulates endogenous growth hormone secretion through activation of the GHRH receptor in the pituitary gland. ## Overview Tesamorelin is a synthetic 44-amino-acid peptide analogue of human growth hormone-releasing hormone (GHRH). The peptide is designed to stimulate endogenous growth hormone secretion through activation of the GHRH receptor in the pituitary gland. The structure is based on native GHRH(1-44) with a trans-3-hexenoic acid group attached to the tyrosine residue at position 1, which protects the N-terminus from degradation and extends the peptide's half-life compared to native GHRH. For UK research laboratories, tesamorelin serves as a reference compound for studies examining growth hormone physiology, metabolic regulation, and the role of the GHRH-GH-IGF-1 axis in cellular and systemic metabolism. ## Mechanism Tesamorelin operates through the following mechanism in research models: **GHRH Receptor Activation** — Tesamorelin binds to the GHRH receptor (GHRHR), a Gs-coupled GPCR located on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cAMP, leading to protein kinase A activation and stimulation of growth hormone gene transcription and secretion. **Growth Hormone Axis Stimulation** — The primary effect of tesamorelin is stimulation of endogenous growth hormone secretion. In research models, this leads to increased circulating GH levels, which subsequently stimulates hepatic IGF-1 production. **Metabolic Effects** — Through the GH-IGF-1 axis, tesamorelin influences multiple metabolic pathways: increased lipolysis and free fatty acid availability, enhanced protein synthesis, and modulation of glucose metabolism. **Body Composition** — Growth hormone is lipolytic and anabolic, increasing fat mobilisation while supporting lean tissue preservation. In cellular and animal models, tesamorelin's effects on body composition are mediated through GH receptor signalling in adipose tissue, muscle, and liver. ## Research Applications Tesamorelin is employed across multiple research domains in UK laboratories: **Endocrine Research** — In vitro studies examine tesamorelin's effects on pituitary somatotroph function, GH secretion patterns, and the regulation of the GH-IGF-1 axis. **Metabolic Disease Research** — Cellular models examine tesamorelin's effects on lipid metabolism, glucose homeostasis, and insulin sensitivity. **Body Composition Studies** — In cellular and animal models, tesamorelin is studied in the context of fat distribution, lean mass preservation, and visceral adiposity. **Ageing Research** — Growth hormone declines with age, and tesamorelin is used in cellular models to examine the effects of restoring GH axis activity. **Comparative GH Secretagogues** — Tesamorelin is compared to other GH secretagogues (GHRP-2, GHRP-6, ipamorelin) in cellular and animal studies. ## Reconstitution Tesamorelin is supplied as a lyophilised powder. Standard laboratory preparation: • **Bacteriostatic water** (0.9% benzyl alcohol) recommended for reconstitution • **Typical concentrations**: 1–10 mg/mL depending on assay requirements • **Solubility**: The peptide is generally soluble in aqueous solutions; gentle vortexing may aid dissolution • **DPP-IV sensitivity**: Although the N-terminal modification confers some protection, researchers should be aware of potential proteolytic degradation in serum-containing media • **pH**: Maintain solutions at pH 6.5–7.5 ## Storage • **Lyophilised powder**: −20°C, protected from light • **Reconstituted solution**: 2–8°C, protected from light • **Stability**: 7–14 days under refrigeration; aliquot and freeze at −20°C for extended studies • **Avoid**: Repeated freeze-thaw cycles ## FAQs ### What is tesamorelin and how does it work? Tesamorelin is a synthetic 44-amino-acid peptide analogue of human growth hormone-releasing hormone (GHRH). It stimulates endogenous growth hormone secretion through activation of the GHRH receptor in the anterior pituitary. The peptide is based on native GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus that protects against degradation and extends half-life. ### How does tesamorelin differ from GHRPs? Tesamorelin is a GHRH analogue that stimulates GH secretion through the GHRH receptor. GHRPs (growth hormone-releasing peptides) such as GHRP-2 and GHRP-6 act through the ghrelin receptor (GHS-R1a). The two approaches produce different GH secretion patterns: GHRH stimulates sustained, physiologically patterned release, while GHRPs produce a pulse-like response. ### What cellular models are used for tesamorelin research? Standard cellular models include: (1) primary pituitary cells and GH3 cells for GH secretion studies; (2) 3T3-L1 adipocytes for lipolysis and adipokine studies; (3) primary hepatocytes for IGF-1 production and hepatic metabolism; (4) C2C12 myotubes for protein synthesis; and (5) transfected cell lines expressing GHRH receptors for binding studies. ### Is tesamorelin legal for research in the UK? Yes. Tesamorelin is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase for legitimate laboratory research. It is not licensed as a medicine by the MHRA. ## Related Products - [Ipamorelin](https://hatipeptides.co.uk/product/ipamorelin) - [BPC-157](https://hatipeptides.co.uk/product/bpc-157) - [Retatrutide](https://hatipeptides.co.uk/product/retatrutide) ## Related Articles - [Tesamorelin UK: Research Reference 2026](https://hatipeptides.co.uk/research/tesamorelin) --- # Ipamorelin URL: https://hatipeptides.co.uk/glossary/ipamorelin Ipamorelin is a pentapeptide that functions as a selective growth hormone secretagogue. It stimulates growth hormone release through the ghrelin receptor (GHS-R1a) without significant stimulation of cortisol, prolactin, or other pituitary hormones. ## Overview Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a selective growth hormone secretagogue. The peptide stimulates growth hormone release through the ghrelin receptor (GHS-R1a) without significant stimulation of cortisol, prolactin, or other pituitary hormones. The peptide was developed as a more selective alternative to earlier GH secretagogues (GHRP-2, GHRP-6) that produced broader pituitary hormone responses. Ipamorelin's selectivity for GH release makes it a valuable tool for research into isolated GH axis manipulation. For UK research laboratories, ipamorelin serves as a reference compound for studies examining selective GH secretion, ghrelin receptor pharmacology, and the metabolic effects of isolated GH stimulation. ## Mechanism Ipamorelin operates through the following mechanism in research models: **Ghrelin Receptor Activation** — Ipamorelin binds to the ghrelin receptor (GHS-R1a), a Gq-coupled GPCR expressed in the pituitary, hypothalamus, and peripheral tissues. Receptor activation increases intracellular calcium and phospholipase C activity, leading to growth hormone secretion from somatotroph cells. **Selective GH Secretion** — Unlike earlier GH secretagogues (GHRP-2, GHRP-6), ipamorelin stimulates GH release without significant increases in cortisol, prolactin, or ACTH. This selectivity is attributed to differential intracellular signalling or receptor conformation stabilisation that favours GH-specific pathways. **Metabolic Signalling** — Through the ghrelin receptor, ipamorelin influences metabolic pathways beyond GH secretion. In cellular models, the peptide affects appetite-regulating circuits, glucose metabolism, and lipid handling. **GH-IGF-1 Axis** — The primary physiological effect of ipamorelin is stimulation of the GH-IGF-1 axis. In research models, this leads to increased IGF-1 production, with downstream effects on protein synthesis, lipolysis, and cellular growth. ## Research Applications Ipamorelin is employed across multiple research domains in UK laboratories: **Selective GH Secretion Studies** — In vitro studies examine ipamorelin's selectivity for GH secretion compared to other pituitary hormones. Researchers use the peptide to model isolated GH axis stimulation. **Ghrelin Receptor Pharmacology** — Ipamorelin serves as a tool compound for studying GHS-R1a receptor biology, biased agonism, and intracellular signalling. **Metabolic Research** — Cellular models examine ipamorelin's effects on metabolism, including glucose handling, lipid oxidation, and energy expenditure. **Comparative Secretagogue Studies** — Ipamorelin is compared to GHRP-2, GHRP-6, and other secretagogues in cellular and animal studies. **Body Composition Research** — In cellular and animal models, ipamorelin is studied in the context of fat metabolism, lean mass preservation, and tissue regeneration. ## Reconstitution Ipamorelin is supplied as a lyophilised powder. Standard laboratory preparation: • **Bacteriostatic water** (0.9% benzyl alcohol) recommended for reconstitution • **Typical concentrations**: 1–10 mg/mL depending on assay requirements • **Solubility**: The peptide is generally soluble in aqueous solutions; brief vortexing may aid dissolution • **Protease sensitivity**: The D-amino acid substitutions confer some protease resistance, but standard protease inhibitors may be included in incubation media • **pH**: Maintain solutions at pH 6.5–7.5 ## Storage • **Lyophilised powder**: −20°C, protected from light • **Reconstituted solution**: 2–8°C, protected from light • **Stability**: 7–14 days under refrigeration; aliquot and freeze at −20°C for extended studies • **Avoid**: Repeated freeze-thaw cycles ## FAQs ### What is ipamorelin and how is it different from GHRP-2? Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that stimulates growth hormone release through the ghrelin receptor (GHS-R1a). Unlike GHRP-2, which stimulates GH, cortisol, and prolactin, ipamorelin is highly selective for GH release with minimal effects on other pituitary hormones. ### What is ipamorelin's mechanism in research models? Ipamorelin binds to the ghrelin receptor (GHS-R1a), a Gq-coupled GPCR in the pituitary. Receptor activation increases intracellular calcium and phospholipase C activity, leading to GH secretion from somatotroph cells. The peptide's selectivity for GH release is attributed to differential receptor signalling that favours GH-specific pathways. ### What cellular models are used for ipamorelin research? Standard cellular models include: (1) primary pituitary cells and GH3 cells for GH secretion and selectivity studies; (2) transfected cell lines expressing GHS-R1a for receptor binding; (3) 3T3-L1 adipocytes for lipolysis; (4) primary hepatocytes for IGF-1 production; and (5) C2C12 myotubes for protein synthesis. ### Is ipamorelin legal for research in the UK? Yes. Ipamorelin is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase for legitimate laboratory research. It is not licensed as a medicine by the MHRA. ## Related Products - [Tesamorelin](https://hatipeptides.co.uk/product/tesamorelin) - [BPC-157](https://hatipeptides.co.uk/product/bpc-157) - [Retatrutide](https://hatipeptides.co.uk/product/retatrutide) ## Related Articles - [Ipamorelin UK: Research Reference 2026](https://hatipeptides.co.uk/research/ipamorelin) --- # Tirzepatide URL: https://hatipeptides.co.uk/glossary/tirzepatide Tirzepatide is a 39-amino-acid peptide engineered as a dual agonist at GLP-1 and GIP receptors. It is used in metabolic research to study incretin biology, glucose-dependent insulin secretion, and energy homeostasis. ## Overview Tirzepatide (development code LY3298176) is a synthetic peptide engineered as a dual agonist at the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The peptide is a 39-amino-acid sequence with a C20 fatty-diacid conjugate, enabling extended half-life through albumin binding. Tirzepatide represents an advance over single-agonist GLP-1 peptides by adding GIP receptor activity, which amplifies insulin secretion and may provide additional metabolic benefits. For UK research laboratories, tirzepatide serves as a reference compound for studies examining incretin biology, metabolic regulation, and dual-receptor pharmacology. ## Mechanism Tirzepatide activates two distinct receptor systems that regulate metabolic physiology: **GLP-1 Receptor Agonism** — Potentiates glucose-dependent insulin secretion, suppresses glucagon release in hyperglycaemic states, delays gastric emptying, and activates brainstem satiety circuits. In cellular models, GLP-1 receptor activation triggers cAMP accumulation and enhanced insulin gene transcription. **GIP Receptor Agonism** — Amplifies insulin secretion in a glucose-dependent manner, promotes lipid storage in adipose tissue, and may support bone formation. GIP receptor activation enhances glucose-stimulated insulin secretion through distinct pathways from GLP-1. **Dual Receptor Synergy** — The combination of GLP-1 and GIP activity creates unique research questions about receptor crosstalk and whether dual agonism produces additive, synergistic, or competitive effects in signal transduction cascades. ## Research Applications Tirzepatide is employed across multiple research domains in UK laboratories: **Metabolic Disease Research** — In vitro studies examine insulin secretion, glucagon suppression, and glucose uptake in isolated islet and hepatocyte cultures. **Energy Homeostasis Studies** — Cellular models of adipocyte differentiation, lipolysis, and thermogenesis are used to study energy balance effects. **Comparative Pharmacology** — Tirzepatide is frequently compared to single-agonist peptides (semaglutide) and triple-agonist peptides (retatrutide) in cellular receptor-binding assays. **Receptor Pharmacology** — The peptide serves as a tool compound for studying class B GPCR biology, receptor oligomerisation, and biased agonism. ## Reconstitution Tirzepatide is supplied as a lyophilised powder. Standard laboratory preparation: • **Bacteriostatic water** (0.9% benzyl alcohol) recommended for reconstitution • **Typical concentrations**: 1–10 mg/mL depending on assay requirements • **Solubility**: The fatty-diacid conjugate may reduce aqueous solubility; gentle vortexing and brief warming (not exceeding 37°C) can aid dissolution • **Albumin binding**: Account for this in binding assays and cellular incubations • **pH**: Maintain solutions at pH 6.5–7.5 ## Storage • **Lyophilised powder**: −20°C, protected from light • **Reconstituted solution**: 2–8°C, protected from light • **Stability**: 7–14 days under refrigeration; aliquot and freeze at −20°C for extended studies • **Avoid**: Repeated freeze-thaw cycles ## FAQs ### What is tirzepatide's primary mechanism? Tirzepatide is a dual agonist at the GLP-1 and GIP receptors. It activates two distinct metabolic signalling pathways simultaneously, enabling researchers to study integrated metabolic regulation and incretin biology. ### How does tirzepatide differ from semaglutide? Semaglutide is a single agonist at the GLP-1 receptor. Tirzepatide adds GIP receptor agonism to create a dual agonist. The GIP component amplifies insulin secretion and may provide additional metabolic benefits beyond GLP-1 alone. ### How does tirzepatide differ from retatrutide? Tirzepatide is a dual agonist at GLP-1 and GIP receptors. Retatrutide adds glucagon receptor agonism to create a triple agonist. The glucagon component in retatrutide adds hepatic glucose output and energy expenditure signals that are absent in tirzepatide. ### Is tirzepatide legal for research in the UK? Yes. Tirzepatide is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase for legitimate laboratory research. It is not licensed as a medicine by the MHRA. ## Related Products - [Retatrutide](https://hatipeptides.co.uk/product/retatrutide) - [Semaglutide](https://hatipeptides.co.uk/product/semaglutide) - [MOTS-C](https://hatipeptides.co.uk/product/mots-c) ## Related Articles - [Retatrutide UK: Research Reference 2026](https://hatipeptides.co.uk/research/retatrutide) - [Retatrutide vs Semaglutide: Research Comparison](https://hatipeptides.co.uk/research/retatrutide-vs-semaglutide) --- # Semaglutide URL: https://hatipeptides.co.uk/glossary/semaglutide Semaglutide is a 31-amino-acid peptide analogue of human glucagon-like peptide-1 (GLP-1) with fatty-acid conjugation for extended half-life. It is used in metabolic research to study GLP-1 receptor signalling, insulin secretion, and energy homeostasis. ## Overview Semaglutide is a 31-amino-acid peptide analogue of human glucagon-like peptide-1 (GLP-1). The peptide incorporates a C18 fatty-diacid chain at the lysine-26 position via a hydrophilic spacer, enabling strong albumin binding and a prolonged circulating half-life compared to native GLP-1. The structure is based on native GLP-1(7-37) with two amino acid substitutions: alanine to serine at position 8 (for DPP-IV resistance) and lysine to arginine at position 34. These modifications, combined with the fatty-acid conjugation, produce a peptide with sustained pharmacokinetics suitable for once-weekly administration in research models. For UK research laboratories, semaglutide serves as a reference compound for studies examining GLP-1 receptor biology, incretin-based metabolic regulation, and the pharmacology of long-acting peptide therapeutics. ## Mechanism Semaglutide operates through the following mechanism in research models: **GLP-1 Receptor Agonism** — Semaglutide binds to the GLP-1 receptor, a class B GPCR expressed on pancreatic beta cells, neurons, and peripheral tissues. Receptor activation triggers intracellular cAMP accumulation via Gs protein coupling, leading to enhanced glucose-dependent insulin secretion. **Glucose-Dependent Action** — The insulinotropic effect of semaglutide is strictly glucose-dependent. In normoglycaemic conditions, the peptide has minimal effect on insulin secretion, reducing the risk of hypoglycaemia in in vivo models. **Incretin Signalling** — Beyond insulin secretion, GLP-1 receptor activation modulates glucagon suppression, delays gastric emptying, and activates satiety circuits in the brainstem and hypothalamus. **Extended Duration** — The fatty-acid moiety binds reversibly to serum albumin, creating a circulating reservoir that slowly releases active peptide. This extends semaglutide's half-life to approximately one week in human studies. ## Research Applications Semaglutide is employed across multiple research domains in UK laboratories: **Metabolic Disease Research** — In vitro studies examine semaglutide's effects on insulin secretion in isolated islets and beta-cell lines (MIN6, INS-1). Glucagon suppression is studied in primary alpha-cell cultures. **Incretin Pharmacology** — Semaglutide serves as a reference long-acting GLP-1 agonist for comparative studies with other incretin-based compounds, including tirzepatide, retatrutide, and experimental GLP-1 analogues. **Receptor Biology** — Cellular models examine GLP-1 receptor internalisation, desensitisation, and biased agonism. Semaglutide's profile is compared to native GLP-1 and shorter-acting agonists. **Appetite and Satiety Research** — In cellular and animal models, semaglutide is used to study GLP-1 receptor activation in hypothalamic and brainstem circuits regulating food intake and energy expenditure. **Comparative Pharmacology** — Semaglutide is frequently used as a benchmark compound in studies comparing metabolic peptide therapeutics, particularly in receptor binding, functional activity, and duration of action assays. ## Reconstitution Semaglutide is supplied as a lyophilised powder. Standard laboratory preparation: • **Bacteriostatic water** (0.9% benzyl alcohol) recommended for reconstitution • **Typical concentrations**: 1–10 mg/mL depending on assay requirements • **Solubility**: The fatty-acid conjugate may reduce aqueous solubility; gentle vortexing and brief warming (not exceeding 37°C) can aid dissolution • **Albumin binding**: Account for this in binding assays and cellular incubations • **pH**: Maintain solutions at pH 6.5–7.5 ## Storage • **Lyophilised powder**: −20°C, protected from light • **Reconstituted solution**: 2–8°C, protected from light • **Stability**: 7–14 days under refrigeration; aliquot and freeze at −20°C for extended studies • **Avoid**: Repeated freeze-thaw cycles ## FAQs ### What is semaglutide's primary mechanism? Semaglutide is a long-acting GLP-1 receptor agonist. It binds to and activates the GLP-1 receptor, a class B GPCR, leading to glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release, delayed gastric emptying, and activation of satiety circuits in the brain. ### How does semaglutide differ from native GLP-1? Semaglutide has two amino acid substitutions (A8S, K34R) compared to native GLP-1(7-37), plus a C18 fatty-diacid chain conjugated at lysine-26. These modifications confer resistance to DPP-IV degradation and enable strong albumin binding, extending the half-life from minutes (native GLP-1) to approximately one week in human studies. ### Is semaglutide legal for research in the UK? Yes. Semaglutide is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase for legitimate laboratory research. It is not licensed as a medicine by the MHRA. ## Related Products - [Retatrutide](https://hatipeptides.co.uk/product/retatrutide) - [Tirzepatide](https://hatipeptides.co.uk/product/tirzepatide) - [MOTS-C](https://hatipeptides.co.uk/product/mots-c) ## Related Articles - [Semaglutide UK: Research Reference 2026](https://hatipeptides.co.uk/research/semaglutide) - [Retatrutide vs Semaglutide: Research Comparison](https://hatipeptides.co.uk/research/retatrutide-vs-semaglutide) --- # BPC-157 URL: https://hatipeptides.co.uk/glossary/bpc-157 BPC-157 is a 15-amino-acid peptide fragment (pentadecapeptide) derived from a protein found in human gastric juice. It is studied in regenerative research for its effects on soft-tissue repair, angiogenesis, and extracellular matrix remodelling in cellular and in vitro models. ## Overview BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide fragment derived from a protein found in human gastric juice, initially identified through studies of gastrointestinal cytoprotection. The peptide represents a stable fragment of the larger body protection compound (BPC) sequence. The peptide is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its small size and stability make it suitable for various laboratory investigation protocols. For UK research laboratories, BPC-157 serves as a reference compound for studies examining soft-tissue repair mechanisms, angiogenic signalling, and extracellular matrix dynamics in controlled in vitro environments. ## Mechanism BPC-157 operates through the following mechanisms in research models: **Angiogenic Signalling** — BPC-157 promotes angiogenesis through upregulation of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) signalling. In cellular models, the peptide enhances endothelial cell proliferation, migration, and tube formation. **Extracellular Matrix Modulation** — The peptide stimulates collagen type I and III synthesis in fibroblast cultures and modulates matrix metalloproteinase (MMP) activity. This affects extracellular matrix turnover and tissue remodelling. **Cytoprotective Pathways** — BPC-157 upregulates heat shock proteins and antioxidant defence mechanisms in cellular stress models. The peptide protects cells from oxidative stress and inflammation-induced damage through modulation of NF-κB signalling. **Growth Factor Regulation** — The peptide influences expression of multiple growth factors, including VEGF, FGF, TGF-β, and IGF-1, creating a coordinated tissue repair response in cellular models. ## Research Applications BPC-157 is employed across multiple research domains in UK laboratories: **Soft-Tissue Repair Studies** — In vitro models of tendon and ligament fibroblasts examine BPC-157's effects on collagen synthesis, cell proliferation, and matrix organisation. **Angiogenesis Research** — Endothelial cell models (HUVEC, HMVEC) are used to study BPC-157's angiogenic properties, including tube formation, cell migration, and VEGF signalling. **Gastrointestinal Research** — Cellular models of gastric epithelial integrity and mucosal protection examine BPC-157's cytoprotective properties. **Extracellular Matrix Studies** — Fibroblast and keratinocyte cultures are used to study BPC-157's effects on collagen deposition, MMP activity, and tissue remodelling. **Inflammation Models** — Macrophage and fibroblast co-culture systems examine BPC-157's effects on inflammatory cytokine production and resolution of inflammation. ## Reconstitution BPC-157 is supplied as a lyophilised powder. Standard laboratory preparation: • **Bacteriostatic water** (0.9% benzyl alcohol) recommended for reconstitution • **Typical concentrations**: 1–10 mg/mL depending on assay requirements • **Solubility**: The peptide is highly soluble in aqueous solutions; gentle vortexing aids dissolution • **pH**: Maintain solutions at pH 6.0–7.5 ## Storage • **Lyophilised powder**: −20°C, protected from light • **Reconstituted solution**: 2–8°C, protected from light • **Stability**: 7–14 days under refrigeration; aliquot and freeze at −20°C for extended studies • **Avoid**: Repeated freeze-thaw cycles ## FAQs ### What is BPC-157 and where does it come from? BPC-157 is a 15-amino-acid peptide fragment (pentadecapeptide) derived from a protein found in human gastric juice, initially identified through studies of gastrointestinal cytoprotection. It is synthesised chemically for research purposes. ### What is BPC-157's primary mechanism in research models? BPC-157 promotes angiogenesis through VEGF and FGF upregulation, stimulates collagen synthesis in fibroblast cultures, modulates MMP activity for extracellular matrix remodelling, and activates cytoprotective pathways including heat shock proteins and antioxidant defences. ### What cellular models are used for BPC-157 research? Standard models include: (1) primary tendon and ligament fibroblasts for collagen synthesis; (2) HUVEC and HMVEC endothelial cells for angiogenesis; (3) keratinocyte and dermal fibroblast co-cultures for tissue repair; (4) macrophage cultures for inflammation studies; (5) gastrointestinal epithelial cell lines for barrier function. ### Is BPC-157 legal for research in the UK? Yes. BPC-157 is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase for legitimate laboratory research. It is not licensed as a medicine by the MHRA. ## Related Products - [TB-500](https://hatipeptides.co.uk/product/tb-500) - [GHK-Cu](https://hatipeptides.co.uk/product/ghk-cu) - [Ipamorelin](https://hatipeptides.co.uk/product/ipamorelin) ## Related Articles - [BPC-157 UK: Research Reference 2026](https://hatipeptides.co.uk/research/bpc-157) - [BPC-157 vs TB-500: Research Comparison](https://hatipeptides.co.uk/research/bpc-157-vs-tb-500) --- # TB-500 URL: https://hatipeptides.co.uk/glossary/tb-500 TB-500 is a synthetic peptide fragment of thymosin beta-4 (Tβ4), a naturally occurring actin-binding protein. It is studied in regenerative research for its effects on cell migration, cytoskeletal dynamics, and tissue remodelling in cellular and in vitro models. ## Overview TB-500 is a synthetic peptide fragment derived from thymosin beta-4 (Tβ4), a 43-amino-acid naturally occurring protein that is the major actin-sequestering molecule in eukaryotic cells. Tβ4 is expressed in most mammalian tissues and plays a role in cytoskeletal organisation, cell migration, and development. The active peptide fragment represents the actin-binding domain of Tβ4. By mimicking the actin-binding region, TB-500 influences cellular dynamics and migration pathways. For UK research laboratories, TB-500 serves as a reference compound for studies examining cell motility, cytoskeletal dynamics, and tissue remodelling in controlled in vitro environments. ## Mechanism TB-500 operates through the following mechanism in research models: **Actin Sequestration** — TB-500 binds to monomeric G-actin, preventing its polymerisation into F-actin filaments. This regulates the pool of available actin monomers and modulates cytoskeletal dynamics. **Cell Migration** — Through its effects on actin dynamics, TB-500 influences cell migration and motility in cellular models. The peptide modulates the formation of lamellipodia and filopodia, structures essential for directed cell movement. **Angiogenic Modulation** — In endothelial cell models, TB-500 influences angiogenesis through effects on cell migration and tube formation. The peptide modulates VEGF receptor expression and downstream signalling. **Extracellular Matrix Interactions** — The peptide influences cell-matrix adhesion dynamics through modulation of integrin expression and focal adhesion turnover. This affects cell spreading and migration on extracellular matrix substrates. ## Research Applications TB-500 is employed across multiple research domains in UK laboratories: **Cell Migration Studies** — Wound healing assays (scratch assays) and transwell migration assays examine TB-500's effects on cell motility in fibroblast, endothelial, and epithelial cell models. **Cytoskeletal Dynamics** — Cellular models examine TB-500's effects on actin filament organisation, cytoskeletal architecture, and cell morphology using fluorescence microscopy and live-cell imaging. **Angiogenesis Research** — Endothelial cell models (HUVEC) are used to study TB-500's effects on tube formation, cell migration, and angiogenic signalling pathways. **Tissue Remodelling** — Fibroblast and keratinocyte co-culture models examine TB-500's effects on extracellular matrix deposition, matrix remodelling, and tissue organisation. **Comparative Tissue Repair Studies** — TB-500 is frequently compared to other tissue repair compounds (BPC-157) in cellular migration and matrix remodelling assays. ## Reconstitution TB-500 is supplied as a lyophilised powder. Standard laboratory preparation: • **Bacteriostatic water** (0.9% benzyl alcohol) recommended for reconstitution • **Typical concentrations**: 1–10 mg/mL depending on assay requirements • **Solubility**: The peptide is generally soluble in aqueous solutions; gentle vortexing may aid dissolution • **pH**: Maintain solutions at pH 6.0–7.5 ## Storage • **Lyophilised powder**: −20°C, protected from light • **Reconstituted solution**: 2–8°C, protected from light • **Stability**: 7–14 days under refrigeration; aliquot and freeze at −20°C for extended studies • **Avoid**: Repeated freeze-thaw cycles ## FAQs ### What is TB-500 and where does it come from? TB-500 is a synthetic peptide fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-binding protein expressed in most mammalian tissues. The fragment represents the actin-binding domain and is synthesised chemically for research purposes. ### What is TB-500's primary mechanism in research models? TB-500 binds to monomeric G-actin, regulating the pool of available actin monomers and modulating cytoskeletal dynamics. This influences cell migration, motility, and the formation of lamellipodia and filopodia in cellular models. ### How does TB-500 differ from BPC-157 in research? TB-500 primarily affects cell migration and cytoskeletal dynamics through actin sequestration. BPC-157 affects angiogenic signalling and collagen synthesis. While both are studied in tissue repair contexts, they operate through distinct cellular mechanisms and may target different aspects of the repair process. ### Is TB-500 legal for research in the UK? Yes. TB-500 is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase for legitimate laboratory research. It is not licensed as a medicine by the MHRA. ## Related Products - [BPC-157](https://hatipeptides.co.uk/product/bpc-157) - [GHK-Cu](https://hatipeptides.co.uk/product/ghk-cu) - [Ipamorelin](https://hatipeptides.co.uk/product/ipamorelin) ## Related Articles - [TB-500 UK: Research Reference 2026](https://hatipeptides.co.uk/research/tb-500) - [BPC-157 vs TB-500: Research Comparison](https://hatipeptides.co.uk/research/bpc-157-vs-tb-500) --- # GHK-Cu URL: https://hatipeptides.co.uk/glossary/ghk-cu GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding tripeptide complex. It is studied in regenerative research for its effects on dermal matrix synthesis, cellular proliferation, and extracellular matrix remodelling in cellular and in vitro models. ## Overview GHK-Cu is a copper-binding tripeptide complex consisting of the amino acid sequence glycyl-L-histidyl-L-lysine (GHK) complexed with copper(II) ions. The GHK tripeptide occurs naturally in human plasma, saliva, and urine, with concentrations decreasing with age. The copper complex is the biologically active form of the peptide. Copper is an essential cofactor for several enzymes involved in extracellular matrix maintenance, including lysyl oxidase (collagen cross-linking) and superoxide dismutase (antioxidant defence). For UK research laboratories, GHK-Cu serves as a reference compound for studies examining dermal matrix biology, copper-mediated cellular signalling, and extracellular matrix remodelling in controlled in vitro environments. ## Mechanism GHK-Cu operates through the following mechanisms in research models: **Collagen Synthesis** — GHK-Cu stimulates collagen type I, III, and IV synthesis in fibroblast cultures. The copper ion activates lysyl oxidase, an enzyme essential for collagen and elastin cross-linking. **Cellular Proliferation** — The peptide complex promotes fibroblast and keratinocyte proliferation in cell culture models. GHK-Cu modulates growth factor signalling pathways, including TGF-β and VEGF. **Antioxidant Activity** — Copper is a cofactor for copper-zinc superoxide dismutase (SOD1), an important antioxidant enzyme. GHK-Cu may influence cellular antioxidant defences and protect against oxidative stress in cellular models. **Matrix Remodelling** — GHK-Cu modulates matrix metalloproteinase (MMP) activity and tissue inhibitor of metalloproteinase (TIMP) expression, influencing extracellular matrix turnover and remodelling. **Gene Expression** — The peptide complex influences the expression of multiple genes involved in extracellular matrix production, cellular proliferation, and differentiation, acting through copper-dependent signalling pathways. ## Research Applications GHK-Cu is employed across multiple research domains in UK laboratories: **Dermal Matrix Research** — Fibroblast cultures examine GHK-Cu's effects on collagen synthesis, elastin production, and extracellular matrix organisation. **Cellular Proliferation Studies** — Keratinocyte and fibroblast proliferation assays measure GHK-Cu's effects on cell growth and cell cycle progression. **Copper Biology Research** — Cellular models examine copper transport, copper-dependent enzyme activity, and the role of copper signalling in cell function. **Antioxidant Research** — Oxidative stress models measure GHK-Cu's effects on cellular antioxidant defences and protection against reactive oxygen species. **Extracellular Matrix Remodelling** — MMP and TIMP expression studies examine GHK-Cu's effects on matrix turnover in fibroblast and co-culture models. ## Reconstitution GHK-Cu is supplied as a lyophilised powder. Standard laboratory preparation: • **Bacteriostatic water** (0.9% benzyl alcohol) recommended for reconstitution • **Typical concentrations**: 1–10 mg/mL depending on assay requirements • **Appearance**: The reconstituted solution has a characteristic blue colour due to the copper complex • **Solubility**: The peptide complex is soluble in aqueous solutions; gentle vortexing may aid dissolution • **pH**: Maintain solutions at pH 6.0–7.5; acidic conditions may dissociate the copper complex ## Storage • **Lyophilised powder**: −20°C, protected from light • **Reconstituted solution**: 2–8°C, protected from light • **Stability**: 5–7 days under refrigeration; aliquot and freeze at −20°C for extended studies • **Avoid**: Repeated freeze-thaw cycles; protect from prolonged light exposure ## FAQs ### What is GHK-Cu and how does it work? GHK-Cu is a copper-binding tripeptide complex (glycyl-L-histidyl-L-lysine copper) that occurs naturally in human plasma. It stimulates collagen synthesis through copper-dependent enzyme activation, promotes fibroblast and keratinocyte proliferation, and modulates matrix metalloproteinase activity for extracellular matrix remodelling. ### What cellular models are used for GHK-Cu research? Standard models include: (1) primary dermal fibroblasts for collagen synthesis; (2) keratinocyte cultures for proliferation; (3) fibroblast-keratinocyte co-cultures for matrix remodelling; (4) oxidative stress models for antioxidant studies; and (5) copper-depleted media for studying copper-dependent processes. ### Is GHK-Cu legal for research in the UK? Yes. GHK-Cu is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase for legitimate laboratory research. It is not licensed as a medicine by the MHRA. ## Related Products - [BPC-157](https://hatipeptides.co.uk/product/bpc-157) - [TB-500](https://hatipeptides.co.uk/product/tb-500) - [Epithalon](https://hatipeptides.co.uk/product/epithalon) ## Related Articles - [GHK-Cu UK: Research Reference 2026](https://hatipeptides.co.uk/research/ghk-cu) --- # Selank URL: https://hatipeptides.co.uk/glossary/selank Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics in Moscow. It is studied in neuroimmune and neuropharmacological research for its effects on neurotransmitter systems and immune modulation in cellular and in vitro models. ## Overview Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The peptide was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, as part of research into regulatory peptides that modulate nervous system function. The peptide is structurally related to tuftsin, a naturally occurring immunomodulatory tetrapeptide, with additional amino acids that confer distinct pharmacological properties. Selank has been studied in research contexts for its effects on neurotransmitter metabolism, immune function, and neuroplasticity. For UK research laboratories, selank serves as a reference compound for studies examining peptide-based modulation of neurotransmitter systems, neuroimmune interactions, and the relationship between immune signalling and nervous system function in controlled in vitro environments. ## Mechanism Selank operates through the following mechanisms in research models: **Neurotransmitter Modulation** — In cellular and biochemical models, selank influences the metabolism of monoamine neurotransmitters. The peptide modulates the activity of enzymes involved in serotonin, dopamine, and noradrenaline turnover, affecting neurotransmitter availability. **Enzyme Regulation** — Selank modulates the activity of enkephalin-degrading enzymes, including enkephalinase and aminopeptidase N. By regulating peptide neurotransmitter breakdown, selank may influence endogenous opioid signalling in cellular models. **Immune Modulation** — Studies indicate selank has immunomodulatory properties in cellular models. The peptide influences cytokine production in immune cell cultures and modulates inflammatory mediator release. **BDNF Expression** — Selank has been studied for its effects on brain-derived neurotrophic factor (BDNF) expression in neural cell cultures and tissue models. **GABAergic Modulation** — The peptide may influence GABA receptor function in neural models, with effects on inhibitory neurotransmission balance. ## Research Applications Selank is employed across multiple research domains in UK laboratories: **Neuropharmacology** — In vitro receptor binding and enzyme activity assays examine selank's effects on neurotransmitter systems, monoamine metabolism, and enkephalin-degrading enzymes. **Neuroimmune Research** — Microglial cell cultures examine selank's effects on cytokine production, neuroinflammation markers, and immune signalling pathways. **Regulatory Peptide Studies** — Selank serves as a model compound for studies examining how short regulatory peptides modulate complex biological systems. **Protease Research** — Enkephalinase and aminopeptidase inhibition assays use selank as a tool compound for studying peptide neurotransmitter degradation. **Comparative Peptide Pharmacology** — Selank is compared to related regulatory peptides (tuftsin, noopept) in receptor binding and enzyme activity studies. ## Reconstitution Selank is supplied as a lyophilised powder. Standard laboratory preparation: • **Bacteriostatic water** (0.9% benzyl alcohol) recommended for reconstitution • **Typical concentrations**: 1–10 mg/mL depending on assay requirements • **Solubility**: The peptide is readily soluble in aqueous solutions; gentle vortexing aids dissolution • **pH**: Maintain solutions at pH 6.0–7.5 ## Storage • **Lyophilised powder**: −20°C, protected from light • **Reconstituted solution**: 2–8°C, protected from light • **Stability**: 7–14 days under refrigeration; aliquot and freeze at −20°C for extended studies • **Avoid**: Repeated freeze-thaw cycles ## FAQs ### What is selank and where does it come from? Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics, Russian Academy of Sciences. It is structurally related to tuftsin, a naturally occurring immunomodulatory tetrapeptide, with additional amino acids conferring distinct pharmacological properties. ### What is selank's primary mechanism in research models? Selank modulates neurotransmitter metabolism, particularly affecting enzymes involved in serotonin, dopamine, and noradrenaline turnover. It also regulates enkephalin-degrading enzymes, influences cytokine production in immune cells, and may affect BDNF expression in neural cell cultures. ### Is selank legal for research in the UK? Yes. Selank is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase for legitimate laboratory research. It is not licensed as a medicine by the MHRA. ## Related Products - [GHK-Cu](https://hatipeptides.co.uk/product/ghk-cu) - [Epithalon](https://hatipeptides.co.uk/product/epithalon) - [BPC-157](https://hatipeptides.co.uk/product/bpc-157) ## Related Articles - [Selank UK: Research Reference 2026](https://hatipeptides.co.uk/research/selank) --- # Epithalon URL: https://hatipeptides.co.uk/glossary/epithalon Epithalon (also known as epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed from studies of the pineal gland's role in biological ageing. It is studied in longevity research for its effects on cellular senescence, telomere biology, and the regulation of biological rhythms in cellular and in vitro models. ## Overview Epithalon (also known as epitalon) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly. The peptide was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, based on research into the regulatory functions of the pineal gland. The peptide is derived from studies of pineal polypeptide extracts and represents a minimal active sequence capable of influencing cellular ageing processes. Epithalon has been extensively studied in the context of cellular senescence and biological rhythm regulation. For UK research laboratories, epithalon serves as a reference compound for studies examining peptide-based regulation of cellular ageing, telomere biology, and the relationship between biological rhythms and cellular senescence in controlled in vitro environments. ## Mechanism Epithalon operates through the following mechanisms in research models: **Telomerase Activity** — In cellular models, epithalon has been studied for its effects on telomerase activity. The peptide may influence the expression or activity of telomerase, the enzyme responsible for maintaining telomere length during cell division. **Cellular Senescence** — Epithalon affects markers of cellular senescence in cell culture models. The peptide influences the expression of senescence-associated genes and proteins, potentially modulating the rate of cellular ageing in vitro. **Cell Cycle Regulation** — Studies indicate epithalon may influence cell cycle progression in various cell types. The peptide affects the expression of cell cycle regulatory proteins and may promote proliferation in certain cellular contexts. **Gene Expression** — Epithalon modulates the expression of multiple genes involved in cellular metabolism, stress resistance, and ageing processes. The peptide affects transcription factors and signalling pathways related to cellular maintenance and repair. **Melatonin Synthesis** — In pinealocyte cultures, epithalon has been studied for its effects on melatonin synthesis and circadian rhythm regulation, reflecting its origins in pineal gland research. ## Research Applications Epithalon is employed across multiple research domains in UK laboratories: **Cellular Senescence Research** — Fibroblast and epithelial cell models examine epithalon's effects on senescence markers, including senescence-associated β-galactosidase activity, p16INK4a expression, and telomere length dynamics. **Telomere Biology** — Telomerase activity assays and telomere length measurements in cell culture models examine epithalon's effects on telomere maintenance. **Biological Rhythm Studies** — Pinealocyte and suprachiasmatic nucleus cell cultures examine epithalon's effects on circadian gene expression and melatonin production. **Longevity Research** — Cellular models of chronological ageing examine epithalon's effects on cellular stress resistance, metabolic function, and maintenance of proliferative capacity. **Comparative Regulatory Peptides** — Epithalon is compared to other peptide bioregulators in cellular assays examining ageing-related markers and gene expression. ## Reconstitution Epithalon is supplied as a lyophilised powder. Standard laboratory preparation: • **Bacteriostatic water** (0.9% benzyl alcohol) recommended for reconstitution • **Typical concentrations**: 1–10 mg/mL depending on assay requirements • **Solubility**: The tetrapeptide is highly soluble in aqueous solutions; gentle vortexing aids dissolution • **pH**: Maintain solutions at pH 6.0–7.5 ## Storage • **Lyophilised powder**: −20°C, protected from light • **Reconstituted solution**: 2–8°C, protected from light • **Stability**: 7–14 days under refrigeration; aliquot and freeze at −20°C for extended studies • **Avoid**: Repeated freeze-thaw cycles ## FAQs ### What is epithalon and where does it come from? Epithalon (also known as epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson based on research into the regulatory functions of the pineal gland. It represents a minimal active sequence from pineal polypeptide extracts. ### What is epithalon's primary mechanism in research models? Epithalon is studied for its effects on telomerase activity, cellular senescence markers, and gene expression related to ageing processes. In cellular models, the peptide influences telomere maintenance, senescence-associated gene expression, and cell cycle regulation. ### Is epithalon legal for research in the UK? Yes. Epithalon is not a controlled substance under UK law. It is classified as a research peptide and is legal to purchase for legitimate laboratory research. It is not licensed as a medicine by the MHRA. ## Related Products - [NAD+](https://hatipeptides.co.uk/product/nad-plus) - [MOTS-C](https://hatipeptides.co.uk/product/mots-c) - [GHK-Cu](https://hatipeptides.co.uk/product/ghk-cu) ## Related Articles - [Epithalon UK: Research Reference 2026](https://hatipeptides.co.uk/research/epithalon) --- # NAD+ URL: https://hatipeptides.co.uk/glossary/nad-plus NAD+ (nicotinamide adenine dinucleotide, oxidised form) is a fundamental biochemical coenzyme found in all living cells. It is essential for cellular energy metabolism, serving as an electron carrier in redox reactions and as a substrate for enzymes including sirtuins and PARPs. ## Overview NAD+ (nicotinamide adenine dinucleotide, oxidised form) is a fundamental biochemical coenzyme found in every living cell. It exists in two forms: NAD+ (oxidised) and NADH (reduced), which cycle continuously as they carry electrons in cellular metabolism. Beyond its role as an electron carrier, NAD+ serves as an essential substrate for several classes of enzymes, including sirtuins (SIRT1-7), poly-ADP-ribose polymerases (PARPs), and CD38. These enzymes consume NAD+ as part of their catalytic activity, linking NAD+ availability to cellular signalling and maintenance pathways. For UK research laboratories, NAD+ serves as a reference biochemical for studies examining cellular energy metabolism, mitochondrial function, enzyme kinetics, and the role of NAD+-dependent signalling in cellular ageing processes. ## Mechanism NAD+ operates through the following mechanisms in research models: **Redox Carrier** — NAD+ accepts electrons from metabolic pathways including glycolysis, the citric acid cycle, and fatty acid oxidation, becoming NADH. NADH then donates electrons to the mitochondrial electron transport chain for ATP production. **Sirtuin Substrate** — NAD+ is an essential co-substrate for sirtuin deacetylases (SIRT1-7). These enzymes remove acetyl groups from proteins in an NAD+-dependent manner, linking cellular energy status to protein acetylation and gene expression. **PARP Substrate** — Poly-ADP-ribose polymerases (PARPs) consume NAD+ to synthesise ADP-ribose polymers on target proteins involved in DNA repair, genomic stability, and cellular stress responses. **CD38 Substrate** — CD38 is an NAD+-consuming ectoenzyme that generates calcium-mobilising second messengers and regulates extracellular NAD+ levels. **Cellular Energy Sensing** — The NAD+/NADH ratio serves as a key indicator of cellular energy status, influencing metabolic enzyme activity, gene expression, and signalling pathways that respond to energy availability. ## Research Applications NAD+ is employed across multiple research domains in UK laboratories: **Cellular Energy Metabolism** — Biochemical assays measure NAD+/NADH ratios in cell extracts to assess metabolic state and mitochondrial function. Enzyme kinetics studies examine NAD+-dependent dehydrogenases and oxidoreductases. **Sirtuin Research** — In vitro deacetylase assays use NAD+ as the essential co-substrate for studying sirtuin enzyme activity, inhibition, and regulation. Cellular models examine NAD+ availability and sirtuin-mediated gene expression. **Ageing Research** — Cellular models examine NAD+ levels in the context of chronological ageing, with measurements of NAD+ decline, sirtuin activity, and mitochondrial function in aged cells. **DNA Repair Studies** — PARP activity assays measure NAD+ consumption as a readout of DNA damage response. Cellular models examine the relationship between NAD+ availability and DNA repair capacity. **Comparative Biochemistry** — NAD+ is used as a reference in studies comparing NAD+ precursors (nicotinamide riboside, NMN, nicotinamide) for their effects on cellular NAD+ levels and NAD+-dependent processes. ## Reconstitution NAD+ is supplied as a lyophilised powder. Standard laboratory preparation: • **Sterile water or buffer** recommended for reconstitution (avoid bacteriostatic water if benzyl alcohol interferes with downstream assays) • **Typical concentrations**: 10–100 mM depending on assay requirements • **Solubility**: NAD+ is highly soluble in aqueous solutions • **Light sensitivity**: Protect from prolonged light exposure • **pH**: Maintain solutions at pH 6.0–8.0; NAD+ is unstable at extreme pH • **Storage**: Use fresh for most applications; avoid multiple freeze-thaw cycles ## Storage • **Lyophilised powder**: −20°C, desiccated, protected from light • **Reconstituted solution**: −20°C for short-term; −80°C for extended storage • **Stability**: Lyophilised powder stable for months at −20°C; reconstituted solution stable for 1–2 weeks at −20°C • **Avoid**: Repeated freeze-thaw cycles; prolonged exposure to light, heat, or alkaline pH ## FAQs ### What is NAD+ and what does it do in cells? NAD+ (nicotinamide adenine dinucleotide) is a fundamental coenzyme found in all living cells. It serves two essential roles: (1) as an electron carrier in redox reactions for energy metabolism, cycling between NAD+ and NADH; and (2) as a substrate for enzymes including sirtuins, PARPs, and CD38, which consume NAD+ for protein deacetylation, DNA repair, and calcium signalling. ### How is NAD+ used in research? NAD+ is used in cellular energy metabolism assays, sirtuin enzyme kinetics studies, PARP activity measurements for DNA repair research, and ageing studies examining NAD+ decline. It also serves as a reference for comparing NAD+ precursor compounds in cellular models. ### Is NAD+ legal for research in the UK? Yes. NAD+ is a naturally occurring biochemical coenzyme and is not a controlled substance under UK law. It is legal to purchase for legitimate laboratory research. ## Related Products - [Epithalon](https://hatipeptides.co.uk/product/epithalon) - [MOTS-C](https://hatipeptides.co.uk/product/mots-c) - [GHK-Cu](https://hatipeptides.co.uk/product/ghk-cu) ## Related Articles - [NAD+ UK: Research Reference 2026](https://hatipeptides.co.uk/research/nad-plus) --- # Bacteriostatic Water URL: https://hatipeptides.co.uk/glossary/bacteriostatic-water Bacteriostatic water is sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative. It is the standard diluent for reconstituting lyophilised research peptides in laboratory settings. ## Overview Bacteriostatic water is sterile water for injection containing 0.9% (weight/volume) benzyl alcohol as a bacteriostatic preservative. The benzyl alcohol inhibits bacterial growth, allowing multiple uses from a single vial over a period of days to weeks. The preparation is manufactured according to pharmaceutical standards for sterility and purity. The water is processed through reverse osmosis, distillation, and terminal sterilisation, with the benzyl alcohol added under aseptic conditions. For UK research laboratories, bacteriostatic water is an essential accessory for peptide reconstitution. It provides a sterile, preserved diluent that maintains peptide stability and prevents microbial contamination during repeated sampling. ## Mechanism Bacteriostatic water serves the following laboratory functions: **Peptide Reconstitution Diluent** — The primary use of bacteriostatic water is as a diluent for lyophilised peptide powders. The sterile water rehydrates the peptide into a solution suitable for laboratory assays and administration. **Benzyl Alcohol Preservative** — The 0.9% benzyl alcohol inhibits the growth of bacteria that may be introduced during vial sampling. This bacteriostatic action allows multiple withdrawals from a single vial over 14–28 days without significant microbial contamination risk. **pH Buffering** — The water has a neutral pH (approximately 5.5–7.0), which is compatible with most peptides. The absence of buffers or additives means researchers can adjust pH as needed for specific assays. **Sterility Assurance** — The terminal sterilisation process ensures the water is free of microorganisms, endotoxins, and particulate matter that could interfere with sensitive cellular or biochemical assays. ## Research Applications Bacteriostatic water is employed across multiple laboratory applications in UK research: **Peptide Reconstitution** — The primary application is reconstituting lyophilised peptides at precise concentrations for laboratory use. The preserved formulation allows multiple uses from a single vial. **Dilution Series** — Bacteriostatic water is used to create precise dilution series of peptide stock solutions for dose-response and concentration-dependence studies. **Vehicle Control** — In cellular assays, bacteriostatic water serves as a vehicle control for peptide-treated samples. The minimal benzyl alcohol concentration does not affect cell viability at typical peptide volumes. **Sterile Technique Training** — Bacteriostatic water is used in laboratory training for aseptic reconstitution technique, providing a safe medium for practicing sterile vial access and dilution protocols. **Buffer Preparation Base** — The sterile, endotoxin-free water serves as a base for preparing custom laboratory buffers and solutions for peptide research. ## Reconstitution Bacteriostatic water is supplied as a sterile liquid in sealed vials. No reconstitution is required — it is ready for immediate laboratory use: • **Storage**: 2–8°C (refrigeration) or controlled room temperature (15–25°C) • **Shelf life**: Use within 28 days of first vial puncture • **Single vial multiple use**: The benzyl alcohol preservative allows multiple withdrawals over the 28-day period • **Visual inspection**: Do not use if the solution is cloudy, discoloured, or contains visible particles • **Aseptic technique**: Wipe the septum with 70% isopropyl alcohol before each withdrawal; use sterile needles and syringes ## Storage • **Unopened vial**: 2–25°C, protected from light • **Opened vial**: 2–8°C (refrigeration recommended) • **In-use period**: 28 days maximum after first puncture • **Discard**: Any unused portion after 28 days or if contamination is suspected • **Do not freeze**: Freezing may cause vial breakage and compromise sterility ## FAQs ### What is bacteriostatic water and what is it used for? Bacteriostatic water is sterile water for injection containing 0.9% benzyl alcohol as a preservative. It is the standard diluent for reconstituting lyophilised research peptides, allowing multiple uses from a single vial over a 28-day period. ### Can normal sterile water be used instead of bacteriostatic water? Sterile water without preservative can be used for peptide reconstitution but has significant limitations: it must be used immediately or discarded after a single use as it lacks antimicrobial preservation. Bacteriostatic water is preferred because the benzyl alcohol inhibits bacterial growth during repeated vial access. ### Does the benzyl alcohol affect peptides or cell assays? At the volumes typically used for peptide reconstitution, the final benzyl alcohol concentration in cell culture medium is below 0.1%, which has negligible effects on most cell types. Researchers should include appropriate vehicle controls in their assays. Certain sensitive assays or cell types may require preservative-free water. ## Related Products - [Semaglutide](https://hatipeptides.co.uk/product/semaglutide) - [BPC-157](https://hatipeptides.co.uk/product/bpc-157) - [Retatrutide](https://hatipeptides.co.uk/product/retatrutide) ## Related Articles - [Bacteriostatic Water UK: Research Reference 2026](https://hatipeptides.co.uk/research/bacteriostatic-water) --- --- # Stacks # Recovery Stack URL: https://hatipeptides.co.uk/stacks/recovery Combine BPC-157 and TB-500 to target complementary phases of the tissue repair cascade — angiogenesis and structural remodelling. ## Mechanism BPC-157 (Body Protection Compound-157) drives angiogenesis and upregulates growth factors including VEGF and TGF-β, building the vascular infrastructure needed for tissue repair. TB-500 (Thymosin Beta-4) facilitates actin-mediated cell migration and stem cell recruitment, enabling cellular execution of the repair program. Together they address distinct but converging pathways in the healing cascade. ## Research Rationale - BPC-157 upregulates angiogenic growth factors (VEGF, TGF-β) to build vascular infrastructure — TB-500 provides the actin-binding platform for cell migration into the repair site - BPC-157 modulates nitric oxide synthesis and protects endothelial integrity, while TB-500 regulates inflammatory signalling and reduces oxidative stress - The two peptides target separate phases of tissue repair: BPC-157 drives early-stage angiogenesis and granulation, TB-500 supports later-stage matrix remodelling - Each compound is individually vialled and batch-traceable with independent COAs — stack at your chosen concentrations ## Research Applications This stack is used in laboratory models of soft tissue repair, wound healing assays, endothelial cell migration studies, and inflammation-modulation research. Typical in vitro models include fibroblast scratch assays, endothelial tube formation assays, and macrophage polarisation studies. ## FAQs ### How does BPC-157 differ from TB-500 in mechanism? BPC-157 primarily drives angiogenesis and growth factor upregulation (building the vascular infrastructure), while TB-500 facilitates actin-mediated cell migration and stem cell recruitment (enabling cellular execution of repair). They target distinct phases of the healing cascade. ### What ratio is typically used in research models? There is no standardised ratio — concentrations depend on your specific assay. Most published in vitro work uses individual dose-response curves for each peptide. Stacking allows you to test each at its optimal concentration. ### Can I use BPC-157 and TB-500 from different batches? Yes. Each peptide is individually vialled and batch-traceable with its own Certificate of Analysis. You can mix and match lots as needed for your research protocol. --- # Metabolic Stack URL: https://hatipeptides.co.uk/stacks/metabolic Pair Retatrutide (triple GLP-1/GIP/glucagon agonist) with MOTS-C (mitochondrial-derived peptide) to investigate multi-receptor metabolic signalling and cellular energy regulation. ## Mechanism Retatrutide is a 39-amino-acid triple agonist that activates GLP-1, GIP and glucagon receptors simultaneously, modulating insulin secretion, glucagon suppression, and energy expenditure. MOTS-C is a 16-amino-acid mitochondrial-derived peptide that regulates metabolic homeostasis at the cellular level, influencing AMPK signalling, glucose uptake, and lipid metabolism. The combination allows researchers to study both endocrine and mitochondrial metabolic pathways in parallel. ## Research Rationale - Retatrutide addresses systemic energy homeostasis through incretin and glucagon receptor signalling — MOTS-C targets cellular energy sensing via AMPK and mitochondrial regulation - Triple agonism (GLP-1 + GIP + glucagon) provides broader receptor coverage than single or dual agonists, while MOTS-C adds a mitochondrial dimension not addressed by incretin-based compounds - Retatrutide modulates insulin and glucagon secretion in glucose-dependent in vitro models — MOTS-C enhances glucose uptake and fatty acid oxidation in cultured myocytes and hepatocytes - Each peptide is individually vialled with independent batch COAs — titrate each separately in your assay design ## Research Applications Commonly employed in metabolic disease research using beta-cell lines (MIN6, INS-1), primary hepatocyte cultures, and 3T3-L1 adipocyte differentiation models. Also used in mitochondrial function assays and AMPK signalling pathway studies. ## FAQs ### How does MOTS-C complement Retatrutide in metabolic research? Retatrutide works at the endocrine level (receptor-mediated signalling), while MOTS-C acts at the cellular/mitochondrial level. This allows researchers to investigate both systemic and intracellular metabolic pathways simultaneously. ### Are both peptides reconstituted the same way? Both are lyophilised powders typically reconstituted with bacteriostatic water. However, each has different solubility profiles — always follow the individual COA recommendations. Retatrutide's fatty-diacid conjugate may require gentle warming. ### What controls should I use for this stack? Standard controls include individual peptide treatments (Retatrutide alone, MOTS-C alone) to isolate synergistic vs additive effects, plus vehicle controls. A GLP-1-only agonist (e.g., semaglutide) can serve as a reference comparator. --- # Longevity Stack URL: https://hatipeptides.co.uk/stacks/longevity Combine Epithalon (Epitalon) with NAD+ to investigate telomere biology, gene expression regulation, and cellular energy metabolism — targeting parallel hallmarks of ageing. ## Mechanism Epithalon is a 4-amino-acid tetrapeptide that upregulates telomerase activity and modulates gene expression patterns associated with biological ageing, particularly in neuroendocrine tissues. NAD+ (Nicotinamide Adenine Dinucleotide) is a central coenzyme in cellular redox reactions and a substrate for sirtuins and PARP enzymes that regulate DNA repair, mitochondrial function, and metabolic homeostasis. Together they address complementary ageing hallmarks: Epithalon targets telomere maintenance and neuroendocrine regulation, while NAD+ supports energy metabolism and genomic integrity. ## Research Rationale - Epithalon upregulates telomerase and modulates rhythmic gene expression in neuroendocrine models — NAD+ fuels sirtuin-dependent DNA repair and mitochondrial biogenesis - The two compounds target distinct hallmarks of ageing: Epithalon addresses telomere attrition and epigenetic regulation, while NAD+ supports cellular energy sensing and redox balance - Epithalon's effects on the pineal-hypothalamic axis complement NAD+'s role in mitochondrial function and cellular stress resistance - Each compound is supplied independently with batch COAs — design your own dosing schedule for in vitro models ## Research Applications Used in cellular senescence models, telomerase activity assays, mitochondrial function studies (Seahorse assays), and gene expression analysis of ageing markers. Frequently employed in fibroblast, neuronal, and hepatocyte culture systems for longevity research. ## FAQs ### Are Epithalon and NAD+ used together in published studies? Most published studies examine each compound individually. The stacking rationale is based on their complementary mechanisms targeting distinct ageing hallmarks. Combination studies are an emerging area of geroscience research. ### How should NAD+ be handled in cell culture? NAD+ is water-soluble but can degrade in solution. Prepare fresh for each experiment, protect from light, and use appropriate stabilisation buffers depending on your assay. Epithalon is more stable but should still be aliquoted and stored at -20°C. ### What is the typical concentration range for Epithalon in vitro? Published in vitro studies typically use Epithalon in the 10 nM–1 µM range depending on cell type and endpoint. Always perform a dose-response pilot to determine optimal concentrations for your specific model. --- # Skin Stack URL: https://hatipeptides.co.uk/stacks/skin Pair GHK-Cu (copper-binding tripeptide) with BPC-157 to investigate extracellular matrix remodelling, angiogenesis, and tissue regeneration pathways. ## Mechanism GHK-Cu is a naturally occurring copper-binding tripeptide that stimulates collagen synthesis, glycosaminoglycan production, and wound healing responses. It also modulates gene expression related to extracellular matrix remodelling and possesses antioxidant properties. BPC-157 drives angiogenesis and growth factor upregulation, building the vascular infrastructure needed for tissue repair. Together they target distinct aspects of tissue regeneration: GHK-Cu addresses matrix synthesis and structural integrity, while BPC-157 ensures adequate blood supply and growth factor signalling. ## Research Rationale - GHK-Cu stimulates collagen Type I and III synthesis and promotes fibroblast proliferation — BPC-157 drives VEGF-dependent angiogenesis to supply the repair site - GHK-Cu modulates matrix metalloproteinase (MMP) activity for controlled ECM remodelling — BPC-157 regulates inflammatory cytokine expression and protects endothelial integrity - The copper-peptide has documented antioxidant and anti-inflammatory properties that complement BPC-157's effects on growth factor signalling and cell survival pathways - Each compound is individually vialled with independent COAs — customise concentrations independently for your specific assay ## Research Applications Applied in dermal fibroblast culture models, wound healing scratch assays, collagen synthesis quantification (hydroxyproline assay), endothelial tube formation assays, and MMP activity studies. Relevant for research into extracellular matrix biology and tissue regeneration. ## FAQs ### Can GHK-Cu and BPC-157 be used together in the same culture? Yes. They are compatible in cell culture media at standard concentrations. However, always test for potential interactions in your specific medium formulation. The copper ion in GHK-Cu may chelate with certain media components. ### What cell types are commonly used for this stack? Primary dermal fibroblasts, keratinocytes, and endothelial cells (HUVECs) are the most common models. Each cell type responds to each peptide differently, so individual dose-response curves are recommended. ### How does GHK-Cu compare to non-copper GHK? The copper complex (GHK-Cu) is the biologically active form. Without copper, GHK has significantly reduced activity in collagen synthesis and wound healing assays. Always verify you are using the copper-bound form. ---